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ABSTRACT  
 
In bone reconstructive surgery, biomaterials commonly replace the missing tissue, 
and can also serve as vectors for local drug delivery. Due to its inhibitory action on 
bone-resorbing cells (osteoclasts), a semi-metallic element gallium (Ga) is used for 
the treatment of disorders associated with accelerated bone resorption. Since Ga 
can be incorporated into the structure of bone substitutes, we embarked on 
characterising the biological properties of novel Ga-loaded biomaterials.  In vitro, in 
the presence of Ga-loaded biomaterial, we observed a decrease in osteoclast 
differentiation and the upregulated expression of several osteoblastic markers (bone-
forming cells). In vivo, using a rat bone defect model, we showed an increase in 
newly formed bone tissue in implants filled with Ga-loaded biomaterial. Taken 
together, our data indicate that Ga-loaded biomaterial improved bone 
reconstruction by modifying the balance construction/degradation. Taking into 
account known antitumoral effects of Ga, we also investigated its impact on a bone 
metastatic model. Using an aggressive human cancer cell line selected for its ability 
to invade bone tissue, we showed that Ga could reduce cancer cell proliferation 
and viability, and reverse excessive osteoclastogenesis in bone metastatic 
environment. Moreover, we demonstrated that Ga modulated the expression of 
several marker genes hindering the tumour-propagating potential of cancer cells. 
Thus, due to its inhibitory action on cancer cells, Ga could represent an attractive 
additive to biomaterials used for bone tissue reconstruction after tumour resection. 
 
Keywords: gallium, biomaterials, osteoporosis, bone metastases, second-harmonic 
generation 
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En français 
 
RESUME DETAILLE DE LA THESE 
 
Ce projet de thèse s’inscrit dans la problématique générale du comblement 
des pertes de substance osseuse résultant de traumatismes, de pathologies ostéo-
articulaires ou de la résection de tumeurs osseuses.  
La structure et la physiologie du tissu osseux sont présentées dans le premier 
chapitre de l’introduction. La différentiation et l’activité des  éléments cellulaires 
clefs de l’os sont détaillées en commençant par les ostéoblastes, les cellules 
formatrices de l’os, puis les osteocytes et enfin les ostéoclastes, les cellules qui 
résorbent le tissu osseux. Le mécanisme et les molécules impliquées dans la 
régulation du remodelage osseux sont aussi décrites.   
Le deuxième chapitre qui porte sur la physiopathologie osseuse est plus 
particulièrement concentré sur l’ostéoporose, le trouble le plus récurent du 
remodelage osseux avec 440 000 nouveaux patients par an dans les pays de l’Union 
Européenne. Cette maladie est caractérisée par une activité excessive des 
ostéoclastes qui résulte en une diminution de la densité osseuse et se manifeste 
cliniquement par des fractures ostéoporotiques. Le deuxième accent fort de ce 
chapitre est mis sur les métastases osseuses - la complication récurrente des 
nombreux cancers solides, comme le cancer de la prostate et le cancer du sein. Il a 
été montré que les métastases osseuses sont capables de moduler le 
microenvironnement osseux en favorisant l’activité ostéoclastique et donc la 
formation de lésions ostéolytiques, mauvais pronostique pour les  patients.  
Le troisième chapitre introduit les biomatériaux synthétiques à base de 
phosphate de calcium (CaP) qui sont couramment utilisés comme substituts en 
chirurgie reconstructive de l’os. Ces matériaux biocompatibles remplacent le tissu au 
sein de défauts osseux permettant de rétablir partiellement ses propriétés 
mécaniques. En même temps, ils servent de matrice pour la reconstruction de l’os et 
en fonction de la structure chimique, ils sont résorbés au cours du temps et 
remplacés par le tissu osseux du patient.  Dans le cadre de pathologies telles que 
l’ostéoporose ou les tumeurs osseuses, ces biomatériaux pourraient également 
assurer un délivrage local de molécules actives.  
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Dans le traitement de plusieurs pathologies osseuses, de nombreuses données 
issues de la recherche et de la pratique clinique mettent en évidence les effets 
bénéfiques de l’élément semi-métallique, le gallium (Ga).  
Il a été montré que le Ga exerce des effets inhibiteurs sur les cellules cancéreuses et 
également sur les ostéoclastes, les cellules résorbantes de l’os. Dû à cet effet, le 
gallium est utilisé dans le traitement de différentes pathologies liées à la résorption 
ostéoclastique accélérée du tissu osseux, telle que l’hypercalcémie maligne. 
 
 En partenariat avec la société Graftys et dans le but de développer de 
nouveaux biomatériaux de comblement pour les pertes de substance osseuse, qui 
seront également pharmacologicalement actifs, ce travail de thèse a évalué les 
propriétés biologiques d’un ciment phosphocalcique (CPC) incorporant du gallium 
dans sa structure (CPC/Ga). Ce biomatériau composé pourrait être utilisé dans le 
cadre de la prévention de fractures ostéoporotiques ou bien pour le comblement 
de cavités après la résection de tumeurs osseuses. Considérant les effets majeurs 
que le Ga exerce sur l’ensemble du tissu osseux, il est important d’étudier de façon 
approfondie son impact sur le recrutement et la différenciation des cellules osseuses, 
ainsi que sur la formation du tissu osseux lui-même. 
 
In vitro, la culture de cellules osseuses sur les pastilles de CPC/Ga a mis en 
évidence une diminution de la prolifération des ostéoclastes et une sous-expression 
des marqueurs tardifs de la différenciation ostéoclastique. D’autre part, nous avons 
montré une sur-expression de plusieurs marqueurs caractérisant les ostéoblastes sur le 
CPC/Ga par rapport au CPC contrôle. Les propriétés reconstructives de 
biomatériaux chargés en Ga ont aussi été étudiées in vivo dans un modèle murin de 
comblement du défaut osseux. Pour tous les biomatériaux implantés, nous avons pu 
observer une bonne ostéointegration, accompagnée d’une reconstruction avec 
colonisation par la moelle osseuse. De plus, pour un des biomatériaux galliés, 
l’analyse quantitative en 3D par micro-CT a révélé une augmentation du 
remplissage total du défaut osseux par rapport au contrôle.  
 
Néanmoins, la technique de micro-CT ne permet pas de distinguer clairement 
la phase minérale des biomatériaux phosphocalciques et la phase minérale du tissu 
osseux dû à la grande ressemblance des leurs structures chimiques. Au cours de 
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cette thèse, et en collaboration avec Sébastien Schaub de la plateforme PRISM de 
l’iBV, nous avons pu développer un outil de quantification en 3D du tissu osseux au 
sein des implants par la microscopie SHG (angl. second- harmonic generation). Le 
constituant organique majeur du tissu osseux, les fibres de collagène, ont la propriété 
d’émission de « second harmonique » grâce à leur structure physico-chimique. C’est 
pourquoi, dans l’analyse de nos échantillons, le signal SHG est spécifiquement lié au 
tissu osseux. Dans notre modèle du défaut osseux, la quantification en 3D du signal 
SHG au sein des implants galliés a montré une augmentation du tissu osseux par 
rapport aux implants contrôles. En effet, ce résultat a confirmé l’effet observé 
précédemment en analyse quantitative par micro-CT suggérant que la microscopie 
SHG ouvre une nouvelle piste non-destructive pour la quantification spécifique du 
tissu osseux dans le domaine de l’ingénierie tissulaire de l’os.   
 
D’autre part, étant donné que des effets anti-tumoraux du Ga sont largement 
rapportés dans la littérature, nous nous sommes également intéressés aux effets 
cellulaires que le Ga pourrait exercer sur les cellules tumorales dans l’os. En utilisant 
une lignée cellulaire métastatique agressive, choisie pour son affinité pour le tissu 
osseux, nous avons montré que le Ga réduit la prolifération des cellules cancéreuses 
et également la différentiation ostéoclastique induite pas les cellules cancéreuses. 
De plus, nous avons mis en évidence que le Ga module l’expression de gènes 
susceptibles de réduire le potentiel tumoral des cellules métastatiques.  
 
L’ensemble de ces données indique que les biomatériaux chargés en Ga sont 
des substrats non-cytotoxiques et compatibles avec la survie et la prolifération des 
cellules osseuses in vitro et in vivo. De plus, en agissant à la fois sur les ostéoclastes et 
les ostéoblastes, le Ga améliore la repousse osseuse intervenant au sein des 
biomatériaux phosphocalciques implantés. Cette propriété peut être un avantage 
dans le contexte ostéoporotique où le remodelage et la reconstruction osseuse sont 
fortement impactés. Il serait donc intéressant d’évaluer le potentiel ostéogénique 
des biomatériaux galliés dans un modèle ostéoporotique. Enfin, dû au fait de ses 
effets inhibiteurs sur les cellules cancéreuses, le Ga constitue un candidat intéressant 
pour le couplage avec des substituts phosphocalciques destinés à la reconstruction 
osseuse  après la résection tumorale. 
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1. Bone structure and physiology 
 
1.1. Bone systemic functions 
 
Bone is composed of several tissues, predominantly a highly specialized 
connective tissue that enables locomotion and provides mechanical protection for 
the vital organs. It serves as an environment for blood forming and fat storage, and 
acts as a homeostatic reservoir of growth factors, cytokines, and minerals important 
for the body.  
Amongst different minerals deposited in the bone, the most important ones 
are calcium with 95% and phosphorus with 85% of total body content contained in 
the bone tissue. The minerals can be mobilized and replaced in bone to meet 
systemic homeostatic needs regardless of reduction of skeletal structural integrity. 
Hence, this particular metabolic function of bone tissue outweighs its structural 
function (Kini & Nandeesh, 2012). 
Mineralized bone matrix serves also as a depository for a great number of 
prominent cytokines and growth factors, such as insulin-like growth factors (IGFs), 
transforming growth factor-b (TGF-β) and bone morphogenetic proteins (BMPs) that 
can be released upon bone resorption and act locally or systemically. Regarding the 
endocrine function, one of the notable hormones released by bone is osteocalcin, 
known to increase bone density by helping to funnel calcium and other minerals into 
the bone matrix. Osteocalcin also contributes to the regulation of blood glucose 
metabolism and fat deposition (Kini & Nandeesh, 2012). The yellow bone marrow 
acts as storehouse of adipocytes that can secrete leptin, a hormone largely involved 
in energy balance that also participates in bone mass control (Ducy et al., 2000). 
Residing in red bone marrow, self-renewing haematopoietic stem cells (HSCs) are 
progenitors to all of the different mature blood cell types (Alenzi et al., 2009). And by 
its capacity to store heavy metals and other extraneous elements and to remove 
them from the circulation, bone also participates in body detoxification (Kini & 
Nandeesh, 2012).  
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Numerous cell types are found in bone, with the main ones being (i) 
mesenchymal stem cells that can differentiate in (ii) osteoblasts, the bone forming 
cells that endure maturation becoming (iii) osteocytes, the cells orchestrating bone 
remodelling. The forth main cell type, (iv) osteoclast, is derived from hematopoietic 
cell lineage and is responsible for bone tissue resorption. These cell types are 
entrapped in osteoid matrix built up of collagen and noncollagenous proteins with 
deposits of inorganic mineral salt (Kini & Nandeesh, 2012). 
 
Based on the spatial pattern of collagen forming the osteoid, two types of 
bone are distinguished: the woven bone, which is characterized by a haphazard 
organization of collagen fibers, and mechanically stronger lamellar bone, 
characterized by a regular parallel alignment of collagen into sheets (lamellae). A 
rapid osteoid production result in woven bone and this occurs initially in all foetal 
bones and in fracture healing. The woven bone is replaced in a process called 
remodelling by the deposition of more resilient lamellar bone and virtually all the 
bone in the healthy mature adult is lamellar bone (Eriksen et al. 1994).  
 
1.2.2. Mesenchymal stem cells 
 
 Mesenchymal stem cells (MSCs), or bone stromal cells, are progenitor cells 
present in adult bone marrow, adipose tissue, muscles, synovial and placental tissue, 
and teeth. They participate in synthesis of extracellular matrix, immune tolerance, 
development, inflammation and fibrosis. MSCs are currently being studied for tissue 
engineering applications, including bone and cartilage repair, because of their 
potential to differentiate into different lineages such as chondrocytes, osteoblasts or 
adipocytes. Recently, these cells have also been shown to have immunosuppressive 
and healing capacities, to improve angiogenesis and to prevent fibrosis (Pers & 
Jorgensen, 2013). 
 
1.2.3. Osteoblasts and bone lining cells 
 
Osteoblasts are bone-forming cells developed from the mesenchymal stem 
cell lineage. They secrete organic matrix at the bone resorption sites and further they 
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1.2.4. Extracellular matrix composition and mineralization 
 
Bone matrix is constituted of water (5%), inorganic mineral component (69%), 
predominantly hydroxyapatite (99 %), and organic component (22%) constituted 
mostly of collagen type I (90-95%) and noncollagenous structural proteins including 
proteoglycans, sialoproteins, osteocalcin, alpha-2-HS-glycoprotein and gla-
containing proteins (Kini & Nandeesh, 2012). Osteoblasts synthesize and lay down 
precursors of collagen 1, which are deposited in parallel or concentric layers to 
produce mature (lamellar) bone. When bone is rapidly formed, as in the fetus or 
certain pathological conditions (e.g., fracture callus, fibrous dysplasia, 
hyperparathyroidism), the collagen is not deposited in a parallel array but in a 
basket-like weave resulting in immature woven bone. Osteoblasts also secrete 
noncollagenous proteins, such as osteocalcin, the most abundant noncollagenous 
protein of bone matrix, glycosylated proteins such as alkaline phosphatase, and g-
carboxylated (gla) proteins (Kini & Nandeesh, 2012). 
The hardness and rigidity of bone is due to the presence of mineral salt in the 
osteoid matrix, which is a crystalline complex of calcium and phosphate. Amorphous 
calcium phosphate matures through several intermediate stages to form crystalline 
hydroxyapatite [Ca10(PO4)6(OH)2], which is progressively substituted with carbonate 
to increase its solubility. Finally, the mineral component of the bone is deposited 
along the collagen fibrils forming a particular mineral-collagen network that ensures 
the structural integrity of the bone tissue and supports its mechanical function (Kini & 
Nandeesh, 2012).  
 
1.2.5. Osteocytes 
 
The most abundant cells in bone are the osteocytes. These terminally 
differentiated osteoblasts embedded in bone matrix change their morphology by 
extending cellular processes for connection and intercommunication with other cell 
types present in bone. They are considered to be the mechanosensors of the bone, 
instructing osteoblasts and osteoclasts to start bone remodelling in response to 
mechanical stimuli (You et al., 2008). Osteocytes are interlinked metabolically and 
electrically through gap junctions composed primarily of connexin (You et al., 2008). 
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In aging bone, the presence of empty lacunae suggests that osteocytes may 
have undergone apoptosis, probably caused by disruption of their intercellular gap 
junctions or cell-matrix interactions. It is also known that estrogen deficiency or 
glucocorticoid treatment is harmful to bone structure because it induces osteocyte 
apoptosis. As a consequence of this, estrogen and bisphosphonate therapy 
accompanied by physiologic loading of bone may help in prevention of osteoblast 
and osteocyte apoptosis (Plotkin, Aguirre, Kousteni, Manolagas, & Bellido, 2005). 
 
1.2.6. Osteoclasts 
Osteoclasts, the bone resorbing cells, originate from monocytes/macrophage 
lineage and their differentiation requires direct contact with the surrounding 
osteoblasts, stromal cells, and immune cells (Weiss, Iqbal, Zaidi, & Mechanick, 2010). 
Mature polarized osteoclasts adhere to the bone surface through αvβ3 
integrin, form an actin ring, and acidify the sealed zone by secreting hydrogen ions.  
Proteases (i.e. cathepsin K) that degrade matricellular proteins such as type I 
collagen (Kini & Nandeesh, 2012) are also secreted in the sealing zone.  
Osteoblasts and marrow stromal cells secrete macrophage colony stimulating 
factor (M-CSF) and receptor activator of nuclear factor NFκB ligand (RANKL) that 
direct certain hematopoietic precursor cells to become mature multi-nucleated 
osteoclasts (M. Nakamura, Hentunen, Salonen, Nagai, & Yamashita, 2013). As shown 
in Figure 3, the binding of RANKL to its cognate membrane receptor activates wide 
downstream pathways which include nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB), c-Fos and mitogen-activated protein kinases (MAPKs) such 
as c-Jun N-terminal kinase (JNK), extracellular-signal-regulated kinases (ERK) or p38. 
Afterwards, NF-κB, MAPK and c-Fos are implied in the regulation of “nuclear factor of 
activated T-cells, cytoplasmic 1” (NFATc1) expression that is the master regulator of 
osteoclast differentiation. It is responsible for the induction of many osteoclast-typical 
markers such as (ACP5/TRAP) tartrate-resistant acid phosphatase (TRAP), cathepsin K 
(CTSK), β3-integrin (ITGB3), calcitonin receptor (CTR), and matrix metalloproteinase 9 
(MMP9) (Takayanagi et al., 2002). Although many different pathways target NFATc1 
expression, NFκB is the main inducer of the early phase of its transcription. RANKL has 
been shown to induce a specific set of about 70 genes, including chemokines and 
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growth factors [RANTES, platelet-derived growth factor (PDGFα) or IGF-1], which are 
indispensable for osteoclastic differentiation (Borovecki et al., 2007). 
 
Figure 3. Central signalling pathways in osteoclastogenesis. 
Activation of RANK by RANKL represents a well-accepted signalling mechanism that initiates 
osteoclast differentiation and leads to the the activation of NFATc1, the principal transcription 
factor in osteoclastogenesis (taken from Edwards & Mundy, 2011). 
 
Osteoprotegerin (OPG) is an endogenous decoy receptor of RANKL and thus 
inhibits the recruitment, proliferation, and activation of osteoclasts. In vivo models 
show that the overexpression of OPG, or the deletion of RANK or RANKL cause severe 
osteopetrosis, this demonstrating the critical role of this pathway in 
osteoclastogenesis (Weilbaecher, Guise, & McCauley, 2011). Indeed, abnormalities 
in the balance of RANK/RANKL/OPG can lead to an increased bone resorption that 
underlies for example the bone damages observed upon postmenopausal 
osteoporosis, Paget’s disease, bone loss in metastatic cancers or rheumatoid arthritis. 
Further supporting the importance RANK/RANKL/OPG balance, the canonical Wnt/β-
catenin signalling pathway was shown to inhibit osteoclastogenesis via the 
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modulation of RANKL expression in osteoblasts (Spencer, Utting, Etheridge, Arnett, & 
Genever, 2006).  
 
 
Figure 4.  The Wnt signalling pathway with its ability to inhibit osteoclastogenesis.  
Wnt-signaling proteins are able to block osteoclastogenesis via induction of OPG 
expression. Under physiological circumstances, OPG binds to RANKL and provides a balance 
between bone resorption and bone formation. Through increased induction of DKK1, the 
Wnt/β catenin signaling is inhibited, which consequently leads to a decrease in production of 
OPG and more active osteoclastogenesis (taken from Herman, Krönke, & Schett, 2008). 
 
In addition to RANK/RANKL/OPG system, calcium functions as an important 
second messenger in the regulation of skeletal cells. Indeed, calcium signalling 
pathway is pivotal for osteoclastic maturation due to, for example, its involvement in 
the late phase of NFATc1 nuclear translocation. Cytoplasmic calcium can originate 
either from intracellular calcium stores or extracellular calcium uptake. Oscillations in 
intracellular calcium level activate the major calcium-binding protein calmodulin, 
which can notably activate multifunctional CaMKs (calmodulin-dependent kinases). 
Binding of Ca2+/ calmodulin to CaMKs induces a conformational change that leads 
to an active form of these kinases. In the case of CaMKIV, maintaining maximal 
levels of activity requires either autophosphorylation or phosphorylation by another 
calmodulin-dependant upstream kinase. Further, p-CaMKIV induces CREB-mediated 
transcription through its phosphorylation (CREB, C-AMP Response Element-binding 
protein). Then, phosphorylated CREB (p-CREB) cooperates with the master regulator 
NFATc1 to induce the transcription of osteoclast-typical markers mentioned above. 
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Furthermore, p-CREB is also involved in activation of c-Fos transcription factor (Sato et 
al., 2006). 
1.3. Bone dynamics 
 
Bone is a highly metabolically active tissue that undergoes continuous 
remodelling by two counteracting processes: bone formation by osteoblasts and 
bone resorption involving osteoclasts. Under normal physiological conditions, bone 
resorption and formation are tightly coupled to each other, so that the amount of 
bone removed is always equal to the amount of newly formed bone at each 
remodelling site. This critical balance preserves the skeletal integrity and is mediated 
by the activation of mechanosensing osteocytes (Seibel, 2005). In addition, bone 
remodelling is influenced by numerous paracrine and endocrine factors, including 
osteoblast- and osteoclast-specific signalling proteins and transcription factors, as 
well as hormones and growth factors (Borovecki et al., 2007). These processes also 
control the reshaping or replacement of bone during growth (bone modeling) and 
following injuries like fractures.  
 
 
1.3.1. Bone modeling 
 
Bone modeling (reshaping) can be found both in cancellous and cortical 
bone of evolutionary higher mammals. In a growing mammalian skeleton, 
cancellous bone turnover is dominated by modeling, whereas remodelling is the 
major turnover activity in a mature skeleton (Erben, 2015). Modeling is the process by 
which bones change their overall shape (longitudinal and radial growth) responding 
to physiological or biomechanical stimuli in order to gradually adjust to the forces 
that skeleton encounters. Longitudinal growth occurs at the growth plates, where 
cartilage proliferates in the epiphyseal and metaphyseal areas of long bones, before 
subsequently undergoing mineralization to form primary new bone (Clarke, 2008). 
Bone widening occurs with aging as a result of periosteal new bone apposition and 
old bone removal on the endosteal surface. Additionally, modeling may be modified 
in hypoparathyroidism (Ubara et al., 2005), renal osteodystrophy (Ubara et al., 2003), 
or as a consequence of treatment with anabolic agents (Lindsay et al., 2006).  
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1.3.2. Bone remodelling 
 
Following the changes in biomechanical forces, and with a goal to replace 
old micro-damaged bone with new and mechanically stronger tissue, the skeletal 
system is subjected to lifelong remodelling. Both trabecular and cortical bone are 
continuously renewed by removal of discrete packets of old bone, replacement of 
these packets with newly synthesized proteinaceous matrix, and subsequent 
mineralization of the matrix (Fernández-Tresguerres-Hernández-Gil, Alobera-Gracia, 
del-Canto-Pingarrón, & Blanco-Jerez, 2006). Although cortical bone makes up 75 % 
of the total bone volume, the turnover rate is ten times higher in trabecular bone, 
since the surface area-to-volume ratio is much higher in the later. Therefore, 
trabecular bone turnover is more important in mineral homeostasis. Approximately 5–
10 % of total bone turnover per year is adequate to maintain biomechanical strength 
of bone,  with 25 % of trabecular and 2-3 % of cortical bone tissue being remodeled 
annually (Kini & Nandeesh, 2012).  
Intracortical bone remodelling results in typical microanatomical structures, 
named Haversian canals or osteons. In this type of bone remodelling, osteoclasts 
and osteoblasts are organized in a complex structure called basic multicellular unit 
(BMU). Each BMU comprises a cutting cone of osteoclasts, followed by a closing 
cone lined by osteoblasts, together with connective tissue, blood vessels, and nerves. 
The average lifespan of a typical human BMU is 2–8 months, with the greater part of 
this time being used for bone formation. In cancellous bone, and at least in post-
menopausal osteoporosis, it is not entirely established whether BMUs exists as distinct 
entities because the time lapse between the end of resorption and the beginning of 
new bone formation at one remodelling site appears to be quite variable (Andersen 
et al., 2013).  
It is currently believed that remodelling can be initiated by either hormone-
driven stochastic mechanism, or microdamage-driven targeted mechanism. 
Stochastic remodelling is considered to be under endocrine control, with sex steroids 
and parathyroid hormone being the most salient endocrine determinants of bone 
metabolism (Khosla, Oursler, & Monroe, 2012). On the other hand, the purpose of 
targeted remodelling is to remove microdamage that occurs during normal physical 
activities. However, the distinction between stochastic and targeted remodelling 
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may be arbitrary, because there is currently no sufficient data supporting the fact 
that these two mechanisms operate really independently (Erben, 2015). 
In the adult skeleton bone remodelling is a balanced process, with the 
amount of resorbed bone proportional to the newly formed tissue. In the third 
decade of life, bone mass peak is attended and maintained with small variations 
until the age of 50. Periosteal bone balance is mildly positive, whereas endosteal and 
trabecular bone balances are mildly negative, this resulting in cortical and 
trabecular thinning with aging. These relative changes occur with endosteal 
resorption outstripping periosteal formation. Bone turnover actually increases in 
perimenopausal and early postmenopausal women, but the balance is shifted 
towards resorption resulting in a decrease of bone mass. With further aging, turnover 
rate slows down but remains higher than in premenopausal women (Kini & 
Nandeesh, 2012).  
At least in humans, the initial event in bone remodelling is most likely the 
detachment of bone lining cells from the quiescent bone surface. Following this, 
blood-borne osteoclastic precursors can attach to the bone surface and start bone 
resorption (Sims & Martin, 2014). Normal bone remodelling cycle takes place in a 
highly coordinated fashion with a complex time-space coupling between bone 
resorption and bone formation. Osteocytes appear to be the main cell type 
orchestrating the bone remodelling process, due to their unique ability to detect 
microdamages in old bone and to secrete RANKL, a crucial cytokine for osteoclastic 
differentiation (Xiong et al., 2011).  
Bone remodelling can be divided into six phases namely, quiescent, 
activation, resorption, reversal, formation, and mineralization (Fernández-Tresguerres-
Hernández-Gil et al., 2006). 
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These cavities are called Howship’s lacunae in cancellous bone or cylindrical 
Haversian canals in cortical bone. 
 
4. Reversal phase: when a resorption cavity is created, osteoclasts detach from the 
bone surface and are replaced by cells of the osteoblast lineage that initiate bone 
formation. The preosteoblasts are attracted by the growth factors liberated from the 
matrix. These factors act as chemoattractants and in addition, they stimulate 
preosteoblasts proliferation. The biochemical signals linking the end of bone 
resorption and the beginning of bone formation are not yet firmly established, but 
some of the candidates are bone matrix-derived factors such as TGF-β, IGF-1, IGF-2, 
bone morphogenetic proteins (BMPs), PDGF, or fibroblast growth factor (FGF) 
(Bonewald & Mundy, 1990; Locklin, Oreffo, & Triffitt, 1999). 
 
5. Formation phase: the preosteoblasts now present in the resorption cavity 
synthesize a cementing substance upon which the new tissue will be attached. A 
few days later, some of the osteoblasts fill the resorption cavity by secreting the 
osteoid matrix (Lind et al., 1995). The remaining osteoblasts continue to synthesize 
bone until they evolve into quiescent lining cells that completely cover the newly 
formed bone surface and connect with the osteocytes embedded in the bone 
matrix. 
 
6. Mineralization phase: 30 days after osteoid secretion, minerals are deposited in the 
bone matrix and this process lasts up to 90 days in the trabecular and up to 130 days 
in the cortical bone. When the cycle is completed at one remodelling site, with the 
amount of bone formed equal to the amount of bone resorbed, the quiescent 
phase is reached.  
 
1.3.2.1. Bone resorption  
 
Bone development and turnover, as well as systemic mineral homeostasis, are 
essentially influenced by osteoclasts activated to resorb calcified cartilage, enamel, 
dentin, and mineralized bone. Mature osteoclasts display different levels of actin and 
vinculin distribution and organisation (Väänänen & Horton, 1995). The podosome belt 
found in mature osteoclasts is thought to evolve into thick circular band of actin, 
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referred to as a sealing zone in actively resorbing osteoclasts. This zone enables tight 
osteoclastic attachment to the bone surface and seals the resorption cavity where 
protons and proteases are released (Lakkakorpi & Väänänen, 1991). Compact 
osteoclasts have greater bone substrate resorption efficacy than spread osteoclasts 
(Arkett, Dixon, & Sims, 1992). The morphology of the actin ring depends on surface 
roughness, crystallinity, energy, and solubility (Nakamura et al., 2013). Osteoclasts 
recognize bone surface through the detection of bone matrix proteins (type I 
collagen, osteopontin) through β1 integrins and vitronectin receptor αvβ3 (Helfrich et 
al., 1996; Nakamura et al., 2007). Osteoclastic recognition of the substrate 
determines whether they behave as resorbing or non-resorbing osteoclasts. 
Osteoclasts cultured on bone slices have been shown to have thick actin rings and 
TRAP localized in their upper levels and around the nuclei. By contrast, osteoclasts 
cultured on glass coverslips have been shown to have thin actin rings and TRAP 
evenly distributed in the cytoplasm (Nakamura et al., 2013). The involvement of 
integrins in the recognition by osteoclasts of synthesized inorganic substrates is not 
yet completely elucidated. The differences in actin ring structure between 
osteoclasts cultured on hydroxyapatite (HA) and carbonate-substituted 
hydroxyapatite (CA) substrates indicate that inorganic components have also an 
important role in the recognition mechanism. For example, actin ring morphology is 
similar between osteoclasts cultured on bone slices and CA, while the ring quality is 
inferior when osteoclasts are cultured on HA and  tricalcium phosphate (TCP) 
(Nakamura et al., 2013). One of the indicators for a resorbing osteoclast is also the 
morphology and localization of vinculin. Indeed, noticeable amounts of cytoskeletal 
structures co-localize with actin and are found in cytoplasmic sites close to the 
resorption lacuna (Lakkakorpi & Väänänen, 1991). 
Polarized and activated multinuclear osteoclasts exhibit high levels of 
expression of genes associated with the dissolution of bone mineral or involved in the 
degradation of bone organic matrix. Carbonic anhydrase II (CAII) is a good genetic 
marker for activated osteoclast. Actually, its function to supply protons for the 
vacuolar-type proton-ATPase is essential for the dissolution of bone mineral (Riihonen 
et al., 2007). Another good marker for functional osteoclasts is CTSK, which is essential 
for the degradation of bone organic matrix (Troen, 2006). Protons and CTSK are 
transported from the ruffled border areas of osteoclasts into resorption lacuna, where 
the actual resorption takes place in low pH conditions. The carbonate-substituted HA 
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of the bone is more soluble that the stoichiometric HA, which increases the 
advantages of decalcification and the release of calcium ions. In turn, calcium ions 
contribute to the activation of non-resorbing osteoclasts (Helfrich et al., 1996). 
 
1.3.2.2. Bone formation  
 
Ossification (or osteogenesis) is the process of formation of new bone by cells 
called osteoblasts. A rapid formation of bone mass occurs in the foetus and infant, 
while it slows somewhat during childhood until the age of 11 for females and 12 for 
males. Adolescence is characterized by tremendous bone formation and most of 
adult bone mass is acquired by the age of 18, with only a small amount added 
during the next ten years (Kini & Nandeesh, 2012). Two important processes 
contribute to normal healthy bone synthesis: 
 
1. Intramembranous ossification characterized by lying down of bone into the 
primitive connective tissue (mesenchyme), this resulting in the formation of bones 
(e.g. skull, clavicle, mandible). This process also occurs in the healing of compound 
fractures treated by open reduction and stabilization by metal plate and screws. 
 
2. Endochondral ossification where a cartilage model acts as a precursor for 
bone formation (e.g. femur, tibia, humerus, radius). This is the most important process 
occurring during fracture healing when treated by cast immobilization. 
 
Both types of ossification include synthesis of extracellular organic matrix 
(osteoid) and its subsequent mineralization yielding the newly formed bone. The 
boundary between the old and new bone is called a cement line or reversal line, 
and it can be distinguished on an hematoxylin and eosin (H&E) histological sections 
as a blue (basophilic) line. If the process of bone tissue formation occurs at an 
extraskeletal location, it is termed as heterotopic ossification(Kini & Nandeesh, 2012). 
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1.3.2.3. Intramembranous (mesenchymal) ossification 
 
During foetal development of the mammalian skeletal system, bone tissue is 
formed from connective tissue such as mesenchyme. It mainly occurs during 
formation of the flat bones of the skull, but also the mandible, maxilla, and clavicles. 
It is also an essential process during the natural healing of bone fractures or during 
the rudimentary formation of bones of the head. The steps in intramembranous 
ossification are:  
1. Formation of ossification center  
2. Calcification  
3. Formation of trabeculae 
4. Development of periosteum. 
 
Located within human mesenchyme or in the medullary cavity at the site of a 
bone fracture, mesenchymal stem cells (osteoprogenitor cells) initiate the process of 
intramembranous ossification. These unspecialized cells undergo characteristic 
changes as they develop into an osteoblast. The process of membranous ossification 
is essentially the direct mineralization of a highly vascular connective tissue, and it 
starts at certain constant points known as centers of ossification. At such a center, 
the mesenchymal cells proliferate and condense around a profuse capillary 
network. The space between the cells and around the vessels is filled by the 
amorphous ground substance with a fine meshwork of collagen fibers. The MSCs 
then differentiate into osteoblasts, which secrete an osteoid matrix in the center of 
the aggregate. Consequently, they become entrapped in bone matrix and develop 
into osteocytes. At this point, the mineralization of osteoid begins, forming a nidus 
structure that contains osteocytes and that is lined by active osteoblasts. The process 
of entrapping of osteoblasts proceeds, the trabeculae gradually thicken, and the 
intervening vascular spaces (spongy layer) become progressively narrowed. The 
nidus that began as a diffuse collection of MSCs has now become rudimentary bone 
tissue. Where the bone persists as cancellous bone, the process slows down and the 
spaces later become occupied by hemopoietic tissue. As changes in the ossification 
center proceed, the surrounding mesenchyme condenses as a fibrovascular 
periosteum around its edges and surfaces. Then, the periosteum is formed and bone 
growth continues at the surface of trabeculae. The increasing growth of trabeculae 
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results in interconnection and this network is called woven bone. Eventually, woven 
bone is replaced by lamellar bone (Kini & Nandeesh, 2012). 
 
1.3.2.4. Intracartilaginous (endochondral) ossification 
 
In endochondral ossification, bone tissue grows from hyaline cartilage. It 
occurs during the growth of the length of long bones, most of the other bones in the 
body, as well as in natural fracture healing (Kini & Nandeesh, 2012). The basic steps 
include: 
1. Development of cartilage model  
2. Growth of cartilage model  
3. Development of the primary ossification centre  
4. Development of the secondary ossification centre 
5. Formation of articular cartilage and epiphyseal plate. 
 
The process begins at points within the cartilage called “primary ossification 
centres.” They mostly appear during fetal development with the exception of a few 
short bones that begin their primary ossification after birth. They are responsible for 
the formation of the diaphysis of long and short bones, and certain parts of irregular 
bones. After birth, secondary ossification forms the epiphyses of long bones and the 
extremities of irregular and flat bones. A growing zone of cartilage (the epiphyseal 
plate) separates the diaphysis and epiphyses of a long bone. When the child 
reaches skeletal maturity at age 18–25, all of the cartilage is replaced by bone tissue 
that fuse the diaphysis and both epiphyses together in a process called epiphyseal 
closure (Kini & Nandeesh, 2012). 
 
 
1.3.2. Models of bone remodelling 
 
Numerous attempts have been made to explain how, in bone remodelling 
cycle, the information about the amount of bone resorbed by osteoclasts is 
transmitted to osteoblasts. It is currently thought that coupling between bone 
resorption and formation occurs (i) through growth factors stored in the bone matrix 
and released during resorption, (ii) through soluble cytokines secreted by osteoclasts, 
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and (iii) through molecules expressed in the cell membrane of osteoclasts (Sims & 
Martin, 2014). Most of our current understanding of the mechanisms involved in 
coupling comes from experiments in gene-targeted mice. However, mice and rats 
lack true intracortical Haversian remodelling. Therefore, it is uncertain whether there 
are differences in the coupling mechanisms between intracortical and cancellous 
bone remodelling (Erben, 2015). 
The current explanatory models of the coupling mechanism are associated 
with a number of problems. First, none of these models can precisely explain why the 
amount of bone formed during the formation phase matches the amount of bone 
resorbed during the resorption phase. Second, and perhaps more critical, is the fact 
that in human cancellous bone remodelling, the time span between the end of 
osteoclastic resorption and the initiation of bone formation is in the range of several 
weeks (Delaisse, 2014). Any biochemical signal linking bone resorption to bone 
formation will have dissipated during this long period of time. Therefore, it is unclear 
how information is actually transmitted from osteoclasts to osteoblasts. Moreover, a 
diligently conducted histomorphometric study in human iliac biopsies of patients with 
postmenopausal osteoporosis revealed a large percentage (~30%) of remodelling 
cycles that were arrested in the reversal phase (Andersen et al., 2013), suggesting 
that in humans and in cancellous bone remodelling, formation is not always tightly 
coupled to resorption.  
These problems led certain authors to hypothesize that coupling in cancellous 
bone remodelling may rather be a mechanically controlled process within the newly 
formed bone package. An extensive review of cell-based and biomechanical bone 
remodelling theories is presented in Hambli et al. (Hambli, 2014). Using finite element 
models, Ruimerman et al. (Ruimerman et al., 2005) and Smit and Burger (Smit & 
Burger, 2000) provide mathematical descriptions of cancellous bone remodelling 
and of the potential strain distributions around a resorption cavity in cortical bone. 
They suggest that strains sensed by osteocytes within resorption cavities could 
account for subsequent activation of osteoclasts and osteoblasts. Additionally, 
based on the microanatomy of newly formed bone packages during cancellous 
bone remodelling, Erben (Erben, 2015) proposes that self-regulating mechanism are 
involved in the refilling control of the resorption cavity. In this model, the resorption 
cavity created by osteoclasts results in mechanical weakening of the structural 
element and thus, in increased strain around the resorption cavity under constant 
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loading conditions. The increased strain is detected by osteocytes entrapped in the 
underlying bone matrix. When the strain exceeds a certain threshold, the osteocytes 
initiate bone formation by secreting osteogenic signals through the canalicular 
network opened by osteoclastic bone resorption. After osteoblastic bone formation 
has started, because the underlying osteocyte canaliculi system is sealed by the new 
cement line, it is the newly built osteocyte–osteoblast network that detects strain. In 
addition, newly formed bone is less mineralized and has, therefore, different material 
properties compared with the higher mineralized surrounding old bone. It is likely that 
the differences in material properties between old and new bone affect strain 
energy distribution within the newly formed bone package and thus, 
mechanosensing of matrix-embedded osteocytes. Once the mechanical strain 
within the newly built bone structural unit falls below a certain threshold, bone 
formation stops (Erben, 2015).  
These provocative biomechanical strain-driven models challenge the notion 
of hemiosteonal remodelling with predetermined BMUs acting during cancellous 
bone remodelling. Indeed, they suggest that osteoclastic bone resorption and 
osteoblastic bone formation are not directly associated but rather indirectly linked 
through mechanosensing osteocytes.  
 
1.3.3. Regulation of bone remodelling 
 
The sensitive balance between bone resorption and bone formation rates is 
maintained through the action of various interrelated factors such as genetic, 
mechanical, vascular, nutritional, hormonal and local determinants. 
Genetic factors determine between 60 and 80 % of the bone mass. In 
humans, black population has greater bone mass than Caucassians, who in turn 
have higher mass than Asians. Also, daughters of mothers with osteoporosis are more 
predisposed to developing this condition themselves (Grant & Ralston, 1997). Bone 
tissue adapts its structure in response to the mechanical loading, one of the major 
driving forces in remodelling. Physical activity is essential for the correct development 
of the bone. It is considered that muscular action transmits tension to the bone, 
which is detected by osteocyte network, and that new trabeculae tend to align with 
maximum stresses in many bones. Loading improves bone strength by influencing 
collagen alignment as new bone is being formed. In cortical bone tissue, regions 
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subjected to predominantly tensile stresses have a higher percentage of collagen 
fibers aligned along the bone long axis. In regions of predominant compressive 
stresses, fibers are more likely to be aligned transverse to the long axis. On the other 
hand, the absence of muscular activity has an adverse effect on bone by 
accelerating its resorption.  
Vascularization is a prerequisite in the first phase of ossification since it supplies 
blood cells, oxygen, minerals, ions, glucose, hormones, and growth factors. In 
endochondral ossification, blood vessels invade the cartilage, allowing later 
resorption via the osteoclasts originating from the nearby vessels. In the same way, 
angiogenesis is one of the first events in the repair of fractures and bone 
regeneration. 
Lastly, nutritional factors such as caffeine, alcohol, excess salt and smoking 
constitute risk factors for lowering bone mineral density. On the other hand, calcium 
uptake accompanied by sufficient vitamine D levels contributes to systemic calcium 
homeostasis, this impacting the mobilization of calcium stores from the skeleton.  
 
1.3.3.1. Systemic regulators of bone remodelling 
 
Normal development of the skeleton is conditioned by the correct activity of 
the endocrine system. The main hormones that regulate bone metabolism are 
summarized in Table 1., with PTH, calcitonin, and vitamin D being the most prominent 
ones that regulate the bone minerals (calcium and phosphorus). 
 
Table 1. Hormones involved in the regulation of bone remodelling. 
Increase bone formation growth hormone, vitamin D metabolites, androgens, 
insulin, low-dose PTH/PTHrP, progesterone 
Decrease bone formation glucocorticoids 
Increase bone resorption PTH/PTHLH, glucocorticoids, thyroid hormones, high-dose 
vitamin D 
Decrease bone resorption calcitonin, estrogens 
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Acting on both bone resorption and formation, thyroid hormones are critical 
for the maintenance of normal bone remodelling. Firstly, favoring the synthesis of IGF-
I, they stimulate the synthesis of the osteoid matrix and its mineralization. Secondly, 
increasing the number and activity of osteoclasts, a contrary effect is produced. The 
clinical manifestation of this effect is the bone loss occurring in hyperthyroidism (Kini 
& Nandeesh, 2012). 
Parathyroid hormone (PTH) controls the homeostasis of calcium and 
phosphorous by direct action on the bone and the kidneys, and indirectly on the 
intestine. It is produced by the parathyroid glands in response to hypocalcaemia. Its 
skeletal effects are mediated through the osteoblast, which are the major expressers 
of PTH receptors in bone. PTH is a potent stimulator of bone resorption and exerts 
dual effects on bone formation. High concentrations of PTH result in an inhibition of 
collagen synthesis. Plasma PTH tends to increase with age, and this may produce an 
increase in bone turnover and a loss of bone mass, particularly of cortical bone. 
Conversely, a prolonged intermittent administration of PTH stimulates bone formation, 
and this is clinically exploited in the treatment of osteoporosis and hypothyroidism 
(Dempster, Cosman, Parisien, Shen, & Lindsay, 1993). 
Calcitonin is a hormone produced by parafollicular C cells of the thyroid and 
other neuroendocrine cells. It is an inhibitor of bone resorption through the reduction 
of the number and activity of osteoclasts. However, this action is rather transitory 
since osteoclasts seem to become insensitive to calcitonin within a few days (Kini & 
Nandeesh, 2012). 
Vitamin D is a steroid hormone that favours bone mineralization by stimulating 
the intestinal absorption of calcium and phosphorous. It is necessary for normal 
growth of the skeleton (Raisz, 1993). It comes from both an endogenous (vitamin 
D3/cholecalciferol) and an exogenous (vitamin D2/ergocalciferol) supply. The 
endogenous form of vitamin D, (cholecalciferol) is synthesized in the skin from the 
cholesterol metabolite 7-dehydrocholesterol under the influence of ultraviolet 
radiation. The exogenous form of vitamin D (ergocalciferol) is produced by ultraviolet 
irradiation of the plant sterol ergosterol and is available through the diet. Both forms 
of vitamin D require further metabolism to be activated. Vitamin D regulates the 
expression of several bone proteins, notably osteocalcin by promoting its gene 
transcription. It has also bidirectional effects on the transcription of type I collagen 
and alkaline phosphatase. 
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Concerning sex hormones, androgens have an anabolic effect on bone 
through the stimulation of the osteoblasts. Likewise, they act as mediators of the 
growth hormone in puberty. Androgens increase cortical bone size via stimulation of 
both longitudinal and radial growth. While androgen deficiency is associated with 
lower bone density, administration of testosterone in young people before the 
closure of the epiphyses increases bone mass. In the same way, women with an 
excess of androgens present higher bone densities. Androgens present a dual effect 
on endochondral bone formation. Indeed, at the start of puberty, they stimulate 
endochondral bone formation, whereas they induce epiphyseal closure at the end 
of puberty. This effect of androgens may be important because bone strength in 
males seems to be determined by relatively higher periosteal bone formation and 
therefore, greater bone dimensions relative to muscle mass at older age. Estrogen 
receptors have been described in human osteoblasts, osteocytes, and osteoclasts. 
They are essential for the closure of the growth plates and have an important role in 
the development of the skeleton. Estrogens can affect bone formation by increasing 
the number and function of osteoblasts. On the other, they can reduce resorption. 
Several studies have found that estrogens can increase the levels of OPG, an 
inhibitor of osteoclastic differentiation. By doing so, they may play an important role 
in the regulation of osteoclastogenesis (Hofbauer et al., 1999). Alternatively, 
estrogens may enhance local factors involved in bone formation and inhibit those 
that result in its impairment. For this reason, estrogen deficiency during menopause 
constitutes the most important pathogenic factor in bone loss associated with 
osteoporosis. Lastly, loss of estrogens or androgens increases the rate of bone 
remodelling by removing restraining effects on osteoclastogenesis. This also causes a 
focal imbalance between resorption and formation by prolonging the lifespan of 
osteoclasts and shortening the lifespan of osteoblasts (Kini & Nandeesh, 2012). 
Called “the pregnancy hormone”, progesterone has an anabolic effect on 
bone, either directly through the osteoblasts that possess progesterone receptors, or 
indirectly through a competition for the binding of glucocorticoids to their 
osteoblastic receptors. 
Indeed, glucocorticoids are indispensable for bone cell differentiation during 
development, but their greatest postnatal effect is to inhibit bone formation (at high 
doses, they have a catabolic effect on bone), since they inhibit the synthesis of IGF-I 
by the osteoblasts and directly suppress BMP-2, critical factors in osteoblastogenesis. 
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This is the major mechanism in glucocorticoid-induced osteoporosis. Indirect effects 
of glucocorticoids on calcium absorption and steroid hormone production may, 
however, increase bone resorption (Manolagas, 2000).  
The growth hormone acts directly on the osteoblasts. It stimulates their activity, 
this leading to an increased synthesis of collagen, osteocalcin, and alkaline 
phosphatase. An indirect action is produced through the upregulation of IGF-I and II 
synthesis by the osteoblasts. In turn, these two factors further stimulate the 
proliferation and differentiation of premature osteoblasts (Hull & Harvey, 1998; Rosen 
& Donahue, 1998). 
The adipocyte-derived hormone leptin binds to its receptors in hypothalamic 
region and, via the sympathetic nervous system, activates β2-adrenergic receptors 
situated on osteoblast surface. The activation of these receptors is adverse to 
osteoblastic proliferation and reduces the rate of bone formation (Fu et al., 2005). On 
the opposite, they switch on the activating transcription factor 4 (ATF4) and stimulate 
RANKL expression, this favouring the bone resorption (Takeda et al., 2008). 
Lastly, Insulin stimulates bone matrix synthesis both directly and indirectly by 
increasing the hepatic synthesis of IGF-I. 
 
1.3.3.2. Local regulators of bone remodelling 
 
Growth factors, cytokines, and bone matrix proteins are implicated as 
modulators in local bone metabolism (Fernández-Tresguerres-Hernández-Gil et al., 
2006). 
 
Growth factors 
Bone contains a large number of growth factors. These are polypeptides 
produced by bone cells themselves or coming from extraosseous tissue, and which 
act as modulators of cellular functions including proliferation, and differentiation. 
Among the most abundant are the IGFs (Fraher, 1993; Hakeda et al., 1996; Rosen & 
Donahue, 1998) , TGF-β, and the related family of BMPs that have important 
functions not only in remodelling but also in skeletal development. Other growth 
factors, such as PDGF, PTHLH, and FGF may play an important role in physiologic 
remodelling, and an even more important role in skeletal repair. 
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IGF-I and IGF-II are synthesized by the liver and osteoblasts, and these factors 
are found in high concentrations in the osteoid matrix (Cohick and Clemmons 1993). 
They stimulate collagen synthesis by increasing the number and function of the 
osteoblasts. They circulate linked to IGF-binding proteins (IGFBP), which in turn can 
exercise stimulatory or inhibitory effects on bone (Conover 2008). IGFs synthesis is 
upregulated by growth hormone, estrogens, and progesterone, while the 
glucocorticoids inhibit it. They also mediate osteoblast-osteoclast interactions and 
actively participate in bone remodelling (Hill et al. 1995). IGF-II is the most abundant 
factor in the bone matrix and it plays an important role during embryogenesis 
(Canalis et al. 1989; Mohan and Baylink 1991). 
TGF-β is the second most represented superfamily in bone tissue. These 
proteins are latently present in the matrix, and are activated during osteoclastic 
resorption. TGF-β is a potent stimulator of bone formation, promoting osteoblastic 
differentiation and the synthesis of the osteoid matrix. Conversely, it inhibits the 
synthesis of proteases, especially the matrix metalloproteinases (MMPs) that degrade 
bone organic matrix (Bonewald and Dallas 1994). TGF-β inhibits bone resorption by 
reducing the formation and the differentiation and the activity of osteoclasts, as well 
as stimulating their apoptosis (Baylink et al. 1993). 
BMPs are comprised in the TGF-β family as a group of 15 proteins able to 
achieve the transformation of connective tissue into bone tissue. Thus, they are 
considered as osteoinductive factors (Sakou 1998). They are highly abundant in 
bone tissue and during embryogenesis; they participate in the formation of bone 
and cartilage. They stimulate the differentiation of the mesenchymal stem cells 
toward different cell lines (adipose tissue, cartilage, bone) (Yamaguchi et al. 2000). 
They strongly promote osteoblastic differentiation and they are believed to inhibit 
osteoclastogenesis (Canalis et al. 2003).  
PDGF, on one side stimulates protein synthesis by osteoblasts and, on the 
other, favors bone resorption. Its other effects favour scarring since it stimulate 
fibroblast and smooth muscle cells proliferation, neovascularization, as well as 
collagen synthesis (Nash et al. 1994). 
FGF has an anabolic effect on bone, as it is a mitogen for osteoblasts, vascular 
endothelial cells, and fibroblasts. For example, it is known that mutations in FGF 
receptors produce alterations in the craniofacial skeleton such as achondroplasia, 
Apert’s syndrome, and Crouzon’s syndrome (Marie 2003). 
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Epidermal growth factor (EGF) is a powerful mitogen for cells of mesodermic 
or ectodermic origin. It has a dual formative and destructive action, although the 
latter is the most well known. 
VEGF induces angiogenesis and vascular endothelial proliferation. It produces 
vasodilation and an increase in vascular permeability. It is produced upon hypoxia 
and is currently considered as one of the key factors in the first phases of fracture 
repair, for bone regeneration, and in tumor growth (Kini & Nandeesh, 2012). 
Granulocyte / macrophage - colony stimulating factor (GM-CSF) is important 
in osteoclastogenesis and may play a role in the pathogenesis of osteopetrosis. 
Osteoblasts and medullar stromal cells produce M-CSF, an essential factor 
that is required for osteoclastogenesis initiation and the formation of giant 
multinucleated cells. However, it has no effect on osteoclastic activity. 
Concerning TNF, in vitro it stimulates resorption activity and consequently, it 
has been related with bone loss in arthritis and in periodontal disease. 
 
Cytokines 
Through both autocrine and paracrine effects, polypeptides synthesized in 
lymphocytic and monocytic cells play an important role in immunological response, 
inflammation, and hematopoiesis.  The following are the most important in bone.  
(a) Interleukin 1 (IL-1) directly increases osteoclastic resorption through the 
stimulation of preosteoclastic cells proliferation and differentiation. It also enhances 
osteoclasts activity, while inhibiting their apoptosis (Compston 2001). More 
specifically, three different related molecules (IL-1 a, IL-1 b, and their inhibitor IL-1 
receptor antagonist) act both directly and indirectly on resorption through the 
synthesis of prostaglandins. 
(b) Interleukin 6 (IL-6) stimulates bone resorption and appears to be 
implicated in the development of Paget’s disease (Roodman 1999). It is believed to 
play an important role during the initial stages of osteoclastogenesis and it is 
produced in response to PTH, IL-1, and vitamin D. 
(c) Interleukin 11 (IL-11) is produced in bone marrow and also induces 
osteoclastogenesis. 
(d) Prostaglandins (PGs), particularly prostaglandin E2 (PGE2), stimulate bone 
resorption (Kawaguchi et al. 1995). This cytokine could also be important in 
inflammatory bone loss. The first step in PGE2 synthesis is mediated by an enzyme 
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called cyclooxygenase 2 (COX2), and inhibitors of this enzyme can prevent bone 
formation in response to mechanical stress in animals. PGE2 may be required for 
exercise-induced bone formation. 
(e) Leukotrienes are another set of lipid molecules that appear to regulate 
bone remodelling.  
 
Matrix proteins 
Since matrix proteins are found in concentrations about 1,000 times higher 
than growth factors, they could play a more pivotal role in the regulation of the 
different bone cells functions, and thus in bone remodelling (Horowitz 2003). For 
example, collagen I is one of the earliest markers that regulate osteoprogenitor cells.  
Additionally, alkaline phosphatise (ALP) is a surface protein that could participate in 
the regulation of the proliferation, migration, and differentiation of osteoblastic cells. 
Lastly, osteonectin, fibronectin, and osteocalcin promote the migration, the 
attachment, and the activation of bone cells. 
 
1.3.3. Markers of bone metabolism 
 
Biochemical markers provide useful dynamic informations about the turnover 
of bone tissue, and they are used in diagnosis and management of different 
metabolic bone diseases. They are usually classified according to the metabolic 
process they are considered to reflect. Most biochemical indices of bone resorption 
are collagen breakdown products such as hydroxyproline or the various collagen 
cross-links and telopeptides. Other markers of bone resorption include non-
collagenous matrix proteins such as bone sialoprotein (BSP), or osteoclast-specific 
enzymes like TRAP or CTSK. In contrast, markers of bone formation are either by-
products of collagen neosynthesis (e.g. N- and C-terminal propeptides), or 
osteoblast-related proteins such as osteocalcin (OCN) and alkaline phosphatase 
(ALP).  
However, this distinction is not as sharp as it may appear since certain marker 
components reflect both bone formation and bone resorption (e.g. hydroxyproline, 
certain OC fragments). Furthermore, most of the molecules used as markers of bone 
turnover are also present in tissues other than bone, and non-skeletal processes may 
therefore influence their circulating or urinary levels. Finally, changes in markers of 
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bone turnover are not disease specific, but reflect alterations in the metabolism of 
the entire skeleton independently of the underlying cause (Seibel, 2005). 
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2. Bone tissue physiopatology 
 
2.1. Bone strength and disease 
 
Bone strength depends on several structural properties. The bone mass 
accounts for 50–70% of bone strength (Pocock et al. 1987) and peak bone mass is 
determined largely by genetic factors, with contributions from nutrition, endocrine 
factors, physical activity, and health during growth. Bone geometry and composition 
are important as well. The strength of bone increases by the radius of the involved 
bone raised to the fourth power. Consequently, larger bones are stronger than 
smaller bones with the equivalent bone mineral density (BMD). On the other hand, at 
a given skeletal site, the amount and proportion of trabecular and cortical bone 
independently affect bone strength.  
Bone strength can be compromised by abnormalities in bone 
metabolism/remodelling. Subsequently, a variety of skeletal disorders appear such as 
fractures, osteomalacia/rickets, vitamin D deficiency, Paget’s disease, or 
osteoporosis. Bone tissue can be weakened by mutations occurring in certain bone-
typical proteins (e.g., collagen defects in osteogenesis imperfecta, impaired g-
carboxylation of gla proteins), but also by fluoride therapy, or hypermineralization 
states (Kini & Nandeesh, 2012). Regarding bone metabolism, cytokines such as IL- 1, 
IL-6, and TNF, as well as growth factors, have been implicated in pathologic 
responses, particularly in osteoporosis associated with oestrogen deficiency, 
hyperparathyroidism, and Paget’s disease (Lorenzo, 1991; Mills & Frausto, 1997; 
Papanicolaou et al., 1998; Raisz, 1999). 
 
2.2. Fracture healing 
 
One of the notable characteristics of bone tissue is its potential for repair in 
response to injury or surgical treatment. Because of their great importance in 
orthopaedic, maxillofacial, and periodontal treatment, a great effort is taken in 
understanding the basis of these regeneration mechanisms. 
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2.2.1. Fracture repair 
 
Fracture repair is a well-orchestrated multistage process conducted by 
numerous cell types, growth factors, and the extracellular matrix. In fracture healing, 
the pathway of normal embryonic development of bone is recapitulated through 
the coordinated and precisely timed activation of cells originating from the cortical 
bone, periosteum, bone marrow and surrounding soft tissue (Ferguson et al., 1999; 
Gerstenfeld et al., 2003). Most fractures heal by the combination of both 
intramembranous and endochondral ossification, with the later one being the 
predominant form (Ai-Aql, 2008). Endochondral bone formation usually occurs 
externally to the periosteum in regions that are mechanically less stable and 
immediately adjacent to the fracture site. On the other hand, intramembranous 
ossification that forms hard callus occurs internal to the periosteum at the proximal 
and distal edges of the callus (Dimitriou et al., 2005) The eventual bridging of hard 
callus areas across the central fracture gap, which helps to regain bone 
biomechanical functions, is the first step in defect stabilization (Gerstenfeld et al., 
2006). Fracture repair can be divided into four overlapping phases presented in 
Table 2. (Ai-Aql, 2008). Firstly, an immediate inflammatory response appears at the 
injury site. Inflammatory cytokines are believed to initiate the repair cascade 
following an injury. Secondly, MSCs are recruited to the site where they differentiate 
into osteoblasts and chondrocytes, the later ones producing the cartilage. Thirdly, 
the cartilage matrix is mineralized and subsequently resorbed. This process is followed 
by primary bone formation performed by osteoblasts. At last, the process of bone 
remodelling begins, in which the initial bony callus is reshaped by resorption and 
secondary bone formation, which restores the anatomical structures that can 
support greater mechanical loads (Gerstenfeld et al., 2003). 
Signalling molecules that can be distinguished into three main groups tightly 
regulate the underlying biological processes in each of these stages: pro-
inflammatory cytokines, TGF-β superfamily members, and angiogenic factors (Peng 
et al., 2005).  
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Table 2. Summary of the multiple stages of fracture healing and the accompanying 
expression of signalling molecules. (Based on published results from Kon et al., 2001; 
Cho et al., 2002; Gerstenfeld et al., 2003 ; Dimitriou et al., 2005 and taken from Ai-Aql, 2008). 
 
Stage of Fracture Repair Biological Processes Expression of Signalling Molecules and their Proposed 
Functions  
 
 
 
 
Inflammation 
 
Hematoma 
 
 
Inflammation 
 
 
Recruitment of 
mesenchymal stem cells 
 
IL-1, IL-6, and INF-a play a role in initiating the repair 
cascade. 
 
TGF-β, PDGF, and BMP-2 expression increases to 
initiate callus formation. 
 
GDF-8 is restricted to day 1, suggesting its role in 
controlling cellular proliferation.  
 
 
 
 
 
 
Cartilage Formation and 
Periosteal Response 
 
 
Chondrogenesis and 
endochondral 
ossification begins 
 
Cell proliferation in 
intramembranous 
ossification 
 
Vascular in-growth  
 
Neo-angiogenesis 
 
TGF-β2, β3, and GDF-5 peak due to their involvement 
in chondrogenesis and endochondral hone 
formation. 
 
  
BMP-5 and -6 rise.  
 
 
 
Angiopoietins and VEGFs are induced to stimulate 
vascular in growth from vessels in the periosteum.  
 
 
 
 
 
 
 
 
Cartilage Resorption and 
Primary Bone Formation 
 
 
Phase of most active 
osteogenesis  
 
Bone cell recruitment 
and woven bone 
formation  
 
 
 
Chondrocyte apoptosis 
and matrix proteolysis 
Osteoclast recruitment 
and cartilage resorption  
 
Neo-angiogenesis  
 
TNF-a rises in association with mineralized cartilage 
resorption. 
 
This promotes the recruitment of mesenchymal stem 
cells and induces apoptosis of hypertrophic 
chondrocytes. 
RANKL and MCSF rise in association with mineralized 
cartilage resorption.  
 
BSIP-3, -4, -7, and -8 rise in association with the 
resorption of calcified cartilage. They promote 
recruitment of cells in the osteoblastic lineage. 
 
 
BMP-5 and -6 remain high during this stage, 
suggesting a regulatory effect on both 
intramembranous and endochondral ossification.  
 
VEGFs ace up-regulated to stimulate neo-
angiogenesis.  
 
 
 
 
Secondary Bone Formation 
and Remodelling 
 
Bone remodelling 
coupled with osteoblast 
activity 
 
Establishment of marrow 
 
IL-1 and IL-6 rise again in association with bone 
remodelling, whereas RANKL and MCSF display 
diminished levels 
 
Diminished expression of members of the TGF-β 
superfamily. 
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2.2.1.1. Pro-inflammatory cytokines in fracture healing 
 
Macrophages, inflammatory cells, and cells of mesenchymal origin secrete 
pro-inflammatory cytokines that are active for a limited time period following an 
injury. Later on, at a mid-stage in healing, some of the inflammatory cytokines are still 
upregulated and stimulate the osteoclastogenesis to remove mineralized cartilage. 
Next, other cytokines are induced at the final stage of healing when bone 
remodelling is triggered (Ai-Aql, 2008).  
Interleukins-1 and 6 (IL-1 and IL-6) and TNF-α have been shown to play a role in 
initiating the repair cascade. They recruit inflammatory cells, enhance extracellular 
matrix synthesis, and also stimulate angiogenesis (Kon et al., 2001). Their expression 
peaks within the first 24 hours following the injury, and then declines rapidly to nearly 
undetectable levels by day 3 (Cho et al., 2002; Kon et al., 2001). IL-1and IL-6 are 
again upregulated, in association with bone remodelling during the stage of 
secondary bone formation (Gerstenfeld et al., 2003). 
After the day 3 decline, the expression of TNF-α rises again in the later stages, 
in association with mineralized cartilage resorption. During this stage of fracture 
healing, TNF-α stimulates osteoclast function, promotes the recruitment of MSCs and 
induces the apoptosis of hypertrophic chondrocytes. Its absence delays the 
resorption of mineralized cartilage and consequently, prevents the primary formation 
of new bone. In pathological situations where TNF-α is over-expressed, such as 
diabetic healing, there is a premature cartilage removal that results in a deficient 
bone formation and healing (Kayal et al., 2007). 
In addition, the expression of RANKL, OPG, and MCSF is upregulated after the 
initial injury and during the resorption of mineralized cartilage. Afterwards, during the 
phase of secondary bone formation and bone remodelling, the expression of RANKL, 
OPG, and MCSF is downregulated (Gerstenfeld et al., 2003). 
 
2.2.1.2. Transforming growth factor beta superfamily in fracture repair 
 
During fracture healing, specific members of this family, such as BMPs (2-8), 
growth differentiation factors (GDFs) (1, 5, 8, and 10), and TGF-β isoforms promote 
various stages of intramembranous and endochondral bone ossification (Cho et al., 
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2002). It has been suggested that BMP-2, 6, and 9 may be the most prominent 
inducers of MSCs differentiation to osteoblasts, while the remaining BMPs promote 
the maturation of already committed osteoblasts (Cheng et al., 2003). 
Mesenchymal cells, osteoblasts, and chondrocytes produce BMPs that trigger 
a cascade of events promoting the formation of cartilage and bone. At the injury 
site, BMPs are largely involved in cellular processes like chemotaxis, mesenchymal 
cell proliferation and differentiation, angiogenesis, and the synthesis of extracellular 
matrix. Suggesting a role in the initiation of the repair cascade, studies of fracture 
healing in mice show maximal levels of BMP-2 expression within 24 hours following the 
injury. Accordingly, Tsuji et al. and Xiong et al. showed that BMP-2 expression is 
genetically associated with the maintenance of normal bone mass, and that it is a 
prerequisite for post-natal bone repair. Interestingly, BMP-2 does not appear to be 
necessary for normal embryological bone formation. Other in vitro studies examining 
bone marrow MSCs have shown that BMP-2 controls the expression of several other 
BMPs, while blocking its activity results in MSCs fail to differentiate into osteoblasts (Ai-
Aql, 2008). 
BMP- 3, 4, 7, and 8 show a restricted period of expression during fracture 
healing (days 14 to 21), when the resorption of mineralized cartilage and 
osteoblastic recruitment are the most active. By contrast, implying that they have a 
regulatory effect on both intramembranous and endochondral ossification, BMP-5 
and 6 are constitutively expressed from day 3 in fracture healing (Cho et al., 2002). 
BMP antagonists also play an important role in fracture healing. It has been 
reported that the expression of noggin, a blocking agent for BMP-2, 4, and 7, is 
modulated during fracture healing (Yoshimura et al., 2001). The pattern of noggin 
expression is similar to that of BMP-4, suggesting that the noggin/BMP-4 balance 
could be an important factor in the regulation of callus formation during fracture 
healing. On the other hand, in the absence of noggin, an excess of bone and 
cartilage formation occur during the development, indicating that noggin plays an 
important role in limiting the formation of new tissue (Ai-Aql, 2008). 
TGF-β, which induces the expression of extracellular matrix proteins, is thought 
to play an important role in chondrogenesis and endochondral bone formation 
(Barnes, Kostenuik, Gerstenfeld, & Einhorn, 1999). All three isoforms of TGF-β are 
involved in fracture repair. They are initially produced by degranulated platelets 
after the injury, which suggests their involvement in the initiation of callus formation.  
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At later stages, they are also produced by osteoblasts and chondrocytes, enhancing 
the proliferation of these cells (autocrine stimulation), as well as MSCs and pre-
osteoblasts multiplication (Lieberman, Daluiski, & Einhorn, 2002). In a mouse model, 
the expression of TGF-β1 remains constant throughout the fracture healing process, 
whereas the expression of TGF-β2 and TGF-β3 peaks on day 7 post-fracture. This 
suggests that TGF-β2 and TGF-β3 may play a more important role during fracture 
healing, since their expression peaks during the critical phase of cartilage formation 
(Cho et al., 2002). 
 
2.2.1.3. The role of angiogenic factors in fracture repair 
 
Optimal bone healing is highly dependent on adequate vascularization and 
therefore, the development of new blood vessels is an imperative in fracture repair. 
In endochondral healing, the transition from a cartilaginous tissue to new bone 
formation is tightly linked to angiogenesis. This transition includes chondrocyte 
apoptosis, cartilaginous matrix degradation, vascularization of the repair site, 
osteogenic cell recruitment and differentiation, and bone matrix production. 
Disruption of any one of these steps leads to delayed or impaired healing. For 
example, disruption of cartilaginous matrix degradation through the loss of MMP-9 
expression leads to a massive expansion of the hypertrophic zone (Vu et al., 1998). 
Moreover, in mmp-9-/- mice, the delay observed in fracture repair can be rescued 
by the addition of exogenous VEGF, suggesting that angiogenesis is linked to the 
apoptosis of chondrocytes (Colnot et al., 2003). 
Embryonic angiogenesis is regulated by two pathways, a vascular endothelial 
growth factor-dependent pathway and an angiopoietin-dependent pathway (Suri 
et al., 1996). Both pathways are believed to be activated during fracture repair.  
It has been demonstrated that VEGFs signalling plays a central role in neo-
angiogenesis and in endochondral bone formation (Street et al., 2002). After an 
injury, existent vessels are first dissociated into a pool of endothelial cells that are kept 
in growth arrest by the action of angiopoietin-2 and vascular endothelial growth 
inhibitor. In the stage of cartilage resorption and primary bone remodelling, VEGFs 
levels rise. This increase stimulates the proliferation of endothelial cells progenitor pool 
and promotes the participation of these cells in neo-angiogenesis (Ai-Aql, 2008). 
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Osteoblasts are known to express considerable amounts of VEGFs and therefore, 
they have been implicated as primary regulators of angiogenesis in fracture healing. 
Moreover, several studies have shown that BMPs stimulate the expression of VEGFs 
and their receptors in different cell types, suggesting a BMPs/VEGF interplay that 
promotes the formation of new bone (Deckers et al., 2002). The VEGF gene family 
members detectable during fracture healing are VEGF-D, VEGF-A, and VEGF-C . The 
VEGF gene family members are expressed throughout the chondrogenic phase of 
healing, reaching maximal levels of expression during the late phases of calcification 
of the cartilage tissues, at the time when resorption is initiated (Ai-Aql, 2008). 
A second pathway involves vascular morphogenetic proteins angiopoietin-1 
and 2 that are associated with the formation of larger vessels and the development 
of collateral branches from existing vessels. The expression of angiopoietin-1 is 
induced during the initial stages of fracture repair suggesting that, in the periosteum, 
initial vascular in-growth from vessels plays an important role in the repair process. 
Nevertheless, the role of angiopoietins in fracture repair is not yet understood as well 
as for the VEGF family members (Ai-Aql, 2008). 
Platelet-derived growth factor (PDGF) is a third, and more distantly related 
member of the angiogenic signalling molecules family. PDGFs are secreted from the 
alpha granules of platelets, endothelial cells, vascular smooth-muscle cells, and 
macrophages. Because PDGFs enhance osteoblast migration and proliferation, and 
are secreted from osteoclasts, they have been proposed as key factors in bone 
remodelling ((Kubota, Sakikawa, Katsumata, Nakamura, & Wakabayashi, 2002) 
Accordingly, in vitro, PDGF enhances the formation of a mineralizing matrix. In vivo, it 
enhances bone formation in periodontal regeneration. Systemic administration of 
PDGF in ovariectomized rats results in increased bone density and strength. PDGF 
can be detected in the callus tissue obtained from healing fractures during bone 
formation, and exogenous PDGF enhances callus density and bone formation 
associated with healing osteotomies. In contrast, along with TGF-β, fibroblast growth 
factor-β, BMP-2, and BMP-14, PDGF is lacking in fractures that do not heal properly, 
suggesting that PDGF is an essential component of normal fracture healing (Ai-Aql, 
2008). 
The relationship between the expression of some angiogenic factors and pro- 
inflammatory cytokines has also been studied. In mice lacking TNF receptors, the 
expression of angiopoietins, metalloproteinases, and vascular endothelial growth 
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inhibitor is diminished during fracture healing. However, the expression of VEGF family 
members that directly promote new vessel formation is not inhibited (Ai-Aql, 2008).  
 
2.2.2. Distraction osteogenesis 
 
Distraction osteogenesis (DO) is a surgical model used: (i) to bridge gap 
defects such as non-healing fractures; (ii) to treat disease conditions where there has 
been a net destruction of the bone tissues (osteomyelitis); (iii) to augment the 
alveolar bone around lost teeth; (iv) to correct congenital skeletal deformities where 
there is a deficiency in the original structure of the skeleton (Ai-Aql, 2008). With a view 
to creating new bone, it is a controlled procedure that initiates a regenerative 
process and uses mechanical strain to enhance biological responses of the injured 
tissue. Compared to fracture healing, the main differences are three modes of 
ossification that take place during DO. Although endochondral ossification occurs 
during early stages of DO, intramembranous bone formation is the predominant 
mechanism of ossification, particularly in later stages. A third form of ossification is 
called ‘transchondroid bone formation’, where chondroid bone is formed directly by 
chondrocyte-like cells, with a gradual transition from fibrous tissue to bone (Yasui et 
al., 1997; Choi, Chung, Cho, & Yoo, 2002). Cartilage that forms during DO is usually 
observed at the level of the periosteum, but not between the ends of the cortices 
within the distraction gap.  
As in the case of fracture healing, biological mechanisms involved in 
distraction osteogenesis are governed by complex molecular interactions that 
involve local and systemic factors (pro-inflammatory cytokines, TGF-β superfamily, 
angiogenic factors), and cells that are recruited to the surgical site from the 
surrounding tissues and circulation. Angiogenesis was shown to contribute 
significantly to new bone formation in DO. Indeed, results from a study conducted on 
a rat model revealed at the surgical site an increased expression of numerous 
angiogenic factors including angiopoietin (Ang) 1 and 2, Tie 1 and 2 receptors, 
VEGF-A and D, VEGF receptor 2 and neuropilin 1 (Ai-Aql, 2008). 
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2.3. Osteoporosis 
2.3.1. Medical and economical toll 
 
Osteoporosis is the most common bone disease in humans, representing a 
major public health problem as outlined in “A Report of the Surgeon General (2004)” 
by Bone Health and Osteoporosis (Cosman, Lindsay, LeBoff, Jan de Beur, & Tanner, 
2014). It is a silent disease until it is complicated by fractures that occur following 
minimal trauma or, in some cases, with no trauma. For example, osteoporosis is 
responsible for weakening of the structural strength of bone to the extent that normal 
daily activities can create stress that exceeds the vertebra’s strength, resulting in 
osteoporosis-induced vertebral compression fractures. The incidence and associated 
socio-economic costs of these fractures are very high, with about 440,000 new cases 
per year in the European Union countries and 700,000 in the United State (EPOS 
Group, 2002). Annually in the U.S., two million fractures are attributed to osteoporosis, 
causing more than 432,000 hospital admissions, almost 2.5 million medical office visits, 
and about 180,000 nursing home admissions (Cosman et al., 2014). Estimated direct 
annual costs reach US$440 million and US$750 million in the EU countries and in the 
United States, respectively (Johnell, 2003; Melton, 1997) Moreover, increasing life 
expectancy will probably lead to a severe rise in the human and financial costs 
associated with osteoporosis. Osteoporotic fractures often lead to high degree of 
morbidity, a decrease in both general and health-related quality of life, an increase 
in various psychological disorders, and an increase in mortality rate as well (Lewis, 
2006). Osteoporosis can be prevented, diagnosed and treated before fractures 
occur. Importantly, even after the first fracture has occurred, there are treatments to 
decrease the risk of further fractures. Usual recommendations for the management 
of osteoporosis apply to postmenopausal women and men age 50 and older 
(Cosman et al., 2014). After 50 years old, 40% of women are osteoporotic and one in 
three women older than 50 years will develop at least one osteoporotic fracture. 
Therefore, it is rightly regarded as a major health problem. 
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2.3.2. Pathogenesis of osteoporosis 
 
Osteoporosis is characterized by low bone mass, disruption of bone 
microarchitecture, and compromised bone strength, these factors increasing the risk 
of fractures. According to the World Health Organisation (WHO) diagnostic 
classification, and measured at the hip or lumbar spine, osteoporosis is defined by a 
bone mineral density (BMD) that is less than or equal to 2.5 standard deviations 
below the mean BMD of a young-adult reference population.  
The most common fractures are those of the vertebrae (spine), proximal femur 
(hip) and distal forearm (wrist). Some notable exceptions are those of the fingers, 
toes, face and skull, which are primarily related to trauma rather than underlying 
weakened bone tissue. Fractures may be followed by full recovery or by chronic 
pain, disability and death. Hip fractures are associated with an 8.4 to 36% excess 
mortality within one year, with a higher mortality in men than in women. Additionally, 
hip fractures are accompanied with a 2.5-fold increased risk of future fractures. 
Approximately 20% of hip fracture patients require long-term nursing home care, and 
only 40% fully regain their pre-fracture level of independence (Cosman et al., 2014). 
Although the majority of vertebral fractures are initially clinically silent, these fractures 
are often associated with symptoms like pain, disability, deformity and mortality. 
Postural changes associated with kyphosis (height-reduction of vertebrae) may limit 
simple physical activities like bending and reaching. Wrist fractures are less disabling 
but can interfere with some activities of daily living as much as hip or vertebral 
fractures. Pelvic fractures and humerus fractures are also common and contribute to 
increased morbidity and mortality. Fractures can also cause psychosocial symptoms, 
most notably depression and loss of self-esteem, as patients grapple with pain, 
physical limitations and lifestyle changes.  
As mentioned before, the process of bone remodelling that maintains a 
healthy skeleton depends on a delicate regulation of osteoblast-osteoclast activity 
and crosstalk. The well-accepted pathophysiological mechanisms for low bone mass 
include prolongation of the life span of osteoclasts and early apoptosis of osteoblasts 
and osteocytes. With aging and menopause, osteoblastic activity decreases. The 
impairment in osteoblast function can be the consequence of cellular senescence, 
but also may be the result of a decreased synthesis or activity of systemic and local 
growth factors. On the other hand, the lack of sex hormones leads to enhanced 
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osteoclastic resorptive activity. In addition, the amount and variety of 
noncollagenous proteins in bone is altered. Taken together, these events result in 
bone loss and disordered skeletal microarchitecture that increase the appearance 
of bone fractures with a risk of death outcome. With the onset of menopause, the 
rate of bone remodelling increases, magnifying the impact of the remodelling 
imbalance. Figure 6 shows the changes within cancellous bone as a consequence 
of osteoporosis; individual trabecular plates are lost, leaving an architecturally 
weakened structure with a significantly reduced mass (Cosman et al., 2014). 
 
Figure 6. Illustration of healthy bone vs. osteoporotic weakened bone structure. 
In vertebrae, the thinning of trabecular bone structure comprises bone strenght, with 
increased risk of fracture (taken from http://www.drwolgin.com/Pages/osteoporosis.aspx). 
 
Other aging-associated factors contribute to an increased risk of osteoporosis-
related fractures. This includes general factors like sex steroid deficiency, as well as 
specific risk factors such as the use of glucocorticoid treatment that causes 
decreased bone formation and bone loss. Since the majority of osteoporotic 
fractures result from falls, it is also important to evaluate risk factors for falling, such as 
personal history of falling, muscle weakness and gait, selected medications, balance 
and visual deficits, and dehydration (American Geriatrics Society, British Geriatrics 
Society and American Academy of Orthopaedic Surgeons Panel on Falls Prevention, 
2001).  
Depending on the cause, two types of osteoporosis are distinguished: primary 
(postmenopausal/senile) and secondary osteoporosis (nutrition, endocrine, drug, 
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malignancy, chronic disease, idiopathic) (Cosman et al., 2014). The loss of bone 
mass and strength can be attributed to: (i) the failure to reach an optimal peak 
bone mass as a young adult; (ii) an excessive resorption of bone after peak mass has 
been attained; (iii) an impaired bone formation during remodelling process. 
Several studies have assessed the mechanisms that regulate osteoporosis 
onset from a genomic point of view. A study by Klein et al. identified the 
lipoxygenase gene Alox15 as a major negative regulator of peak bone mineral 
density in mice. In a more recent report, Liu et al. used the approach of expression 
profiling of circulating monocytes (progenitors of osteoclasts) isolated from patients 
with low BMD. They observed a strong correlation between low BMD scores and the 
upregulation of chemokine receptor 3 (CCR3), histidine decarboxylase and 
glucocorticoid receptor expression. Furthermore, Orlic et al. identified significantly 
enriched pathways in bones of OVX rats. Among bone-specific genes, they 
observed the upregulation of interleukin 7 (IL-7), IL-7 receptor and MMP9 expression, 
while genes such as TGF-β3, procollagen type I and procollagen type VI exhibited a 
significant decrease in their expression. The control animals exhibited marked 
enrichment of IGF-1-related pathways, including IGF-1 receptor pathway, insulin 
signalling pathway, glycogen metabolism, as well as glycolysis and gluconeogenesis. 
Indicating and increased cytokine production in OVX animals, this group showed an 
enrichment of fatty acid metabolism, IL-12 and TNFR2 pathways. In addition, OVX 
animal displayed an enrichment of the caspase pathway that might indicate an 
increased rate of apoptosis. Lastly, pointing to an enhanced protein degradation, 
the proteasome pathway was also significantly enriched following ovariectomy 
(Borovecki et al., 2007; Cosman et al., 2014). 
 
2.3.2. Osteoporosis management 
2.3.2.1. Recommendations for the prevention of osteoporosis 
 
With the objective of strengthening bone, health professionals point out 
several considerations. These include an adequate intake of dietary calcium and 
vitamin D, lifelong participation in regular weight-bearing and muscle-strengthening 
exercise, avoidance of tobacco and excessive alcohol use, and treatment of risk 
factors for falling. National Osteoporosis foundation (NOF) supports 
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sign of impaired bone quality and strength, and a good predictor of new vertebral 
and other fractures. The presence of a single vertebral fracture increases the risk of 
subsequent vertebral fractures 5-fold, and the risk of hip and other fractures 2- to 3- 
fold (Cosman et al., 2014). 
Beside the parameters listed above, different biochemical assays have been 
extensively used as predictive tools in relation to rates of bone loss (total ALP and 
OCN in plasma, hydroxyproline and calcium in fasting urine). They are also useful in 
monitoring the effects of specific anti-osteoporotic treatments (e.g., oestrogens, 
calcitonin and bisphosphonates, or bone-forming agents) in individual patients (Kini 
& Nandeesh, 2012). 
All postmenopausal women and men age 50 and older should be evaluated 
for osteoporosis risk in order to determine the need for BMD testing and/or vertebral 
imaging. Osteoporosis is preventable and treatable during the early phase of the 
disease, but since there are no warning signs prior to a fracture, many patients are 
not being diagnosed in time to receive an effective therapy (Cosman et al., 2014).  
Even though osteoporosis affects a significant number of men, it often remains 
undetected and untreated (Cosman et al., 2014). 
 
2.3.2.3. Current treatments and perspectives 
 
Current FDA-approved pharmacological options for the prevention and/or 
treatment of postmenopausal osteoporosis include: bisphosphonates (alendronate, 
alendronate plus vitamin D, ibandronate, risedronate, zoledronic acid), calcitonin, 
oestrogen, oestrogen agonist/antagonist (raloxifene), tissue-selective estrogen 
complex (conjugated estrogens/bazedoxifene), parathyroid hormone (PTH[1-34], 
teriparatide), and the RANKL inhibitor denosumab (Cosman et al., 2014). None of the 
pharmacological options is considered indefinite in duration, and a comprehensive 
risk assessment should be performed in different stages of disease.  
Due to their pronounced anti-osteoclastic effect, bisphosphonates (BPs) are 
the preferred anti-resorptive agents largely prescribed for osteoporosis prevention 
and treatment. Despite their clinical efficiency, treatment with BPs may be 
associated with complications that are partially due to their mode of administration. 
The major drawbacks resulting from oral administration are: (i) a poor bioavailability; 
(ii) the development of gastrointestinal disorders; (iii) the considerable constraints 
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related to administration modalities that can lead to poor patient compliance. 
However, in patients receiving high doses of BPs by intravenous administration, 
complications such as osteonecrosis of the jaw and low-energy fractures have been 
recently reported (E. Verron & Bouler, 2014).Taking into account the clinical benefit 
of BPs for patients, it is not conceivable to remove them from the anti-osteoporosis 
medication list. Thus, a possible strategy would be to optimize their use or to 
implement alternative modes of administration that are more specific, such as bone 
drug delivery systems. Releasing a controlled dose of BPs directly at the bone site 
that is weakened by osteoporosis, such as the femoral neck or vertebrae, could help 
to circumvent forenamed limitations related to systemic administration. BPs would 
most probably remain localized at the delivery bone site due to their strong affinity 
for hydroxyapatite (E. Verron & Bouler, 2014). Indeed, measurements of released BPs 
locally or at bone sites distant from implants support this hypothesis (Stadelmann et 
al., 2008).  
Although primarily known as a major bone resorption hormone, PTH has been 
approved as a first bone anabolic therapy for treatment of osteoporosis. Despite the 
fact that sustained PTH stimulation results in increased bone resorption, an 
intermittent administration of PTH leads to overall anabolic effect and large increases 
in BMD (Borovecki et al., 2007). In a study using RNA microarrays, Reppe et al. 
analysed frozen bone biopsies of patients with primary hyperparathyroidism. Most of 
the differentially expressed genes represented structural and adhesion proteins, as 
well as proteases and protease regulators indicating an increased bone resorption. 
Remarkably, collagen type I and OCN were significantly increased, pointing to 
possible PTH anabolic action (Reppe et al., 2006). 
Beside pharmacological options, vertebroplasty (VP) and kyphoplasty (KP) are 
two procedures that have been introduced to surgically manage vertebral 
compression fractures. They aim to augment the weakened vertebral body, to 
stabilize it, and to restore as much as possible its normal height while relieving the 
pain. To achieve these goals, and using minimally invasive procedures, a paste of 
adaptable bone cement is carefully injected either directly into the fractured 
vertebral body (VP) or into a cavity created in the fractured vertebral body by the 
inflation of a balloon tamp (KP) (Lewis, 2006).  
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2.4. Other disorders of bone remodelling process 
 
In syndromes like osteopetrosis or osteosclerosis, bone resorption is defective 
because of osteoclast impaired formation and/or function. In these disorders, bone 
remodelling is modified and the architecture of the skeleton can be quite abnormal, 
increasing the risk of fractures (Cosman et al., 2014). 
Another well-known disorder of bone remodelling is Paget’s disease. In this 
disorder, osteoclasts are excessively resorbing and osteoblasts in turn respond by an 
intense irregular new bone formation, often in the form of woven bone. This leads to 
increased bone density, but because of the irregular architecture, bone strength is 
compromised and pathologic fractures are commonly occurring in patients with 
Paget’s disease. It is reported that IL-6, which is implicated in the early phases of 
osteclastogenesis, is linked to Paget’s disease development (Kini & Nandeesh, 2012). 
Osteomalacia is a disorder characterized by impaired mineralization of the 
osteoid, resulting in soft or fragile bones. It typically occurs as a consequence of 
vitamin D diet deficiency, or more commonly, when the body is unable to properly 
absorb and metabolize vitamin D, this resulting in an impaired absorption of calcium. 
In children, it is called rickets and is characterized by obvious skeletal deformities, 
whereas in adults the disease has more subtle manifestations, hence being difficult 
to be diagnosed and distinguished from osteoporosis (Kini & Nandeesh, 2012). 
Osteogenesis imperfecta (OI), also known as Lobstein syndrome, is a 
congenital bone disorder characterized by brittle bones that are prone to fracture. 
Patients affected by OI are born with defective connective tissue, or without the 
ability to make it, usually due to the deficiency of type I collagen. Indeed, most types 
of OI are caused by mutations in the COL1A1 and COL1A2 genes (Rauch & Glorieux, 
2004). 
Both parathyroid hormones and thyroid hormones can stimulate bone 
formation as well as resorption. Although not a direct orthopaedic disorders, 
hyperparathyroidism and hyperthyroidism result in increased bone turnover that is 
sometimes accompanied by a decrease in bone mass. Increased levels of IL-6, a 
stimulating interleukin in bone resorption, have been reported in hyperparathyroidism 
(Kini & Nandeesh, 2012). 
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2.5. Bone metastases 
2.5.1. Generalities 
 
Bone metastases are a common complication of different cancers and occur 
in 65–80% of patients with metastatic breast and prostate cancers (Coleman et al., 
2008) The incidence of bone metastases is also increasing in other cancers, probably 
owing to improved tumour control at primary disease sites. Once they have 
metastasized to bone, tumours are generally considered incurable. After lung and 
liver, bone tissue is the third most common site for metastatic disease and it is more 
prevalent in adult patients (>40 years of age) (Davila, Antoniou, & Chaudhry, 2015). 
More than 600 000 cases of cancer bone metastases are diagnosed every year in 
the USA (Randall, 2014). Some of the notorious complications provoked by bone 
metastases are: fractures, hypercalcaemia, spinal cord compression, immobility, and 
ultimately mortality (Quinn, 2013). 
The special milieu of bone microenvironment provides a fertile soil for many 
cancer types. Most solid tumours metastasize to bone and induce both destructive 
osteolytic and/or bone-forming osteoblastic lesions. Although there is considerable 
bone deposition in osteoblastic lesions, these abnormal structures are weak and are 
subjected to fractures. The distinction between these two types of lesions is not 
absolute, and an individual metastatic lesion can contain both osteolytic and 
osteoblastic components (Krzeszinski & Wan, 2015). 
 Tumour invasion into the bone is tightly associated with osteoclast 
recruitment, resulting in the release of growth factors and calcium from mineralized 
bone matrix. This liberation further enhances tumour growth, forming the ‘vicious 
cycle’ of bone metastases (Weilbaecher et al., 2011). Indeed, when anti-resorptive 
bisphosphonate therapy is applied in patients with bone osteolytic metastases, an 
improved survival rate is observed due to the suppression of bone resorption. In 
addition to the effects on osteoclasts, tumours in the bone microenvironment induce 
the formation of new blood vessels, while recruiting and modulating the function of 
osteoblasts, platelets, myeloid cells, immune and nerve cells. The bone marrow 
compartment also serves as a reservoir for dormant tumour cells that can resist 
chemotherapy, and later emerge again as metastases in bone or other organs 
(Weilbaecher et al., 2011).  
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2.5.2.1. Epithelial to mesenchymal transition (EMT)  
 
Although still under debate, increasing evidence suggest that the EMT process 
is essential for carcinoma cells to undergo fundamental cytoskeleton reorganization, 
which results in the loss of cell cohesiveness and enables certain cancer cells to 
escape from primary disease site (Lamouille, Xu, & Derynck, 2014). 
It is proposed that EMT activators drive tumour cells specifically to the bone. 
Thus, a pro-EMT factor Snail is believed to direct prostate cancer cells to bone and 
stimulate tumour-bone vicious cycle through calcium and RANKL signalling. By 
examining the immunohistochemical expression of EMT markers (i.e., E-cadherin, 
vimentin, NF-kB, Notch-1, ZEB1, and PDGF-D), Sethi et al. identified Notch-1 as a 
signature gene in the EMT involved in prostate cancer bone metastases (Sethi, 
Macoska, Chen, & Sarkar, 2010). In addition, showing that it up regulates the 
expression of the proinvasive factor miR-10b, Croset et al. proposed TWIST1, a well-
known EMT-inducing transcription factor, as an important contributor to breast 
cancer bone metastases (Croset et al., 2014).  
 
2.5.2.2. Degradation of the extracellular matrix (ECM)  
 
The invasion of carcinoma cells requires degradation of ECM, which forms the 
structural framework of most tissues. Several genes related to the ECM degradation 
have elevated expression in highly metastatic tumours (Eckhardt et al., 2005). Various 
types of proteinases are implicated in ECM degradation, with the most prominent 
ones being the Zn2+-endopeptidases MMPs that cleave the constituents of the ECM. 
MMP-2 and 9 are the predominant MMPs responsible for ECM protein degradation, 
and thus play key roles in tumour development, growth, and metastasis (Coussens, 
Fingleton, & Matrisian, 2002). In addition, besides its strong implication in synthesis of 
ECM, TGF-β participates also in ECM degradation (Hubmacher & Apte, 2013).  
 
2.5.2.3. Angiogenesis  
 
After ECM degradation, tumour cells produce angiogenic stimuli that 
endothelial cells into the perivascular space to form new blood vessels (Papetti & 
63 
 
Herman, 2002). As other steps in metastatic cascade, this is also a highly regulated 
process that involves essential signalling factors such as VEGF, VEGF receptors 
(VEGFRs), anti-angiogenic (e.g., thrombospondin-1) and pro-angiogenic factors 
(e.g., HIFs), Notch, and several ECM proteins (Dimova, Popivanov, & Djonov, 2014).  
Endothelial cells that constitute tumour blood vessels have generally weak cell-to-cell 
junctions. This renders them leaky and facilitates cancer cell entrance into new-
formed vessels (intravasation). As an illustration of this, circulating factors found in 
patients with breast cancer bone metastases may promote angiogenesis, 
intravasation and survival of circulating tumour cells (Krzeszinski & Wan, 2015). On the 
other hand, the extravasation of tumour cells at a specific bone site is linked to 
CXCR4, IL-11, OPN, and MMP1 expression. Indeed, in a bone-metastatic model of 
human breast cancer cell line MDA-MB-231, it has been demonstrated that 
combined over-expression of these markers in the parental cell line enhances the 
extravasation of circulating tumour cells into the bone niche (Y Kang et al., 2003). In 
the same line, it was shown that targeting stromal and endothelial cells present the 
bone marrow with the tyrosine kinase inhibitor sunitinib resulted in bone marrow 
vessel leakage, stromal cells apoptosis. By doing so, sunitinib disrupts bone 
colonization by lung cancer cells, as well as the subsequent osteolysis (Weilbaecher 
et al., 2011).  
 
2.5.2.3. Survival in the circulation 
 
 After intravasation, a small percentage of tumour cells is able to survive in the 
circulation, mostly through the expression of various genes, the cooperation with 
other cell types, and the escape from immune system recognition (Krzeszinski & Wan, 
2015). Cooperation with platelets and surface shielding from natural killer (NK) cells 
are thought to be the major approaches that circulating tumour cells use to survive 
and successfully develop into metastases (Palumbo et al., 2007). It has also been 
shown that platelet-derived TGFb, and direct platelet-tumour cell contacts, 
synergistically activate TGFb/Smad and NF-kB pathways in cancer cells, this 
enhancing the metastatic potential of tumour cells (Labelle, Begum, & Hynes, 2011). 
  
 
 
 
 
 
 
 
 
 
F
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2.5.2.4. Homing to the bone  
 
Ample evidences strongly suggest that bone homing of tumour cells depends 
on both tumour-intrinsic traits and various factors supplied by the bone niche itself 
(Krzeszinski & Wan, 2015). Cells at the tumour primary site may produce circulating 
factors that modulate the microenvironment at distant organ sites, thus generating 
pre-metastatic niches conducive to secondary tumours localization and 
colonization. In preclinical melanoma and lung cancer models for example, VEGFR1-
positive bone marrow-derived haematopoietic cells home to the sites of future 
metastasis and form cellular clusters that precede tumour cell arrival and increase 
fibronectin production in tumour target sites (Kaplan et al., 2005). On the other hand, 
endocrine-like actions further support the development of a pre-metastatic niche in 
the bone microenvironment. Examples include: (i) heparanase produced by breast 
cancer cells, and which increases bone resorption (Kelly et al., 2005); (ii) OPN 
secreted by tumour cells and/or senescent fibroblasts, and which promotes bone 
marrow cells recruitment or tumour formation (Anborgh et al., 2010; McAllister et al., 
2008; Pazolli et al., 2009); (iii) MMPs produced by osteoclasts, and which support 
prostate cancer skeletal metastasis (Lynch et al., 2005). 
Among factors implied in organ-specific cancer metastasis, chemokines and 
their receptors are believed to play a key role (Krzeszinski & Wan, 2015). The best-
studied example is C-X-C chemokine receptor type 4 (CXCR4) and its ligand the 
stromal-derived factor-1 (SDF-1). Multiple bone-metastatic tumours including breast, 
prostate, and multiple myeloma express CXCR4. This chemokine receptor controls 
the metastatic destination of cancer cells by directing them to organs where SDF-1 is 
abundant, such as the bone marrow. Therefore, the disruption of the CXCR4/SDF-1 
axis is a promising therapeutic strategy to prevent bone colonization by tumour cells 
(Hirbe et al. 2010). In mice, an intracardiac injection of CTCE-9908, a peptide 
analogue of SDF-1 and a competitive inhibitor of CXCR4, reduces the size of 
metastatic lesions derived from MDA-MB-231 cancer cell line (Richert et al., 2009). 
Plerixafor/AMD3100, a small-molecule antagonist of CXCR4, also delays metastatic 
outgrowth of orthotopically transplanted 4T1 mouse breast cancer cells (Smith, 2004). 
However, the effects of the CXCR4/SDF-1 axis on tumour cell growth within the bone 
are not yet fully defined. Indeed, some studies point out that within the bone 
microenvironment, SDF-1 and CXCR4 could have conflicting roles. Genetic disruption 
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of Cxcr4 in hematopoietic cells seems to enhance osteoclast activity and thereby 
stimulates tumour cell growth in bone (Hirbe et al., 2007). Even more, there is a 
concern that the blockade of this chemokines/receptor axis could impair many 
important physiological processes that include stem cell homing, angiogenesis and 
immune cell trafficking (Lapidot & Kollet, 2002). Therefore, it is desirable to design 
therapeutics that would specifically target CXCR4/SDF in tumour cells (Krzeszinski & 
Wan, 2015). 
Besides CXCR4, a second SDF-1 receptor, CXCR7, has been involved in tumour 
development (Burns et al., 2006). Azab et al. found that the inhibition of CXCR7 
delayed tumour progression in multiple myeloma, by specifically abrogating the 
trafficking of angiogenic mononuclear cells. These results highlight a novel role of 
CXCR7 in the recruitment of angiogenic mononuclear cells to areas of multiple 
myeloma in the bone marrow niche (Azab et al., 2009). 
Similarly, C-X-C motif chemokine 10 (CXCL10) has been shown to facilitate the 
trafficking of CXCR3-expressing cancer cells to bone, which augments its own 
production, enhances tumour growth, and promotes osteoclastic differentiation. 
Thus, CXCL10/CXCR3 axis may be another attractive therapeutic target for osteolytic 
metastases prevention (Lee et al., 2012). 
Several cytokine products of breast cancers, such as PTHLH, IL-11, and IL-8 , 
have been shown to modify the bone microenvironment and promote bone 
resorption and colonization by tumour cells (Krzeszinski & Wan, 2015). More recently, 
an over-expression of adrenomedullin, a small peptide secreted by breast cancer 
cells and increased in hypoxia conditions, was shown to accelerate osteolytic bone 
metastasis development and to increase osteoclastic activity. On the contrary, a 
small-molecule antagonist of adrenomedullin dramatically suppressed both tumour 
burden in bone and osteoclastic activity (Siclari et al., 2014). 
TGF-β is one of the most abundant cytokines released upon bone tissue 
resorption. It stimulates tumour cell expression of PTHLH, which activates osteoclasts 
(Johnson et al., 2011). More bone resorption results in additional release of TGF-β that 
again promotes tumour cell proliferation and survival. Consequently, the inhibition of 
TGF-β with small molecules or neutralizing antibodies can reduce osteolytic lesion 
and tumour burden in mouse models for breast cancer and melanoma 
(Bandyopadhyay et al., 2006; Mohammad et al., 2011).  
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High serum levels of IGFs are linked to high risk for breast, prostate, and 
colorectal cancer. As for bone metastases, neutralizing antibody against IGF-1 
receptor (IGF-IR) blocks breast cancer bone anchorage. This supports an important 
role of bone-derived IGF-1 in the crosstalk between the bone microenvironment and 
the cancer cells (Hiraga et al., 2012). 
The bone marrow microenvironment where HSCs are thought to reside 
comprises of several cell types such as vascular endothelium and endosteal 
osteoblasts (Kiel et al., 2005; Xie et al., 2009). Components of the HSC niche constitute 
fertile ground and it has been speculated that bone metastatic cells disseminate in 
the same manner as HSCs home to bone marrow, that is to say, via the CXCR4/SDF1 
axis (Müller et al., 2001; Taichman et al., 2002). In addition, HSC-derived BMPs, such as 
BMP-2 and 6, can promote osteoblast differentiation (Jung et al., 2008). Osteoblasts 
in turn maintain the HSC niche, creating a positive feedback loop with HSCs. In line 
with this, it has been shown that prostate cancer cells could interfere with BMP 
signalling pathway and alter the regulation of normal bone formation. Lastly, BMPs 
are involved in HSC quiescence and tumour cell dormancy, therefore representing 
promising candidates for therapeutic targeting of bone metastases (Grassinger et 
al., 2007; Kobayashi et al., 2011). 
 
2.5.2.6. Adhesion of tumour cells to bone  
 
Adhesion between tumour cells and bone marrow stromal cells is crucial for 
cancer colonization of bone tissue.  
Integrins are a family of transmembrane receptors that function as the bridges 
for cell-to-cell and cell-to-ECM interactions. Various in vivo and in vitro experiments 
suggest that αvβ3 integrin increases the potential of human and murine breast 
cancer cells to form bone metastases (Felding-Habermann et al., 2001; Sloan et al., 
2006; Zhao et al., 2007). ATN-161, a peptide that interferes with αvβ1 and αvβ3 
binding, has successfully passed Phase I and II clinical trials (Cianfrocca et al., 2006). 
And in a preclinical animal model using intracardiac injection of MDA-MB- 231 
human breast cancer cells into nude mice, ATN-161 treatment results in a significant 
reduction in the number of bone metastases (Khalili et al., 2006). This further supports 
a crucial role of integrins in cancer metastasis development.  
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2.5.3. Osteoclasts and the vicious cycle 
 
In osteolytic bone metastases, tumour cells enhance osteoclast formation by 
continuingly secreting pro-osteoclastogenic factors including PTHLH, RANKL, 
interleukins, prostaglandin E, TNF, and MCSF. On the other hand, osteoclastic bone 
resorption releases growth factors, such as TGF-β, IGFs, PDGFs, and BMPs that further 
enhance tumour growth. This tumour-osteoclast cooperation is the basic foundation 
of the ‘vicious cycle’ hypothesis (Guise, 2002).     
TGF-β is undoubtedly a major cytokine of bone metastases vicious cycle. 
Over-production of active TGF-β by osteoclastic bone resorption in the skeletal 
metastases, not only increases tumour cell invasiveness and angiogenesis but also 
induces immunosuppression. Thus, blocking the TGF-β signalling pathway to interrupt 
this vicious cycle offers a promising therapeutic approach (Massagué, 2008). Thus, in 
preclinical studies as well as in clinical trials, TGF-β neutralizing antibodies (1D11, 
Fresolimumab), tyrosine kinase inhibitors (LY2109761, LY2157299), and soluble decoy 
receptor proteins have been developed and tested for their efficacy in inhibiting 
bone metastasis (Buijs, Stayrook, & Guise, 2011; Connolly, Freimuth, & Akhurst, 2012). 
 
2.5.4. Osteoblast role in bone metastasis 
 
The role of osteoblasts in skeletal metastasis is less well defined. Whether they 
exert pro-metastatic or anti-metastatic properties may depend on multiple factors 
including, the type of primary cancer, and whether the metastatic lesion is more 
osteolytic or osteoblastic (Krzeszinski & Wan, 2015).  
Activated osteoblasts produce factors including TGF-β, IGFs, IL-6, monocyte 
chemotactic protein-1 (MCP-1), VEGF, and macrophage inflammatory protein-2 
(MIP-2), which in turn favour cancer cell colonization and amplification upon arrival 
in the bone niche (Krzeszinski & Wan, 2015).  
On the other hand, tumour cells are able to produce osteoblast-stimulating 
factors such as BMPs, FGFs and PDGF (Weilbaecher et al., 2011). It is likely that 
canonical WNT signalling is the central point of osteoblast-cancer cell crosstalk. WNT 
signalling results in high levels of RUNX2, a major transcription factor in 
osteoblastogenesis. The WNT signalling inhibitor, dikkopf homologue 1 (DKK1) has a 
crucial role in osteolytic skeletal metastasis in which osteoblast formation is 
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suppressed and osteoclast activity is enhanced. Serum DKK1 levels are increased in 
patients with multiple myeloma and in women with breast cancer skeletal 
metastasis. And in experimental models of prostate cancer, Dkk1 expression is high 
during early carcinogenesis and decreases with skeletal progression, suggesting a 
molecular switch between osteolytic and osteoblastic disease (Weilbaecher et al., 
2011).  
In osteoblastic bone lesions, there is also a vicious cycle between tumour cells 
and osteoblasts. It has been shown that tumour cells can secrete endothelin-1 (ET-1), 
which downregulates Dkk1 expression (Clines et al., 2007) and therefore stimulates 
excessive osteoblast formation responsible for the deposition of poor quality and 
immature bone.  
 
2.5.5. Other cell types involved in bone metastasis 
2.5.5.1. Bone marrow MSCs 
 
It has been argued that bone marrow MSCs are also implicated in tumour 
growth and metastasis through their ability to promote and protect cancer stem 
cells. Interestingly, the potential of MSCs to interact with tumour cells has prompted 
investigations into whether MSCs can be used for the targeted delivery of antitumor 
agents to cancer cells (Weilbaecher et al., 2011).  
 
2.5.5.2. Adipocytes  
 
The number of bone marrow adipocytes increases greatly with aging and 
obesity. Marrow adipocytes secrete adipokines including hormones, cytokines, and 
fatty acids that may have profound effects on hematopoietic niche, neighbouring 
bone cells, and inflammation, hence modifying the local milieu (Krzeszinski & Wan, 
2015). In the same line, MSCs-derived adipocyte stem cells were shown to promote 
prostate tumour growth (Weilbaecher et al., 2011). 
It has been suggested that tumour cells can be attracted to marrow 
adipocytes and are affected by adipokines. Yet, little is known about how exactly 
they modulate tumour colonization of the skeleton. The interaction between these 
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two cell types may create a chronic pro-tumourigenic inflammatory environment 
that promotes the translocation of adipocyte-stored lipids to the metastatic tumour 
cells, increasing their motility. Marrow adipocytes may promote tumour growth in 
bone in a FABP4-dependent manner. FABP4 is a cytosolic lipid chaperone that is 
predominantly expressed in adipocytes, macrophages, and endothelial cells. 
Herroon et al. propose that FABP4 inhibition can block lipid trafficking between 
marrow adipocytes and cancer cells, thus reducing the formation of tumour 
metastases in bone (Krzeszinski & Wan, 2015). 
  
2.5.5.3. Myeloid and immune cells 
 
Bone marrow-derived myeloid cells include macrophages, monocytes, 
myeloid-derived suppressor cells (MDSCs), myeloid dendritic cells, and osteoclasts. In 
addition, lymphocytes are recruited to bone metastases sites. Both myeloid cells and 
lymphocytes have a dual role in the regulation of tumour growth. In a recent report, 
mice with osteoclast and immune cell defects were protected from tumour-
associated bone loss but did not have decreased tumour burden in bone (Vaira et 
al., 2008).  Increasing evidence support myeloid cell participation in angiogenesis, 
but the effective measurement of the vascular supply to a tumour in bone is 
challenging (Stockmann et al., 2008).   
Since many animal models of bone metastasis are immune-compromised 
mice that lack T cells, their role in regulating tumour growth within the bone 
microenvironment remains largely unstudied. Notably, pro-inflammatory CD4+Th17 T 
cells secrete RANKL, TNF and TGF-β. All of these factors activate osteoclasts and 
promote bone resorption (Sato et al., 2006; Takayanagi, 2009), and thus may 
enhance tumour growth in bone by promoting the vicious cycle. It is anticipated 
that future studies will probably set an important role for T cell subpopulations in 
regulating bone metastasis (Weilbaecher et al., 2011). 
For what it concerns the macrophage contribution to tumour growth and 
metastasis, an intense investigation has been conducted in the past few years. 
However, no direct evidence that clearly demonstrates a suppressive effect of 
macrophages on bone metastasis was found. This is mainly due to the fact that most 
strategies for depletion and/or inhibition of macrophages, as well as for manipulating 
macrophage intrinsic factors, also target osteoclasts at the same time (Krzeszinski & 
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Wan, 2015). Regarding their regulation of inflammation, macrophages are classified 
into two main subsets: (i) M1 macrophages that generally promote inflammation; (ii) 
M2 macrophages that suppress inflammation and assist tissue repair (Lawrence & 
Natoli, 2011). M1 macrophages have been proposed to be anti-tumourigenic by 
releasing reactive oxygen species (ROS), nitrogen intermediates, and inflammatory 
cytokines that eliminate cancer cells. By contrast, M2 macrophages are generally 
regarded as pro-tumourigenic, promoting tumour growth and invasion by releasing a 
variety of growth factors such as FGFs and VEGF (Zhang et al., 2014). Consistently 
with this, it was reported that the small GTPase Rac2, which facilitates macrophage 
M1 to M2 polarization, promoted tumour metastasis (Joshi et al., 2014). 
 
2.5.5.4. Platelets and megacaryocytes 
 
Platelets and their megakaryocytic precursors interact with cancer cells 
before, during and after metastasis to bone (Weilbaecher et al., 2011). Activated 
platelets are an important source of pro-angiogenic (VEGF) and anti-angiogenic 
(thrombospondin 1/TSP1) factors whose aggregation at tumour sites affects tumour 
growth (Gay & Felding-Habermann, 2011). Tumour cells that are able to respond to 
platelet-derived lysophosphatidic acid (LPA) have enhanced bone metastatic 
potential in mice, partly through LPA-mediated induction of osteolytic factors such as 
IL-6 and IL-8 (Boucharaba et al., 2004). Likewise, it has been demonstrated that 
genetic and pharmacological inhibition of platelet activation or platelet-specific 
integrins (αIIbβ3) decreases osteolytic bone metastases in mice (Bakewell et al., 
2003; Uluçkan et al., 2008). Platelet progenitors (mature megakaryocytes) are 
located at vascular sinusoids, and are among the first cells to encounter cancer cells 
that enter the bone marrow environment. Conversely to the major platelet effect on 
bone metastasis, bone marrow megakaryocytes inhibit prostate cancer tumour 
growth in bone (Li et al., 2011). Interestingly, bisphosphonates increase 
megakaryocyte proliferation and increase platelet concentration of the anti-
angiogenic integrin ligand TSP1 (Bernasconi et al., 1995; Zaslavsky et al., 2010), which 
suggests that bisphosphonates have additional non-osteoclast mechanisms that 
decrease tumour growth in bone.  
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2.5.6. Tumour cell dormancy in bone 
 
Paradoxically, only 0.001–0.02% of cancer cells that are experimentally 
introduced into the circulation actually forms metastases (Fidler, 1970; Luzzi et al., 
1998; Schneider et al., 2005). Preclinical evidence suggests that metastatic tumour 
cells can home to the HSC niche of the bone, and survive there in a dormant state 
for long periods being often resistant to cancer therapies (Weilbaecher et al., 2011). 
For example, myeloma cells interact with bone marrow stroma, partly through 
integrin α4 and vascular cell adhesion molecule 1 (VCAM1). This facilitates 
quiescence and protection from apoptosis, providing resistance to chemotherapy 
(Damiano et al. 1999). 
It has been speculated that tumour cells have the ability to mimic HSC cells, 
and the research on factors that induce HSC dormancy could explain tumour cell 
dormancy in bone marrow niche. Prostate cancer cells bind to osteoblast annexin II, 
which in turn induces the expression of growth arrest-specific 6 (GAS6) receptors. 
GAS6 receptors are well-known inducers of dormancy in HSCs and were found to 
reduce cell cycle progression in prostate cancer cells as well (Shiozawa et al., 2010).  
Due to a possibility of inducing long-term remission and overcoming resistance to 
anti-cancer treatments , understanding tumour cell dormancy mechanism within the 
bone marrow is one of the priorities in tumour investigation (Weilbaecher et al., 2011). 
 
2.5.7. Bone metastasis current prevention and treatment 
When cancer metastasizes to bone, it causes considerable pain and 
deregulation of bone remodelling, which greatly reduces the possibility of cure. 
Tumour cells are able to modify the bone microenvironment to be receptive to 
tumour cell attachment and tumour growth. Important advances in understanding 
the basic biology of tumour–bone interactions, bone remodelling, and 
haematopoiesis, have uncovered new therapeutic possibilities for the prevention 
and treatment of bone metastasis (Weilbaecher et al., 2011). Improvements have 
been made in the medical management of bone metastases including surgery 
approaches and radiation therapy, as well as targeted pharmacological therapy. 
Nevertheless, to date, these strategies remain only palliative and do not significantly 
improve overall patient survival (Taubenberger, 2014). Identifying more effective and 
specific molecularly targeted therapy to prevent and cure bone metastases as well 
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as enhancing the quality of life of the patients remain one of the major challenges of 
future biomedical research.  
 
Targeting osteoclast resorption 
 
Clinically, anti-resorptive drugs have been effective in slowing down the 
process of cancer bone metastasis (Krzeszinski & Wan, 2015).  
Bisphosphonates are a group of pyrophosphate analogues that preferentially 
bind to calcium, which is abundant in bone tissue. Upon bone resorption, bound 
bisphosphonates are ingested by osteoclasts and induce their apoptosis (Li, Wong, & 
Pavlakis, 2014). Moreover, bisphosphonates can affect directly tumour cells, as well 
as other cell types that promote bone metastases, including γδ-T cells, monocytes, 
MDSCs and endothelial cells. Clinical data suggest that bisphosphonates can limit 
the progression of breast cancer metastasis in bone and in other tissues (Aft et al., 
2010; Gnant et al., 2009);Misso et al., 2012; Santini et al., 2002, 2003, 2007; Vincenzi, 
2003). Thus, bisphosphonate therapy is currently a gold standard in treatment of 
patients with established bone metastases of many tumour types (prostate, breast, 
lung, and multiple myeloma) (Wu, Dahut, & Gulley, 2015). Bone matrix-targeted 
bisphosphonates, such as pamidronate, zoledronic acid (zolendronate) and 
ibandronate, are amino-bisphosphonates that block farnesyl pryrophosphate 
synthase and that disrupt protein prenylation (Rogers, 2003). In one study, 
zolendronate treatment of women suffering from localized breast cancer modulated 
the presence of disseminated tumour cells in the bone marrow (Weilbaecher et al., 
2011). 
Human monoclonal antibodies against RANKL, the main inducer of 
osteoclastogenesis, are also under extensive investigation as potential inhibitors of 
malignant bone resorption. One such antibody, Denosumab, has been approved for 
the treatment of skeletal complications in patients with bone metastases secondary 
to breast or prostate cancer, as well for the treatment of osteoporotic patients 
(Drooger, van der Padt, Sleijfer, & Jager, 2013).  In addition, denosumab may be 
effective in directly targeting subtypes of breast and prostate cancers that express 
RANKL (Gonzalez-Suarez et al., 2010). 
Other osteoclast-targeted therapies under clinical evaluation include CTSK 
inhibitors, SRC inhibitors and αvβ3 inhibitors (Desgrosellier & Cheresh, 2010; Jensen et 
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al., 2010; Rucci, Susa, & Teti, 2008). These therapies can directly affect tumour cells 
and/or stromal components that participate in bone metastases (Weilbaecher et al., 
2011). 
Despite the ability of these osteoclast inhibitor drugs to control and reduce 
bone metastases, significant challenges lie ahead. Firstly, ineligible side effects of 
currently approved bisphosphonates are yet to be tackled. This includes 
osteonecrosis of the jaw (ONJ), hypocalcaemia, and renal toxicity (Brown & 
Coleman, 2012; Coleman, 2012; Khosla et al., 2007).  Secondly, none of these drugs 
can completely eradicate bone metastases, nor increase patient long-term survival. 
Unfortunately, 30–50% of patients on this therapy still develops new bone metastases, 
deteriorating skeletal-related events and disease progression (Weilbaecher et al., 
2011). Hence, with a goal to provide new improved therapeuticals, investigation of 
tumour influence on osteoclasts incessantly continues (Krzeszinski & Wan, 2015).  
 
Targeting osteoblasts 
 
An alternative therapeutic strategic to osteoclast inactivation, is to delay 
bone loss by stimulating osteoblast function. Proteasome inhibitors are reported to 
promote bone formation by stimulating MSCs proliferation and osteoblast 
differentiation. The first FDA-approved therapeutic proteasome inhibitor, bortezomib, 
has shown efficacy in the treatment of multiple myeloma and lymphomas in 
humans. Interestingly, in preclinical models bortezomib has also been shown to inhibit 
breast cancer osteolytic metastasis (Krzeszinski & Wan, 2015).  
On the other hand, treatments for osteoblastic bone lesions are also being 
developed. Endothelin 1 (ET-1) is a vasoconstrictive agent that stimulates osteoblast 
proliferation and differentiation (Nelson et al., 1995; Tang et al., 2009).  ET-1 promotes 
cancer cell proliferation and invasion via upregulating MMPs, inhibiting tumour cells 
apoptosis, and enhancing VEGF-induced angiogenesis (Carducci & Jimeno, 2006). 
Inhibition of ET-1 is reported to have dual suppressive effects on both tumour cells 
and osteoblasts. Both ET-1 neutralizing antibodies and ET-1 receptor antagonists are 
under clinical evaluation (Chiao et al., 2000; Pinto et al., 2012). Atrasentan was the 
first ET-1 receptor subtype A antagonist to be investigated in patients with prostate 
cancer, while zibotentan is a more selective and promising inhibitor that is currently in 
clinical trials (Shepard & Dreicer, 2015). 
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Targeting TGF-β signalling pathway 
 
Several classes of TGF-β inhibitors have been tested in preclinical models and 
clinical trials in the treatment of bone metastases: (i) neutralizing TGF-β antibodies 
that prevent TGF-β ligand–receptor interactions; (ii) small molecules that inhibit T-bRI 
(and T-bRI II) kinase activity; (iii) halofuginone (HFG) thatinhibits TGF-β, although the 
exact mechanism of action remains to be investigated (Weilbaecher et al., 2011). In 
patients with advanced metastatic melanoma, pheochromocytoma, and colon, 
prostate and breast cancer, dose escalation studies demonstrated that the small 
molecule TGF-β inhibitor LY2157299, was well tolerated with minimal toxicity. 
 
Targeting bone metastases angiogenesis 
 
Due to its indisputable role in cancer metastasis, angiogenesis has been 
studied extensively as a potential target of anti-cancer therapy. FDA-approved 
bevacizumab, a monoclonal antibody against VEGF-A, was the first commercially 
available angiogenesis inhibitor that has been clinically used to treat metastatic 
cancers of colorectal, lung, breast, and renal origin. Cabozantinib, a dual inhibitor of 
VEGFR2 and receptor tyrosine kinase MET, has exhibited beneficial effects on 
radiographically evident bone metastases. Other inhibitors of VEGFRs include 
sunitinib, sorafenib, cediranib, and aflibercept, which is a small recombinant protein 
decoy receptor for VEGFs. However, none of these drugs has been proven to 
decrease the mortality rate of the treated patients. In order to achieve significant 
clinical benefit, it is proposed that angiogenesis inhibitors may require concomitant 
administration of cytotoxic chemotherapeutic agents (Krzeszinski & Wan, 2015). 
 
Targeting bone metastases dormancy 
 
Due to their cell cycle arrest, cancer cells homed in the bone marrow are 
often resistant to chemotherapy. An exciting new approach takes advantage of the 
fact that cancer cells use CXCR4 and VLA4 to home to and engraft in the bone 
marrow. In mice, HSC mobilizing agents such as AMD3100 and anti-VLA4-targeted 
molecules were shown to mobilize leukaemia and myeloma cells into the blood, this 
release into bloodstream making cancer cells more susceptible to chemotherapy. 
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This approach is currently being tested in clinical trials in the treatment of acute 
myeloid leukaemia and multiple myeloma (Weilbaecher et al., 2011).  
 
Bone pain treatment  
 
Bone tissue is densely innervated by primary sensory afferent and sympathetic 
neurons located in the periosteum and the intramedullary bone (Goblirsch, Zwolak, 
& Clohisy, 2006). That is why bone metastases result in considerate pain, which is 
extremely difficult to treat and that is often rather resistant to opioids (Meuser et al., 
2001). A study by Honore et al. found that the acidic environment, which is 
produced by resorbing osteoclasts, activates the transient receptor potential 
vanilloid type 1 (TRPV1) expressed by pain neurons (Honore et al., 2000). 
Consequently, bone resorption inhibitors substantially decrease the pain caused by 
the growth of bone metastases (Coleman et al., 2008). Another pain-relieving tactic 
in patients with bone metastases has been the use of radiopharmaceuticals, such as 
strontium, samarium and radium that exhibit strong avidity towards bone calcified 
matrix. These agents can exert only a small and localized anti-tumour effect through 
radiation. However, due to their substantial effects on bone pain, they are primarily 
indicated to provide bone metastases-related pain relief (McEwan, 2000).  
 
2.5.8. Future directions in bone metastasis research 
Most current therapeutic strategies only attenuate the progression of existing 
bone metastases, and do not significantly increase long-term survival. Thus, strategies 
interfering with early stages of metastatic cascade are highly desirable. In order to 
achieve this goal, the major aims for future bone metastasis investigation are the 
following: (i) identification of early bio-markers, ideally circulating factors, for the 
prediction and diagnosis of metastatic disease; (ii) cancer stem cells eradication; (iii) 
inhibition of epithelial-to-mesenchymal transition (EMT); (iv) halt of dissemination of 
circulating tumour cells; (v) better general characterization of the mechanisms by 
which cells of various cancers cooperate with bone cells; (vi) identification of 
genetic or humoral factors that allow cancer cell dormancy reversal; (vii) 
development of therapeutic approaches that can simultaneously target multiple 
steps of the bone metastatic cascade; (viii) the design of pharmacological agents 
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that specifically target tumour cell functions, without considerably interfering with 
normal physiological functions, thus resulting in less side-effects; (ix) improvements in 
relief  of skeletal metastasis-related pain (Nakanishi, 2010);  (x) development of 
powerful imaging technologies to visualize different stromal cell elements that are 
involved in bone metastasis in live animals; (xi) development new improved in vitro 
and animal models that are more representative of  real physiological bone 
metastasis process such as patient-derived cancer cell xenograft models that can 
predict patient-specific predisposition for bone metastasis as well as patient-specific 
efficacy of envisioned treatments (personalized medicine) (Krzeszinski & Wan, 2015; 
Villasante, Marturano-Kruik, & Vunjak-Novakovic, 2014; Weilbaecher et al., 2011). 
Hopefully, the bone metastasis investigation will yield so called theranostic 
agents whose application is at the same time diagnostic and therapeutic. 
Eventually, by using safer agents for treatment and diagnostic, these innovations will 
allow for even more efficient attenuation of bone metastatic disease. Ultimately, 
improving the overall clinical outcome for cancer patients, they will result in effective 
prevention of cancer bone metastasis (Krzeszinski & Wan, 2015). 
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3. Biomaterials in bone tissue engineering 
 
3.1. Applications and properties 
 
Despite the tremendous potential of bone tissue for repair and regeneration in 
response to injury or surgical treatment, different osteoarticular pathologies can result 
in significant loss of bone tissue. Spontaneous bone repair is valid only for small-sized, 
‘non-critical’ defects. In order to replace the missing or damaged bone tissue and to 
restore its mechanical function, a surgical autograft technique is employed as a gold 
standard (Verron et al., 2010c). A secondary site is chosen, most often the patient’s 
iliac crest, where certain amount of healthy bone tissue is harvested and implanted 
at the initial site where bone loss occurred. The main advantages of this technique 
are the absence of immunological reaction and adverse compatibility events, and 
its clinical efficiency due to the living cells and growth factors present in the 
harvested bone. Despite good clinical efficiency in replacing the damaged and/or 
missing bone tissue, this method presents notable limitations in terms of quantity of 
replacement bone tissue that can be harvested, but also in increased morbidity 
(pain, infections) at the secondary operation site. 
Alternatively, allograft, in the form of donor bone from a regular bone bank, 
might partly overcome the drawbacks of bone supply. However, in this technique, 
the sterilization treatment results in degradation of biological factors and impaired 
bone strength. Furthermore, there are concerns regarding immunological reaction 
between the patient and the donor bone, as well as disease transmission (Zhang et 
al., 2014). 
 In the past decades, autograft and allograft limitations have prompted the 
development of synthetic materials that serve as bone substitutes, which aim to 
imitate autograft properties. When implanted at the injury site, these materials 
provide mechanical stability of the damaged area and support bone 
reconstruction. Nevertheless, autograft method is more efficient and remains the 
reference treatment for bone loss indications (Mellier et al., 2015) . 
The development of bone substitutes and their clinical implementation are 
commonly named bone tissue engineering. An ideal bone substitute has at least two 
characteristics:  
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(i) it is well-tolerated by surrounding host tissue = biocompatibility; 
(ii) it is capable to recruit bone cells to form new bone on its surface = 
osteoconductivity  
The first generation of bone substitutes was comprised of a wide range of 
synthetic materials, such as metals, polymers and porous ceramics. The second 
generation introduced injectable calcium phosphate cements (CPCs) that are 
currently under intense investigation. Indeed, their primary mechanical properties are 
close to those of cancellous bone. Moreover, their injectability makes them suitable 
for implantation under minimally invasive surgery, while their adaptability allows them 
to fit with any shape of defect. Further developments of a third bone biomaterials 
generation aim at expanding potential benefits of injectable substitutes by 
combining them with patients own cells, osteogenic factors or active molecules to 
enhance bone regeneration in normal healing and in pathological situations. Thus, 
bone biomaterials would have another valuable role as drug delivery systems (DDS).  
Since calcium phosphate is one of the major mineral components of the bone 
tissue, CaP synthetic substitutes are well tolerated by the surrounding host tissue. In 
this regard, calcium phosphate (CaP) biomaterials, mainly ceramics, cements, 
composites and thin coatings, are considered excellent materials for bone tissue 
engineering (Verron et al., 2010c). 
 
3.2. Calcium phosphate ceramics 
 
 CaP ceramics are characterized by three types of porosity: macro, meso and 
micorporosity. Microporosity comprises of intercrystal pores with a diameter smaller 
than 10 µm, and is formed by high sintering temperatures during biomaterial 
synthesis. This porosity grade enables ionic exchange in biomaterial contact with 
fluids. Mesoporosity refers to pores between 10-100 µm. Macroporosity corresponds 
to pores with a diameter superior to 100 µm. These pores are created by porogens, 
such as naphthalene or sugar, used in ceramic synthesis. High temperature during 
the sintering step results in complete porogen evaporation and pore formation. The 
ratio of these three types of porosity influences biological performance of CaP 
materials. On the other hand, atomic Ca/P ratio is generally inversely proportional to 
dissolution rate and therefore, to ceramics resorption behaviour in vivo.  
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Only two CaP species are resistant to thermal treatment ≥ 1000°C during 
ceramic synthesis, namely hydroxyapatite (HA) and β-tricalciumphosphate (β-TCP) 
HA and β-TCP possess properties required for bone substitute materials and are 
frequently used for implantation in orthopaedic and dental fields (Nakamura et al., 
2013).  
 Hydroxyapatite, with a chemical formula Ca10(PO4)6(OH)2, is the naturally 
occurring mineral that crystallizes in hexagonal system and closely resembles in 
structure to human bone and tooth enamel. Stoichiometric HA has a Ca/P atomic 
ratio equal to 1.67, while the biological apatite present in bone has a Ca/P atomic 
ratio between 1.5-1.67. It has the same crystal structure as stoichiometric HA but their 
chemical composition differs. Calcium can be partly substituted with other ion 
species, forming so-called calcium deficient apatite (CDA), which is more soluble 
that stoichiometric one. Calcium deficiency is commonly attributed to the low 
driving force available for growth under biomineralization conditions. Since Calcium 
deficiency affects mechanical and biological properties of HA, more profound 
understanding of the defect chemistry is essential for the design of novel improved 
synthetic biomaterials based on CDA (Bhat, Waghmare, & Ramamurty, 2014). 
In biological apatite, both phosphate and hydroxyl ions can be partially 
substituted with carbonate ions (2-8%) while calcium ions can be substituted by small 
amounts of sodium, magnesium and potassium (Bhat et al., 2014). This interesting 
characteristic of biological apatite has incited numerous investigations of synthetic 
carbonated hydroxyapatite (CA) as an ideal clinical biomaterial. Indeed, it is 
empirically hypothesized that artificial implants should most closely resemble the 
natural mineral phase of the bone tissue (Nakamura et al., 2013).  
Biomaterials in which HA and β-TCP phases are combined are called biphasic 
calcium phosphates (BCPs). β-tricalciumphosphate (β-TCP), has a chemical formula 
Ca3(PO4)2 and crystallizes in rhomboedric system. With its atomic Ca/P ratio equal to 
1.5, this ceramic is more soluble than HA, and thus, more readily biodegradable. 
Thus, the bioactivity and the resorbability of BCPs are proportional to β-TCP 
percentage. 
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3.3. Injectable bone cements  
 
Bone cements are prepared by mixing a solid powder with a liquid phase, 
which results in the formation of an injectable paste. In vitro properties and in vitro 
behaviour of injectable cements depend highly on: additives to cement paste; 
powder particle size; powder-to-liquid ratio;  the method used to mix the powder 
with the liquid phase (Lewis, 2006). 
Regarding their chemical composition, injectable bone cements can be 
classified into three categories: (i) acrylic bone cements (e.g. PMMA); (ii) calcium 
sulphates, (iii) calcium phosphates (Lewis, 2006). In this chapter, main features of 
each group will be presented, and calcium phosphate cements will be discussed 
more in detail in chapter 3.4.1. 
 
Polymethylmethacrylate (PMMA), commonly described as orthopaedic 
“cement”, is an organic polymer resin with good mechanical properties, widely used 
in orthopaedic applications such as joint replacement, vertebroplasty, arthroplasty, 
and defect repair. The main drawback of PMMA cement is its biological inertness. 
Hence, no biological interaction occurs at the cement-bone interface and no 
material resorption takes place. For this reason, after implantation, aseptic loosening 
and shifting of the prosthesis are a common cause of surgical failure (52-55% of 
surgical revisions) (Li et al., 2015). In total joint replacements, the second important 
inconvenience of PMMA is the thermal necrosis of the periprosthetic soft tissue during 
the cement exothermic setting reaction. However, this risk seems to be lower in the 
case of vertebroplasty and kyphoplasty procedures (Lewis, 2006). Conversely, due to 
the heat-induced necrosis of residual tumoral tissue, exothermic setting reaction of 
PMMA can be beneficial when filling bone cavities after tumour resection.  
Calcium sulphate cements (CSCs), CaSO4, known as plaster of Paris or 
gypsum, have a long clinical history as bone graft substitutes in various skeletal sites. 
Upon mixing with a diluent, the cement powder is converted to calcium sulphate 
dihydrate, producing a paste or putty with a solid or partially solid structure. When 
injected to surgical site, CSCs inhibit fibrous tissue ingrowth and slightly acidify the 
environment, which favours osteogenesis and angiogenesis. CSCs are degradable 
cements and take about 2 months to be resorbed in vivo, depending on the 
implantation site. Although they are eventually replaced by new bone tissue, there is 
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a major concern about their rapid resorption rate that is usually not accompanied by 
immediate bone formation. Hence, the mechanical properties of the implantation 
site are decreased. Consequently, they are employed to a lesser extent in today’s 
clinical practice. 
 
3.3.1. Calcium phosphate cements (CPCs) 
 
Since their initial formulation in the 1980s, injectable bone substitutes based on 
calcium phosphate cements (CPCs) have been extensively developed and 
numerous formulations are commercially available for various orthopaedic 
applications (Zhang et al., 2014). The concept of CPCs was first introduced by 
LeGeros et al. in1982, while Brown and Chow further broadened clinical applications 
of these biomaterials by adding a range of possible indications in orthopaedic 
surgery (i.e. kyphoplasty, vertebroplasty, prosthesis fixation, defect filling after tumoral 
resection), as well as in dental and maxillofacial surgery (i.e. alveolar ridge defect 
filling, sinus lift, implants fixation, bone regeneration after periodontitis, pulp covering 
and protection). In vivo, CPCs are resorbable and exhibit evidenced 
osteoconductive properties. Thus, they are efficient in most non-load bearing clinical 
situations in orthopaedics, dental, ear, nose and throat surgeries.  
 
As bone void fillers, CPCs present many advantages compared to ceramics: 
(i) injectability, which allows for minimal invasive surgery approach, thus limiting 
surgical risks and post-operative complications, as well as reducing patient’s 
hospitalization and recovery time;  
(ii) adaptability to complex irregular defects due to the moldability of the cement 
paste;  
 (iii) generally, greater mechanical support compared to ceramic bone substitutes. 
 
When compared to acrylic cement, important improvements due to CPCs 
are:  
(i) negligible exothermic setting reaction; 
(ii) intrinsic microporosity useful for biological fluids impregnation;  
(iii) resorption rate in vivo that is neither too fast nor too slow, and follows bone 
remodelling kinetics; 
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(iv) osteoconductivity that leads to new bone formation (this phenomenon is 
discussed in details in chapter 3.5.2.). 
 
The synthesis of the cement solid phase (CaP powder) begins by sintering 
(typically, at 1350°C for 1 h), followed by quenching to room temperature in a 
desiccator, and grinding in a planetary ball or attrition mill (typically, at 600 rpm for 
12 h), in ambient air. Regarding powder preparation of commercially available 
CPCs, there are great variations mainly depending on: the sintering temperature and 
time; the atmosphere in which the powder grinding takes place; the planetary ball 
milling time; the rotation rate, mass, and surface area of the balls; the pressure used 
to compact the mixture (Lewis, 2006).  
Thorough mixing of solid powder phase and liquid phase of the cement, in 
defined ratio, results in a viscous and mouldable paste. Solid phase is constituted of 
one or several phosphate- or calcium-based compounds, whereas the liquid phase 
may be water, or solution of calcium or phosphate that can contain alginate, 
chitosan, hyaluronate, gelatine, chondroitin sulphate, succinate or citric acid (Zhang 
et al., 2014). Liquid phase insures the dissolution of initial reactants till solution 
oversaturation is achieved and crystal precipitation begins. The hardening of the 
cement progresses with crystal entanglement while cement mechanical properties 
gradually augment till reaching the final solidified state. Increase in the powder-to-
liquid ratio markedly reduces both initial and final setting time of the cement (Lewis, 
2006). In addition, solid phase initial granulometry and the presence of crystals also 
determine the cement solidifying time. It was demonstrated that CPCs harden 
through a low exothermic reaction (without reaching high curing temperatures), that 
does not result in cement shrinking or thermal necrosis of adjacent bone tissue (Lewis, 
2006). 
Two types of setting reactions are possible when a CPC solid phase is mixed 
with an aqueous solution (Bohner, 2000; Chow & Takagi, 2011) (Figure 8.). 
The first is an acid-base reaction where a relatively acidic CaP phase reacts 
with a relatively basic CaP to produce a relatively neutral CaP. An example is: 
 
Ca4(PO4 )2O + CaHPO4 → Ca5 (PO4 )3OH (1) 
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The final product is brushite cement (dicalcium phosphate  dihydrate, DCPD) that is 
1-2 orders of magnitutde more soluble than apatite cement at physiological pH 
(Zhang et al., 2014), and which is more quickly resorbed in vivo. However, if bone 
ingrowth does not follow the brushite resorption rate, it results in a decrease in bone 
strength at the implantation site (Lewis, 2006). As brushite is a metastable phase, in 
vivo transformation to apatite may occur (Zhang et al., 2014).  
 
 
Figure 8. Synthesis of brushite and apatite cement. 
Two types of calcium phosphate cement synthesis and their final products. Scanning electron 
micrographs of set apatite and brushite cements (taken from Dorozhkin, 2013). 
 
The second type of setting reaction is hydrolysis, where the initial and final 
CaPs have the same Ca/P molar ratio, an example being: 
 
3α-Ca3(PO4)2 + H2O → Ca9(HPO4)(PO4)5OH  (2) 
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This chemical reaction results in the formation of different kinds of apatite cements, 
such as stoichiometric hydroxyapatite, calcium-deficient hydroxyapatite (CDA) or 
carbonated apatite (dahllite) that differ in solubility rates. 
 
Even though they possess superior mechanical properties compared to 
ceramics, CPCs mechanical resistance (in terms of strength, toughness, brittleness 
and reliability) remains rather poor in comparison to healthy bone or autograft (Table 
4.). Thus, for the moment, their use is limited to moderate- or non-load-bearing 
clinical situations (Verron et al., 2010c). Nevertheless, it is not often realized by 
researchers and clinicians that poor mechanical performances are not a critical 
issue for bone repair applications. Indeed, CPCs with compressive strengths 
comparable to those of cortical bones can be produced through densification 
and/or homogenization of the cement matrix. Actually, the real mechanical 
limitation for CPCs appears to be their low fracture toughness and poor mechanical 
reliability (Weibull modulus), which have been so far only rarely studied (Zhang et al., 
2014). 
The second main drawback resulting from CPCs use is the absence of 
macroporosity. These results in vivo in poor cellular colonization of the implant centre, 
leading to the absence of new bone formation inside the CPC. Hence, the material 
resorption is mostly limited to the implant surface and slowly continues layer by layer 
to the interior (Lewis, 2006). Therefore, in current CPC research, there is a focus on 
developing macroporous substitutes by incorporation of soluble crystals during 
synthesis or by adding sodium hydrogencarbonate (NaHCO3) in initial powder 
composition.  
 
Table 4. Typical mechanical resistance of healthy human bone and calcium phosphate 
cement. 
(summarized from Charron, 2008). 
 
 
  
cortical bone 150-200 MPa 
cancellous bone 8-12 MPa 
calcium phosphate cement 20-35 MPa 
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3.4. Calcium phosphate biomaterial behaviour in vivo 
3.4.1. Resorption mechanisms 
 
 In vivo, CaP biomaterials are resorbed from implantation site and partially or 
completely replaced by new bone tissue. It is crucial that no foreign material remains 
permanently in the implantation site and that the load-bearing capability of the 
bone is not affected over the long-term process of implant replacement. Solubility 
rates of different biomaterials stem from their physicochemical 
composition(Nakamura et al., 2013). 
 
After CPC implantation, biological fluids set off the physico-chemical 
dissolution of the material, followed by surface precipitation of carbonated apatite. 
As mentioned before, this kind of apatite is the closest in chemical composition to 
biological apatite. Consequently, bone cells that create a tight interface between 
biomaterial and bone tissue readily colonized the implant, and are responsible for 
CPCs good osseointegration into the surrounding intact host bone.  
 
 The second phase of resorption is performed by joint action of macrophages 
and osteoclasts present at the material-bone interface, and dissolved materials are 
incorporated material dissolution into remodelling process. The cellular resorption 
rate depends on the implantation site and ideally, to assure implant stability, it should 
be close to the rate of new bone formation. In the case where a too-rapid material 
resorption is not accompanied by sufficient new bone ingrowth, issues occur 
regarding the mechanical stability of the implant area. 
Numerous studies on different inorganic biomaterials have been conducted 
to evaluate osteoclast survival and activity in vitro, and to assess bone substitute 
resorption in vivo. In vitro, osteoclast resorption is affected by: the incorporation of 
ions such as carbonate or silicon into the structure of inorganic material; the surface 
energy; the physicochemical dissolution characteristics; the surface roughness; the 
surface crystallinity. For example, the incorporation of carbonate ions into the HA 
lattice has been shown to increase osteoclastogenesis. This is in accordance with the 
fact that main bone mineral is carbonated apatite (Nakamura et al., 2013). On the 
other hand, osteoclast mononuclear precursors fusion is influenced by the material 
surface topography. It has been reported the roughened HA surfaces increased the 
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number of tartrate-resistant acid phosphatase (TRAP)-positive multinucleated cells 
derived from rat bone marrow, as well as the differentiation rate of human peripheral 
blood mononuclear cells (PBMCs) cultured with M-CSF and RANKL. Interestingly, 
regardless of the similar numbers of TRAP-positive multinucleated cells and the similar 
viability of osteoclasts, there were differences in the resorption pits created by 
human and rat osteoclasts, depending on the type of inorganic material. On HA, 
human osteoclasts formed stronger actin rings and thereby deeper resorption pits 
compared to TCP. Conversely, Yamada et al. reported that rabbit osteoclasts 
resorbed TCP but not HA. These differences that result in alternation of biological 
properties are due to cell origin as well as cement characteristics such as sintering 
temperature and time, porosity, surface roughness, and grain size  (Nakamura et al., 
2013).  
 
3.4.2. Bone neoformation 
 
Bioactivity is the property of a material to directly bond new forming bone 
without formation of unmineralized fibrous tissue at the biomaterial-bone interface. 
This property depends on the surface topography (roughness) and also on the 
solubility of the material, responsible for a dissolution/precipitation process. As 
explained above, the dissolution of CaP biomaterials leads to an oversaturation of 
the biological fluid with calcium and phosphate ions. Further precipitation of 
biological carbonated apatite on the material surface permits the new bone 
formation, thus restoring mechanical, metabolic and haematopoietic functions at 
the implantation site. Three fundamental phenomena participate in bone tissue 
neoformation: (i) osteogenesis/osteoinduction; (ii) osteoconduction; (iii) 
osseointegration.  
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Figure 9. Fundamental phenomena in degradable biomaterial-induced bone 
formation. 
Physico-chemical properties of calcium phosphate biomaterials determine the rate of 
its in vivo resorption and subsequent new bone formation (taken from Graftys internal 
brochure Boukhechba, 2011). 
 
Osteogenesis/Osteoinduction 
 
Besides mature cells, undifferentiated cells are found in bone and adjacent 
tissues. At the time of the injury, local biochemical and biophysical stimuli are 
released and help surviving cells to respond in a proper manner. Some of these 
messengers guide the differentiation and organisation of cells, while others function 
as mitogens. In the injury response, both differentiated and osteoprogenitor cells are 
involved for adequate bone repair. Even more, progenitor cells are of utmost 
importance for proper bone healing. The majority of newly formed bone depends on 
mesenchymal stem cells (MSCs) transition to bone-forming osteoblasts. This process 
starts immediately after the injury, and it is very active during the first week, even 
though the action of the newly recruited preosteoblasts is not obvious until several 
weeks later, during the callus stage (Albrektsson & Johansson, 2001). 
At ectopic site, a phenomenon that resembles to osteogenesis, is called 
osteoinduction. The classical papers describing osteoinduction at various non-
skeletal sites were published a long time ago. To demonstrate ectotopic bone 
formation, the authors used gall bladder epithelium, alcohol extracts of bone, 
demineralised bone and transplants to muscles or the anterior chamber of the eye. 
Today, it is considered that the best way to demonstrate the osteoinductive 
properties of a biomaterial is to inject it into the subcutaneous or muscle tissue, where 
bone formation does not occur under normal physiological conditions, and to 
observe the formation of ectopic bone tissue. Inductive agents naturally function in 
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bone surroundings too, but it is difficult to differentiate between bone induction and 
bone conduction in an orthotopic site. That is why it is hard to discuss whether or not 
a particular orthotopically implanted biomaterial acts as a real osteoinductor 
(Albrektsson & Johansson, 2001).  
The assessment of biomaterial osteoinductive properties in ectopic sites has its 
purpose as a fast, easy and discriminating way to test new biomaterials in preclinical 
studies. Meanwhile, it has little importance in actual clinical practice, since the injury 
in itself is sufficient to recruit a great number of osteoprogenitor cells.  
Calcium phosphate materials are generally known to be osteoconductive but 
not osteoinductive. However, several CaP biomaterials have been reported to have 
the ability to form bone in non-bony sites in different animal models without addition 
of exogenous osteogenic factors. These include hydroxyapatite, β-tricalcium 
phosphate, biphasic calcium phosphates with varying HA/β-TCP ratio, as well as 
calcium phosphate cements. Some authors compared different CaP ceramics 
implanted in muscles or in femoral cortical bone in dogs and goats, and concluded 
that the osteoinductive capacities of the biomaterial tested in non-osseous sites in 
large animals is correlated to a better performance in clinically relevant orthotopic 
sites. However, in all these studies, bone formation was much lower in ectopic sites 
than in orthotopic sites.  
To date, the exact mechanism of osteoinduction by biomaterials is still 
unknown, while some authors hypothesize that BMPs could concentrate at the 
material surface after implantation, thus stimulating ectopic bone formation. On the 
other hand, the osteoinductivity of CaP materials could be modulated by their 
intrinsic physicochemical characteristics (geometry, topography, macropore size 
and percent of microporosity.   
 
Osteoconduction 
 
Osteoconduction refers to bone growth from bone defect edges towards the 
the surface or down into the pores of a biomaterial, which serves as a scaffold or 
template to guide the formation of the new bone tissue (Albrektsson & Johansson, 
2001). This phenomenon is regularly seen upon the implantation of bone substitutes 
and is considered dependent both on biological factors for bone repair, but also on 
the intrinsic properties (geometry, porosity) of the implanted biomaterial. Materials of 
89 
 
low biocompatibility, e.g. copper, silver and acrylic cement, show little or no 
osteoconduction (Nakamura et al., 2013). Surprisingly, bone conduction is observed 
with biomaterials such as stainless steel, which is not regarded as ideal from the point 
of view of biocompatibility (Albrektsson & Johansson, 2001). 
Bone growth at the surface of an implant involves differentiated bone cells at 
the injury site and progresses in six stages: (1) serum adsorption; (2) the recruitment of 
various cell types; (3) the attachment, migration and proliferation of recruited cells; 
(4) osteoblast differentiation and osteoid production; (5) osteoid matrix 
mineralization; (6) bone remodelling. In the final stage of osteoconduction, 
osteoclasts have an important role in resorbing the osteoid and implanted 
biomaterial, as well as in interacting with osteoblasts that are responsible for the 
bone formation (Nakamura et al., 2013). 
Importantly, bone growth, including bone conduction, does not occur without 
a proper vascularisation, and the principal action of many growth factors implicated 
in bone repair is both mitogenic and angiogenic.  
The osteoconductive response to a particular material is rather short lived, and 
maintaining the successful bone anchorage over a long period of time is attributed 
to osseointegration phenomenon (Albrektsson & Johansson, 2001).  
 
Osseointegration 
 
Osseointegration is the stable anchorage of an implant achieved by direct 
bone-to-biomaterial contact and maintained over time (Albrektsson & Johansson, 
2001). The same as osteoconduction, it is determined not only by biological factors, 
but also by the response to a foreign material. It was first described by Branemark as 
a direct contact, observed at light microscope magnification levels, between living 
bone and implant. In histological terminology, osseointegration is defined as the 
direct anchorage of an implant by the formation of bony tissue around the implant 
without the growth of fibrous tissue at the bone-implant interface. Another more 
biomechanically oriented definition of osseointegration has also been suggested: “A 
process whereby clinically asymptomatic rigid fixation of alloplastic materials is 
achieved, and maintained, in bone during functional loading”. It is not an isolated 
phenomenon, but instead depends on previous osteogenesis/osteoinduction and 
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osteoconduction. Thus materials that are too toxic to allow osteoconduction will not 
be osseointegrated (Albrektsson & Johansson, 2001). 
In oral and craniofacial implantology, osseointegrated implants have been a 
real breakthrough, yielding excellent functional results, in contrast to alternatively 
anchored implants, which have generally shown very poor success rates. Functional 
osseointegrated implants demonstrate interfacial bone density similar to that of the 
bone area in which the biomaterial was implanted. Screw-type implants inserted 
using a minimally traumatising technique have been convincingly osseointegrated, 
e.g. in hip arthroplasties and interphalangeal implants (Albrektsson & Johansson, 
2001). 
Osseointegration refers to general implant anchorage in the bone, so one- or 
two-point bone-biomaterial contact cannot be characterized as a real 
osseointegration. Even a slight implant displacement can compromise 
osseointegration, and it is shown that interfacial implant movement of more than 150 
µm inevitably lead to soft tissue formation instead of bone (Albrektsson & Johansson, 
2001). 
3.5. Calcium phosphates as drug delivery systems  
 
 In the design of new generation of bone substitutes, there is a growing interest 
in coupling bone biomaterials with pharmacological products. These combined 
devices provide mechanical stability, which stems from the structural properties of 
the material, and they also display enhanced biological activity due to the 
pharmacological action of the loaded drug. Thus, efficient pharmacological effects 
of the drug are confined to specific target site. This strategy overcomes several 
serious limitations of systemic drug administration including: (i) the need for high drug 
doses due to poor bioavailability at the disease site; (ii) low efficiency; (iii) drug side-
effects; (iv) toxicity issues; (v) poor patient compliance (Mellier et al., 2011). The focus 
is on the development of biomaterials capable of precisely timed drug release with 
predictable and reproducible pharmacokinetics (Verron et al., 2012). Special 
attention is paid to the prevention of uncontrolled and excessive drug release that 
could result in local tissue toxicity.  
Although the use of implants as drug delivery systems (DDSs) is well developed 
for cardiovascular applications (drug-eluting stents) and increasing for diabetic 
management (insulin pumps), this concept is still in infancy for bone applications. 
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Regulatory aspects are important obstacles that have to be tackled by orthopaedic 
industry. Indeed, such bone DDS are considered as combination devices by the FDA 
and, correspondingly, the registration of these new systems follows a longer 
procedure than that of traditional orthopaedic implants (Verron et al., 2010c). 
Nowadays, efforts are focused on developing mixed systems that combine 
calcium phosphate bone substitutes with active molecules. Current research on 
these bone drug delivery systems aims to improve the osteogenic potential of CaP in 
healthy bone sites and to provide a bone response in pathological ones.  
Great number of commercially available CaP-based bone substitutes has the 
capacity to integrate molecules of different chemical composition. Excellent 
biocompatibility, complete resorbability, very low exothermic behaviour that does 
not affect loaded drug, as well as clinical efficacy, have prompted calcium 
phosphate cements as attractive candidates for combining with therapeutic agents. 
Physicochemical structure of CPCs (specific surface area, porous size distribution and 
connectivity, roughness, grain size, etc.) (Verron et al., 2012) permits 
pharmacological compounds incorporation either by ionic substitution (chemical 
association) or by surface adsorption (physical association). When implanted, CPCs 
combined with drugs may act, as their primary function, as mechanically resistant 
sacrificial calcium phosphate source for bone reconstruction, but as well as vectors 
for active compounds that address bone-related disorders or infections. Therefore, 
CPCs have been proposed as good carriers for local and controlled supply of 
antibiotics, anti-inflammatory, anti-resorptive or anti-cancer agents (Mellier et al., 
2015).  
As mentioned before, the structure of a biomaterial (macro- and 
microporosity) affects its resorption by dissolution or/and cellular processes, and 
therefore greatly influences the drug-release profile. The degradation of the 
biomaterial carrier and previous sterilization step should not produce toxic 
metabolites or degrade the loaded drug. Figure 11 summarizes general requirements 
of a biomaterial-based DDS to be used in bone tissue engineering (Verron et al., 
2012). 
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Figure 10. General requirements of a bone drug delivery system. 
The implantation of bone substitute reinforces mechanical properties of damaged 
bone site and if resorbed, can induce new bone formation. In pathological situations, bone 
substitutes can have an auxiliary beneficial effect if loaded with active molecules (taken from 
Verron et al., 2012). 
 
 
Combined devices in bone reconstructive surgery 
Combing different osteogenic and angiogenic factors with calcium 
phosphate cements has the potential to improve bone reconstruction at the 
implantation site.  
Numerous studies have analyzed reconstructive properties of cement-bone 
morphogenetic protein combined devices. For example, Haddad et al. (Verron et 
al., 2010c) evaluated bone repair in a critical-size calvarial defect in rabbits, after 
implantation of apatitic cement loaded BMP-2. After 12 weeks of implantation, they 
observed a 45.8% increase of bone formation in cement/BMP-2 group compared to 
unloaded control cement. Moreover, some clinical studies focused on BMP-2, have 
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begun to confirm the encouraging results of preclinical studies (Verron, Bouler, & 
Guicheux, 2012). In a clinical study, Dimar et al. used a vertebral fusion model to 
compare the efficiency of iliac crest autograft versus CaP biomaterial combined 
with BMP-2. The implantation of combined device gave a clear improvement 
compared to the iliac crest bone graft in terms of vertebral fusion rate (88% vs 73%), 
duration of the intervention (2.4 h vs 2.9 h), haemorrhages (273 cm3 vs 465 cm3), and 
morbidity (leg and back pain) (Verron, Khairoun, Guicheux, & Bouler, 2010c). In 
addition, several studies have shown a beneficial effect of associating growth 
factors with CaP during the filling of bone defects (Verron, Khairoun, Guicheux, & 
Bouler, 2010c). 
Due to its osteogenic properties, transforming growth factor-beta also 
constitutes an attractive candidate for a bone DDS. Indeed, Sumner et al. shown 
that the in situ release of TGF-β2 from a CaP-based substitute, increased twofold the 
amount of newly formed after a four week implantation period in the dog proximal 
humerus (Verron, Khairoun, Guicheux, & Bouler, 2010). 
Another preliminary study demonstrated an increased proliferation of MG-63 
cells and the phosphatase alkaline activity of SaOS-2 cell line in the presence of 
insulin growth factor (IGF) released in vitro from a biomaterial composite (Verron, 
Khairoun, Guicheux, & Bouler, 2010c). 
Since VEGF contributes significantly to angiogenesis during bone healing (E. 
Verron, Bouler, & Guicheux, 2012), it has been proposed that a CaP substitute 
loaded with VEGF could enhance new bone formation. A short-term release of VEGF 
is supposed to promote angiogenesis, while a sustained release of VEGF should 
improve bone regeneration thanks to its stimulatory effects on both angiogenesis 
and osteoblast differentiation. However, most studied delivery systems induced the 
release of high amounts of VEGF during the initial phase of biomaterial resorption, 
and high VEGF concentrations are known to provoke an increase in vascular 
permeability with formation of non-functional blood vessels (Verron, Bouler, & 
Guicheux, 2012).  
 
Combined devices in bone pathological situations 
 
 Any pathological situation (e.g. infection, irradiation, tumour) unfavourably 
affects bone implant performances in terms of substitution and/or resorption process. 
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The local administration of active agents has numerous advantages compared with 
systemic treatments in terms of therapeutic efficiency and tolerance, mainly due to 
specific tissue response and optimal bioavailability (Verron, Khairoun, Guicheux, & 
Bouler, 2010c). 
 One major focus is the combinations of CaP materials with antiresorptive 
drugs, such as bisphosphonates (BPs) or strontium. Seshima et al. envisaged apatite 
as a potential vector for alendronate and have studied the influence of certain 
material characteristics (crystallinity, specific surface, solubility) on the drug release 
profile. In another study, various zoledronate concentrations were grafted on 
titanium substitute coated with HA, and implanted in either healthy or osteoporotic 
female rat condyles (Peter et al., 2005; Peter et al., 2006). In both healthy and 
osteoporotic group, a significant increase in the peri-implant bone volume fraction 
was observed, reinforcing the idea of using a local bisphosphonate delivery from 
CaPs. Moreover, injection of BP-loaded calcium-deficient apatite (CDA) within 
proximal femurs of osteoporotic ewes led to a significant increase in relative bone 
content and an improvement of the bone microarchitecture (Verron, Bouler, & 
Guicheux, 2012). Considering strontium, it was recently introduced for the prevention 
and the treatment of osteoporosis. The implantation of strontium-doped CaP in the 
foreleg radius of rabbits showed increased bone formation in Sr-CaP group when 
compared to control group. Interestingly, no difference was observed in terms of 
degradability between both groups 16 weeks after implantation (Tian et al., 2009). 
 Although rare, infections associated with the implantation or the revision of 
orthopaedic devices are known to generate additional morbidity (prolonged 
hospitalization, poor functional outcome, risk of septicaemia, etc.). In extreme cases, 
acute or chronic osteomyelitis can compromise the vital prognosis of the patient. 
Therefore, bone DDSs releasing antibiotics present an interesting clinical approach 
for postoperative infection prevention. A meta-analysis of 19 studies covering 35 659 
patients confirmed the usefulness of loaded cements in treating bone infections. 
They reduced the bone infection rate by half in primary prevention, and by 
approximately 40% in secondary prevention. However, resistance of some 
pathological strains has appeared, suggesting that the application of these loaded 
cements should be restricted only to multi-resistant strains (Elise Verron, Khairoun, 
Guicheux, & Bouler, 2010c). 
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Concerning the field of bone tumours, 80% of osteosarcomas are treated with 
pre- and postoperative chemotherapy coupled to surgery, with a healing rate 
between 60% and 70%. To reduce the risk of developing metastases in other organ 
sites, wide excision of the tumour and curing of the surrounding tissues are 
systematically associated with chemotherapy. Since biomaterials can be used to fill 
the bone cavities after tumour excision, several teams looked into the development 
of combined systems with the goal of providing high anti-cancer drug release at 
bone sites. Considering the major side-effects of chemotherapy (e.g. digestive 
complications, haematotoxicity, nephrotoxicity, hepatotoxicity) that cause the 
interruption of usual systemic treatments, it is anticipated that the local release of 
high chemotherapeutic doses will be more efficient and better tolerated by the 
patient (Elise Verron, Khairoun, Guicheux, & Bouler, 2010c). As an illustration, Itokazu 
et al. characterized the release of anti-cancer compound methotrexate from two 
different CaPs. In the first days, approximately 1 mg/mL of methotrexate was 
released and this reduced progressively to reach, on the 12th day, a local 
concentration of approximately 0.1–1 mg/mL, which remained efficient. In a another 
study, it was reported that the use of combined biomaterial loaded with 
chemotherapeutic agent paclitaxel slowed by 140% the appearance of paralysis 
linked to bone metastases in rat vertebral metastasis model, and increased the 
survival rate by 150% (Elise Verron, Khairoun, Guicheux, & Bouler, 2010c). Lastly, acute 
postoperative pain following bone surgery is a severe complication that 
considerably disturbs patients’ convalescence by reducing mobility, functional 
recovery and increasing hospital stay. Moreover, if this postoperative pain persists, it 
generally turns to chronic pain that is more difficult to cure]. So, to facilitate patients’ 
recovery, it is critical to manage bone postoperative pain by the administration of 
conventional analgesics, such as morphine-derived products or anti-inflammatory 
drugs. In line with this, several preclinical developments have been conducted, 
associating biomaterials with the non-steroidal anti-inflammatory drug indomethacin, 
,aspirin, or bupivacaine, one of the most commonly used local anaesthetics (Verron, 
Bouler, & Guicheux, 2012). 
  
96 
 
4. Gallium 
 
4.1. Physicochemical properties  
 
 Gallium (Ga) was discovered by Lecoq de Boisbaudran in 1875 as a semi-
metallic element with atomic number 31, and position in group IIIa of the periodic 
table of elements. Its main physicochemical properties are summed up in Table 5. In 
most of its compounds, gallium comes in the form of a trivalent ion, Ga3+. Charged 
Ga3+ is almost completely hydrolyzed over a wide pH range, thus, forming hydroxide 
species, particularly gallate (Ga(OH)4- (Hancock & Marsicano, 1980). In aqueous 
solutions, under physiological conditions, essentially all Ga3+ ions (98.4%) are 
incorporated in gallate (Harris & Pecoraro, 1983). Ga hydrolysis is accompanied by 
formation of hydronium ion, H3O+, which lowers the pH of the aqueous solution. 
Conversely, in conditions of elevated pH, the precipitation of highly insoluble 
amorphous Ga(OH)3 occurs (Benézéth et al., 1997).  
 
Figure 11. Gallium typical silver-white appearance. 
(taken from https://www.flickr.com/photos/argentoratum/3305472652). 
 
The chemical behaviour of Ga3+ resembles to that of Fe3+, in terms of electric 
charge, ion diameter, coordination number and electronic configuration (Collery, 
Keppler, Madoulet, & Desoize, 2002). Due to this similarity, in biological systems Ga 
can compete with iron for binding to Fe3+-binding proteins. 
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Table 5. Main physicochemical properties of gallium. 
(adapted from http://www.lenntech.com/periodic/elements/ga.htm) 
 
atomic number 31 
atomic weight 69.72 
melting point 29.78 °C 
boiling point 2400 °C 
crystal structure orthorhombic 
appearance silver-white 
 
4.2. History of clinical application of gallium compounds 
 
 The first mentioning of Ga as a possible therapeutic agent appeared in 1931 in 
the work of Levaditi who tested Ga tartrate effects in syphilis treatment in a rabbit 
model and for the eradication of Trypanosoma evansi in a mouse model. In 1940s, 
the focus was shifted to investigating Ga radioisotopes tissue distribution (Bernstein, 
1998). It was found that Ga presented a strong affinity for growing and remodelling 
tissues like tumours and bone (Dudley & Maddox, 1949). 67Ga and 68Ga radioisotopes 
are readily absorbed by cancer deposits in bone and have been extensively used as 
imaging agents in diagnosis and study of neoplastic diseases (Collery et al., 2002; 
Cutler et al., 2013). 
In bone pathologies, Ga efficiently suppresses accelerated bone resorption 
and bone pain associated with multiple myeloma and more generally, it decreases 
bone malignancy-induced hypercalcaemia (Bernstein, 1998). Citrated Ga(NO3)3 for 
intravenous injection (Ganite®) is a FDA-approved drug for the treatment of 
hypercalcaemia of malignancy (Mellier et al., 2011). In addition, Ga was found to be 
also effective in the treatment of Paget’s disease of bone (R. S. Bockman & Bosco, 
1994), and due to its antiresorptive properties, it was suggested as a possible 
treatment for osteoporosis as well (Verron, Bouler, & Scimeca, 2012b). 
Considering that some similar elements, like platinum, exhibit antitumor 
properties, there was an extensive investigation of Ga potential antitumor effects. In 
clinical trials with patients suffering from relapsed malignant lymphomas, 43% of the 
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subjects responded to a Ga nitrate treatment. On the other hand, Ga efficacy was 
controversial in few cases of treatment of melanoma and epithelial ovarian cancer 
(Verron, Bouler, & Scimeca, 2012b).  
Besides its avid bounding to tumour or bone tissue, Ga also accumulates at 
the sites of inflammation and infection, and can have anti-inflammatory and 
immunosuppressive action. Indeed, subcutaneously administrated Ga nitrate 
suppressed the development of adjuvant arthritis in rats (Verron, Bouler, & Scimeca, 
2012b). 
Despite obvious clinical efficiency, the exact mechanism of Ga action on 
bone and cancer cells remained unknown for a long time. Recent in vitro and in vivo 
studies, which will be discussed later, elucidated important cellular and molecular 
targets of Ga action. 
   
4.3. Gallium interactions with plasma membrane proteins  
 
By the virtue of similarity to Fe3+, Ga3+ can occupy ferric sites in several proteins 
and chelate complexes. Hence, Ga3+ can compete with Fe3+ for binding to 
transferrin (TF), the major iron transport protein (Kubal, Mason, Patel, Sadler, & 
Woodworth, 1993). On the other hand, Ga3+ ion is irreducible under physiological 
conditions so that it could not compete with Fe2+ in binding to haemoglobin, which 
would otherwise result in major haematological toxicity (Verron, Bouler, & Scimeca, 
2012b). Transferrin binds to two different receptors, TF receptors 1 and 2 (TFR1 and 
TRF2). All nucleated cells of the body seem to express either one of these receptors, 
but their concentration varies considerably. TFR1 is highly expressed by rapidly 
proliferating cells, such as cancer cells, that need large amounts of iron. In the 
course of osteoclast differentiation, mitochondrial biogenesis requires an increased 
iron uptake, which results in the upregulation of TFR1 on its plasma membrane. Since 
Ga is capable of binding to TFR1 ligand, transferrin, it is hypothesized that TF/TFR1-
mediated uptake is the mechanism of Ga cellular internalization (Ishii et al., 2009). In 
line with this, Ga concentration was found to strongly correlate with TRF expression in 
malignant tissue. And it has been shown that tumours overexpressing TFR internalised 
Ga more avidly than tumours lacking a functional TFR (Luttropp et al., 1998). 
Accordingly, in lung carcinoma tumour cells, as well as for several types of 
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lymphomas, it was found a high correlation between TFR expression and 67Ga 
binding capacity (Bernstein, 1998).  
TFR-mediated Ga uptake does not exclude the possibility of Ga interaction 
with other membrane transporters. Sohn et al. proposed a TF-independent Ga 
uptake by bone cells, based on the fact that Ga concentration in bone was not 
affected in hypotransferrinemic mice lacking TF protein (Sohn et al., 1993). Lastly, and 
beside Ga transport into cells, calcium channels such as TRPV-5A were also 
proposed as potential partners involved in Ga action on extracellular Ca entry into 
cells (Verron et al., 2010d). 
 
4.4. Gallium and bone tissue  
 
In bone, Ga tends to bind in metabolically active regions, such as 
metaphyseal growth plate, growth cartilage and fracture sites. To a lesser extent, Ga 
also accumulates on the endosteal and periosteal surfaces of dyaphyseal bone 
(Bernstein, 1998). Concerning the mechanism of Ga accumulation within bone tissue, 
it is hypothesized that Ga could attach to the mineral matrix by substitution with 
calcium (Ca) ions (Bockman et al., 1993). This was confirmed later by Korbas et al. 
who found that Ga uptake by bone depends on the maturation stage of the mineral 
phase (Korbas, Rokita, Meyer-Klaucke, & Ryczek, 2004). Indeed, in the initial phase of 
mineralization, Ga substituted Ca and modified the apatite configuration, blocking 
its growth. Thus, further maturation of the mineral phase included only apatite that 
did not contain Ga. In contrast, when added in late mineralization stage, Ga could 
not incorporate into the already formed apatite. Nevertheless, Ga can be adsorbed 
on the surface of already formed apatite crystals, interfering with their solubility.  
 
4.4.1. In vitro studies of gallium effect on bone cells 
 
Ga action on osteoclast  
 
Several studies have established the inhibitory effect of gallium on osteoclast-
mediated bone resorption (Blair, Teitelbaum, Tan, & Schlesinger, 1992; Bockman, 
2003; Hall & Chambers, 1990; Lakatos, Mong, & Stern, 1991; Liewehr et al., 1995; 
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Shaini, Shelton, Marquis, & Shortall, 2000). Blair et al. described in vitro Ga interactions 
with bone slices, bone cells and cell culture medium (Blair et al., 1992). They 
observed a 50% reduction in osteoclastic resorption when bone slices were pre-
treated with Ga. Even more, at high Ga doses, osteoclast activity was totally 
abolished. Similarly, Hall et al. (Hall & Chambers, 1990) found that Ga, in solution at 
391 µM, reduced by 64% the osteoclast-mediated resorption of cortical bone slices. 
However, when bone slices were treated to pre-adsorb Ga, the resorption inhibition 
observed was approximately twice lower (34%). and Ga did not affect cell 
morphology nor altered osteoclast number. By contrast, in another study, it was 
reported that Ga displayed cytotoxicity towards osteoclast for concentrations 
starting from 50 µM (Blair et al., 1992). 
Concerning, the molecular mechanisms underlying Ga anti-osteoclastic 
actions, an early study by Mills et al. (Milles et al. 1988) showed that 67Ga localized 
almost exclusively in the osteoclast nuclei, suggesting that Ga could interfere with 
gene expression. More recently, molecular pathways impacted by Ga treatment 
were more precisely documented by Verron et al. (Verron et al., 2012c; Verron et al., 
2010d). The authors found that 100 µM Ga dramatically reduced in vitro osteoclast 
formation from unfractioned primary rabbit bone cells, and also that Ga dose-
dependently inhibited the resorption activity of differentiated rabbit osteoclasts. 
Using another model, the mouse monocyte-macrophage cell line RAW 264.7, they 
showed that Ga downregulated the expression of several osteoclastic marker genes 
(Nfatc1, Trap, Calcr, Ctsk, Rank, Oc-stamp) in a dose-dependent manner (0-100 µM), 
without any cytotoxic effects.  
A general scheme is proposed in Figure 13, which illustrates Ga action on two 
main signalling pathways involved in RANKL-induced osteoclastogenesis, namely NF-
κB and calcium pathways. NF-κB is constitutively present in cytoplasm, coupled to its 
inhibitor IκB. IkB phosphorylation is a marker for ubiquitination and subsequent 
proteasome-mediated degradation, which unmasks the nuclear localization signal 
motif of NF-κB. Upon its nuclear translocation, NF-κB stimulates the initial induction of 
Nfatc1 gene, the master regulator of osteoclastogenesis. In line with this, gallium 
inhibitory action on IκB degradation leads ultimately to a down-regulation of Nfatc1 
gene expression. Concerning calcium signalling, this pathway is of particular 
importance during osteoclastogenesis. In response to RANKL, the calcium channel 
TRPV-5A would participate in calcium entry into the cell. Indeed, in response to 
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gadolinium, an agonist of TRPV-5A, intracellular [Ca2+] oscillations needed for proper 
osteoclastogenesis are observed. Importantly, Ga completely abolishes gadolinium-
induced intracellular [Ca2+] oscillations. These results strongly suggest that an 
alternative mode of Ga action on osteoclast differentiation may be the blocking of 
specific calcium channels in the plasma membrane of undifferentiated osteoclasts. 
Lastly, Ga completely reversed calcium-induced CREB phosphorylation, thus 
blocking its cooperation with NFATc1 for the induction of osteoclast marker genes 
expression program (Verron et al., 2012c).  
 
Figure 12. Gallium molecular targets in osteoclast differentiation. 
Gallium can interfere at different levels in RANK-L-induced osteoclast 
differentiation (taken from Verron et al., 2012c). 
  
Ga action on osteoblast - osteocytes 
 
Only a few studies addressed Ga effects on bone-forming cells osteoblasts. In 
early works using rat osteogenic sarcoma (ROS) osteoblast-like cells treated with Ga, 
several authors reported an increase in type I collagen gene expression, but also a 
decrease in osteocalcin mRNA and protein levels (Bockman et al., 1993; Jenis, 
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Waud, Stein, Lian, & Baran, 1993). Using rat primary osteoblasts, Bockman et al. 
revealed that Ga stimulated the production of fibronectin and type I collagen, but 
this effect was only transient (Bockman et al., 1993). Lakatos et al. observed that Ga 
inhibited PTH-stimulated calcium transport in UMR-106 osteoblast model (ROS cell 
line), and they speculated that by reducing osteoblastic response to PTH, it is possible 
to decrease PTH-stimulated bone resorption (Lakatos et al., 1991). 
 Later, it was demonstrated that Ga did not affect the viability, the 
proliferation rate nor the alkaline phosphatase activity in MC3T3-E1 cell line or  in 
primary murine osteoblasts (Verron et al., 2010d). In the same study, Ga treatment 
stimulated the expression of Alp, Osx, and Runx2 markers in MC3T3-E1 cells. 
As explained previously, at the end of a bone remodelling cycle mature 
osteoblasts can differentiate in osteocytes. Although they make up 90% of bone 
cells, at the best of my knowledge, so far no studies addressed potential Ga effects 
on osteocytes. This is due to the difficulty to set up a relevant in vitro model to study 
this particular bone cell type. 
 
4.4.2. In vivo studies of gallium effect on bone  
 
Most insights into in vivo Ga properties were obtained from normal or 
osteoporotic rat models. For example, studies by Ma et al. (Ma & Fu, 2009, 2010) 
showed positive Ga effects on ovariectomized osteopenic female rats, which 
received orally 120 µg/kg/day of Ga during eight weeks. Compared to the non-
treated group, Ga-treated rats exhibited an increase in trabecular bone volume 
(37%), trabecular thickness (48.4%), and cortical thickness (32.2%). Reflecting an 
inhibition of bone resorption, a decrease in calcium and phosphate plasma levels 
was also observed, At the same time, the bone mineral content of the vertebrae 
and femur was elevated and femoral neck strength was significantly higher in Ga 
group (110 N) compared to control (80 N). Similarly, Stern et al. demonstrated that 
Ga administration stimulates osteoblasts activity in ovariectomy-induced osteopenia 
associated with low-Ca diet (Stern et al., 1994). Nevertheless, this stimulation was not 
sufficient to prevent osteopenia bone loss in rats. In another study using organic 
yeast-derived Ga, it was shown that Ga can promote callus bone formation in a 
fracture healing model in ovariectomized rats (Pei & Fu, 2011). 
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On the contrary, a study by Wakley et al., in normal rats, evidenced an 
inhibition of bone formation and apposition (32% and 36% respectively) without any 
significant effect on bone resorption, when 900 µg/kg of Ga was injected 
intraperitoneally during 21 days (Wakley et al., 1992). However, at higher doses (1.8-
3.5 mg/kg), Ga lowered calcium and vitamin D serum levels, and inhibited bone 
resorption, but also the bone formation. In another study in normal rats, Jenis et al., 
found that a subcutaneous 3-week Ga treatment (500 µg/kg/day) decreased 
calcium serum levels without any significant effect on bone mineral density (Jenis, 
Waud, Stein, Lian, & Baran, 1993).  
The discrepancy in Ga effects on bone in abovementioned studies could be 
due to the differences in Ga treatment duration, doses and administration mode, as 
well as to the fact that some studies used osteoporotic models while others were 
conducted in normal rats. Thus, although Ga antiresorptive activity in vivo is fairly 
evidenced in the literature, its anabolic effects on bone tissue are still controversial.  
 
4.4.3. Clinical studies of gallium therapeutic potential in bone disorders 
 
Ga clinical efficiency as an antiresorptive agent was first demonstrated in a 
pilot study by Warrell et al. (Warrell, Bockman, Coonley, Isaacs, & Staszewski, 1984). 
Patients suffering from cancer-related hypercalcaemia were treated with gallium 
nitrate by continuous infusion, and all subjects responded by a reduction of total 
serum calcium to normal or subnormal concentrations, indicating that Ga 
suppressed excessive bone resorption related to malignancy. The same group 
showed that a short-term treatment with gallium nitrate could reduce biochemical 
parameters of disease activity in patients with advanced Paget disease of bone (R P 
Warrell et al., 1990). Several other clinical trials confirmed that a daily dose of 100-300 
mg/kg of Ga was effective against cancer-induced hypercalcaemia resulting from 
an excessive bone resorption (Collery et al., 2002). Matkovic et al. (Matkovic et al  
1991) conducted a study on postmenopausal women and found that Ga nitrate 
treatment significantly elevated serum level of alkaline phosphatase, a classical 
marker for bone formation. More recently, a small clinical trial, involving myeloma 
patients receiving chemotherapy, showed that Ga could attenuate the rate of bone 
loss (Niesvizky, 2003). 
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On the whole, in vitro and in vivo studies, as well as clinical trials, are in favour 
of using Ga compounds for the regulation of excessive osteoclastic activity seen in 
osteoporosis or in other osteolytic bone diseases. Although not yet firmly established, 
Ga seems to potentiate also bone formation by acting on osteoblasts.  
4.5. Gallium and tumours 
4.5.1. In vitro studies of gallium antitumor effects 
 
Several molecules and cellular processes are identified as possible Ga targets in 
tumour cells. It was demonstrated that Ga could: (i) bind to phosphates and nucleic 
bases of DNA molecule, thus destabilizing the DNA helix; (ii) compete with 
magnesium for DNA binding (Manfait & Collery, 1984); (iii) induce chromatin 
condensation, an early apoptosis step (Haq, Wereley, & Chitambar, 1995). 
 
When cell growth-inhibiting concentrations of Ga are applied, most of the cell 
biosynthesis is reduced, including the protein synthesis (Collery et al., 2002). Ga was 
reported to decrease osteocalcin, transferrin receptor and haemoglobin levels. 
Conversely, it increases fibronectin and type I procollagen (Bockman et al., 1993; 
Chitambar & Zivkovic, 1987; Guidon, Salvatori, & Bockman, 1993). Ga is also capable 
of interfering with different enzymes’ activity, such as ATPases, DNA polymerases, 
ribonucleotide reductase, and tyrosin-specific protein phosphatases. In the form of 
chloride, Ga destabilizes microtubules and prevents their assembly (Perchellet, 
Ladesich, Collery, & Perchellet, 1999). Due to its chemical similarity with ferric ion, Ga 
can bind to several Fe3+-binding proteins and thus disrupt important intracellular 
pathways in which iron is implicated.  Mitochondrial function can also be altered by 
Ga treatment. It was shown that Ga induced calcium efflux from mitochondria, a 
process that is recognized as a preliminary step in apoptosis (Collery et al., 2002).  
Some authors reported also that Ga disturbed cell cycle of human T 
lymphoblastic cells in a way that it provoked an accumulation of cells in S phase of 
the cycle (Hedley, Tripp, Slowiaczek, & Mann, 1988). 
Lastly, in different tumour cell lines, a combined treatment consisting of Ga 
and one other well-established chemotherapeutic drug showed that Ga could 
circumvent drug resistance of tumour cells. These results are of particular interest for 
the treatment of multidrug resistant cancer cells (Collery et al., 2002).  
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4.5.2. In vivo studies of gallium antitumor effects 
 
In animal models, gallium anticancer properties were first described in a study 
by Hart et al. (Hart & Adamson, 1971), where Ga efficiently inhibited solid tumour 
growth in rodents. In mice, intraperitoneal administration of Ga during 10 days 
inhibited by 90% the growth of subcutaneously transplanted solid tumours. Ga was 
also effective against 256 Walker sarcoma by increasing the survival time by 138%, 
compared to control. In the same line, intraperitoneal Ga injection suppressed 
tumour growth and the formation of metastases after Lewis lung carcinoma 
transplantation (Capel et al.,1981). On the other hand, Ga was not shown to be 
effective against different leukaemia types and Ehrlich carcinoma (Collery et al., 
2002). Carpentier et al. assessed the efficacy of Ga treatment in different tumour 
stages in mouse adenocarcinoma CA755 (Carpentier et al. 1987). They observed a 
rapid decrease in tumour volume when Ga was administered during the exponential 
phase of tumour growth, while the treatment during the plateau phase was less 
efficient.  
Studies on Ga intracellular distribution in tumour cells yielded variable results. 
Some authors found Ga bound to ferritin and mostly localized in the nuclei, while 
others showed high Ga concentration in lysosomes or lysosome-like bodies. 
Additionally, it was reported that Ga also concentrated in lysosomes of tumour-
associated macrophages (Bernstein, 1998). 
  
4.5.3. Clinical studies of gallium antitumor potential  
 
As a result of its antiproliferative and antimitotic properties, gallium is the 
second metal (after platinum) to be used in cancer treatment (Collery et al., 2002). 
Some earlier clinical trials proved Ga efficacy against bladder and urothelial 
carcinomas (Bernstein, 1998). One other study of Ga influence on prostate cancer in 
elder patients proved only modest clinical effects (Senderowicz et al., 1999), and 
although exhibiting no major toxicity, oral administration of Ga yielded only partial 
responses in ovarian cancer treatment (Collery et al., 2002). 
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Certain studies failed to show any anti-cancer effect of gallium compounds 
(Collery et al., 2002). Nevertheless, due to administration modalities, Ga 
concentration at tumours sites was probably low. Thus, poor bioavailability of Ga in 
tumour microenvironment probably explains the absence of Ga effect in these 
studies (Hall et al., 1979). 
It was proposed that Ga could be used to potentiate the action of 
chemotherapeutic agents and consequently, in phase I or II clinical studies, Ga 
efficacy has been tested in patients that are refractory to conventional 
chemotherapeutics. Indeed, its combined administration with 
cisplatin/vinblastine/ifosfamide indicated that Ga can potentiate their anticancer 
effects (Collery et al., 2012, 2002). However, in some of these studies, a high degree 
of toxicity was observed (e.g. renal dysfunction, anaemia, granulocytopenia, 
thrombocytopenia, temporary blindness), probably due to the cumulative effects of 
administered drugs.  
 
4.6. Other potential therapeutic applications of gallium 
 
In addition to bone and tumour sites preference, it is known that Ga also 
concentrates at sites of inflammation or infection, and several animal studies 
describe Ga immunomodulating properties. 
Some authors demonstrated Ga efficacy in asthma (Apseloff et al., 1996), 
type I diabetes (Flynn et al., 1992) in murine models. After being the first studied 
biological effect of gallium, the antibacterial activity of Ga compounds against 
several important pathogens, such as Mycobacterium tuberculosis, Pseudomonas 
aeruginosa, Acinetobacter baumannii, and Staphylococcus aureus has been 
demonstrated both in vitro and in vivo (Rangel-Vega, Bernstein, Mandujano-Tinoco, 
Garc-a-Contreras, & Garc-a-Contreras, 2015). For example, a study on murine sepsis 
model showed that Ga could efficiently suppress the pathogen-induced production 
of nitric oxide (Krecic-Shepard et al., 1999). And, with a view to inhibit bacterial 
infections after bone substitute implantation, it was recently proposed to graft 
gallium and silver ions on titanium bone implants to counteract the biofilm formation 
(Cochis et al., 2014).  
Concerning immunomodulation, it was reported that, in the absence of any 
general immunosuppressive action, Ga suppressed adjuvant-induced arthritis 
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(Matkovic, 1991), experimental encephalomyelitis (Whitacre et al., 1992), 
experimental autoimmune uveitis (Lobanoff et al., 1997), and allograft rejection 
(Orosz et al., 1996). In in vitro studies, Ga also inhibited T cell and macrophage 
activation, without inducing their cytotoxicity (Huang et al., 1994); (Makkonen et al., 
1995); Drobyski, Ul-Haq, Majewski, & Chitambar, 1996). Lastly, in the context of organ 
transplantation, Ga was found to suppress acute tissue rejection of cardiac allografts 
and severe graft versus host disease in mice (Bernstein, 1998). 
 
4.7. Calcium phosphate biomaterials as vectors for local delivery 
of gallium 
 
Oral administration of Ga salts, such as nitrate or chloride, results in the 
formation of an acidic solution due to the Ga3+ hydrolysis and possibly induces tissue 
damage extremely inconvenient for drug administration. Such acidified solutions 
facilitate the precipitation of poorly soluble Ga(OH)3, affecting the pharmacokinetics 
of Ga compounds. The observed low Ga absorption upon oral administration is most 
probably a consequence of formation of poorly soluble Ga species in the 
gastrointestinal tract (Verron, Bouler, & Scimeca, 2012b). Some studies reported that 
the systemic administration (oral or parenteral) of gallium compounds resulted in 
elevated concentration of gallium in kidneys and liver, possibly generating toxicity 
issues together with a poor delivery of Ga to the aimed tissue. These important 
drawbacks related to systemic administration of Ga could be circumvented by a 
local delivery strategy. 
Taking into account Ga anti-resorptive effects on bone tissue, as well as its 
potential use as an antiosteoporotic drug, calcium phosphate bone substitutes are 
suggested as attractive vectors for local delivery of Ga to bone. Even though 
osteoporosis is a systemic bone disease, most osteoporotic fractures occur in three 
common sites: wrist, hip and spine. This preference for particular bone sites justifies 
the idea of Ga delivery only to these specific sites that present high fracture risk. 
These sites often present low bone density or microfractures and so could benefit of: 
(i) new bone ingrowth induced by CaP/Ga composite; (ii) secondly, Ga 
antiosteoclastic properties on a local site usually displaying an excessive bone 
resorption (Verron, Bouler, & Scimeca, 2012b). Thus, delivering Ga locally through 
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CaP biomaterials is proposed as a clinical strategy to reinforce osteoporotic bone. 
Although preclinical research provided strong evidence on Ga antiresorptive 
potential, no clinical trials were conducted to assess Ga effects in the context of 
osteoporosis prevention or treatment.  
In addition, the implantation of CaP/Ga composites could also be beneficial 
after bone tumour or metastases excision, due to the well-documented anticancer 
effects of Ga. In this context, Ga could inhibit the proliferation of eventual remaining 
tumours cells after the excision and thus, prevent cancer local recurrence and 
spreading.  
More generally, a local delivery strategy would provide optimal Ga 
bioavailability at bone site, and help to reduce toxicity issues related to systemic 
administration. A study by Donnelly et al. analysed the properties of Ga-loaded bone 
particles implanted subcutaneously in rats. Particles incorporating Ga were less 
readily resorbed, suggesting that Ga treatment inhibited local mineral resorption 
activity (Donnelly, Bockman, Doty, & Boskey, 1991). The observed effect was not 
associated with a reduction of multinucleated osteoclast-like cells, suggesting that 
Ga did not interfere with their recruitment or their differentiation in vivo. In a recent 
study by Mellier et al. (Mellier, et al., 2015) two different Ga-loaded calcium 
phosphate cements were implanted in rabbit femora for 4 weeks. No significant 
difference was observed in biological performance of theses 2 cements compared 
to control, but the amount of resorbed biomaterial was rather low, and 
consequently, the quantity of released gallium was small. For the moment, these are 
the only two in vivo studies that reported on Ga local delivery. 
 
4.7.1 Incorporation of gallium in calcium phosphate biomaterials 
 
As mentioned before, Ga can be integrated in the structure of calcium 
phosphate materials by partial substitution with calcium. It can be either 
chemisorbed onto the surface of calcium-deficient apatite or inserted in the 
structure of β-tricalcium phosphate. In terms of injectability and setting time, the 
addition of these gallium-doped components into a CaP cement final formulation 
did not significantly affect the main properties of the cement (Mellier, et al., 2015). 
The suitable protocols for combining Ga and calcium phosphate cements, while 
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preserving the textural, mechanical and setting properties, have been developed 
recently by Mellier et al. (Mellier et al., 2011; Mellier et al., 2015). Generally, the 
introduction of gallium(III) ions into an injectable apatitic cement includes: (i) 
dissolution of a gallium salt in the liquid phase; (ii) mixing a gallium salt with the 
ground solid phase; (iii) chemical combination of gallium ions with one of the 
calcium phosphate components of the solid phase (Mellier, et al., 2015). 
4.7.1.1 Incorporation of gallium in calcium-deficient apatite (CDA) 
 
Composites of gallium and calcium-deficient apatite (CDA) were synthesized 
by co-precipitation of a mixture of gallium nitrate hydrate and calcium nitrate 
tetrahydrate with diammonium hydrogen phosphate. The reaction was performed in 
the 9–9.5 pH range with (Ca + Ga)/P molar ratio = 1.515. Electron and X-ray 
diffraction (XRD) analysis of the nanostructure of precipitate confirmed that the 
obtained material is CDA (Charlotte Mellier, Fayon, Boukhechba, Verron, LeFerrec, et 
al., 2015). The nanocrystalline CDA obtained by precipitation is known to possess a 
peculiar structure, which consists of a nearly stoichiometric apatitic crystalline core 
and a disordered hydrated surface layer. This hydrated surface layer, which involves 
labile ionic species with non-apatitic chemical environments, confers specific 
physicochemical properties to CDA such as capability to reversibly exchange ions 
and adsorb organic molecules and proteins. To investigate the nature of the gallium 
species in the obtained CDA, a detailed structural characterization by solid-state 
nuclear magnetic resonance (NMR) was performed (Charlotte Mellier, Fayon, 
Boukhechba, Verron, LeFerrec, et al., 2015). 
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reaction. Interestingly, in comparison to standard preparation protocol, slightly higher 
compressive strengths of the cement were obtained when CDA/Ga was used as a 
solid phase in cement preparation (Charlotte Mellier, Fayon, Boukhechba, Verron, 
LeFerrec, et al., 2015). Indeed, comparative scanning electron microscopy (SEM) 
observations of hardened cement samples showed that, during the cement setting 
process, the presence of CDA/Ga in the cement composition led to the formation of 
significantly larger CDA crystals. This might result from the slower rate of the setting 
reaction observed for these samples, together with a texture of higher fluidity, 
compared to the standard cement without Ga (Mellier, et al., 2015). 
4.7.2 In vitro release of gallium from calcium phosphate cement (Quickset) 
 
In vitro, chemical dissolution of Ga-loaded calcium phosphate cement 
(CPC/Ga) in the cell culture medium was shown to release Ga species at relatively 
low concentration. Using ICP-MS (inductively coupled plasma–mass spectrometry) 
analysis, this release was estimated to correspond to less than 0.001% of the total 
amount of gallium initially loaded in the cement. This is not surprising since the limited 
porosity of the material probably confined the process only to the cement surface. In 
addition, it cannot be excluded that, once released from the CPC, part of the 
gallium species precipitate. More generally, Ga release was found to increase in 
direct relation with the amount of Ga initially loaded in the cement (Mellier, et al., 
2015). Ga release by active cellular resorption from CPC/Ga was also studied using 
murine RAW 264.7 cells seeded on the surface of the cement and stimulated with 20 
nM RANKL. In sharp contrast to the situation where no cells were seeded on cement 
surface, an increase of Ga release was observed in the presence of RAW 264.7 cells  
(Figure 14). This gradual release over a period of 7 days is very likely due to the 
osteoclastic resorption activity that increased with the maturation of RAW 264.7 cells.  
As a whole, these results strongly suggest that Ga release from CPC might 
occur from both passive chemical dissolution and active cellular resorption 
processes (Mellier, et al., 2015). 
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5. Second-harmonic generation microscopy (SHG) 
 
5.1. Current quantitative assessment methods in bone tissue 
engineering and their limitations 
 
Two-dimensional histomorphometry of tissue slides remains the gold standard 
in bone tissue analysis, despite the fact that this time-consuming and destructive 
method is limited to a very small percentage of the sample that can be taken for 
quantitative analysis.  
Micro-computed tomography (micro-CT) is a non-destructive technique, 
based on X-ray absorption, which is widely used for analysis of three-dimensional 
bone structure. Compared to classical 2D histomorphometric analysis, it is far more 
appropriate for assessment of structural parameters of bone, e.g. plates and rods 
dimensions, connectivity, and thickness (Peyrin, 2011). Micro-CT scans can be 
performed at high resolutions, such as few µm, allowing the detailed study of tissue 
microarchitecture in healthy and pathological bone. The 3D quantitative micro-CT 
analysis enables the characterization of disease processes and therapeutic agent 
effects in bone. It has been useful for the assessment of bone reconstructive 
properties of different kinds of biomaterials in the field of bone tissue engineering. In 
the particular case of calcium phosphate-based (CaP) biomaterials, their high 
chemical composition similarity with biological apatite results in the same X-ray 
attenuation coefficients and therefore, to very similar micro-CT images. This arises 
difficulties in manual thresholding between biomaterial and bone mineral phase 
(Peyrin, 2011). Even though some groups reported on automated thresholding of 
micro-CT images (Polak et al., 2012; Tuan & Hutmacher, 2005), to date this approach 
remains limited to a small number of scaffolds, and is not widely applicable for CaP 
biomaterial-bone tissue segmentation.  
In contrast, scanning electron microscopy (SEM) is a commonly used 
technique that provides unambiguous distinction between CaP biomaterials and 
bone tissue (Figure 16). SEM can achieve very high resolution of only few nm. 
However, this approach requires sample surface coating with a heavy metal or 
carbon, which is expensive and also restricts the imaging to the surface, thus 
allowing only for 2D analysis as in histomorphometry (Ambekar et al., 2012). 
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Figure 16. Scanning electron microscopy images of CaP and CDA 80-200 µm microparticles 
in a cavitary femoral defect in rat. 
At 2 months post-operatively, microparticles are surrounded by zones of newly formed bone 
(our unpublished data). 
 
5.2. The principle and simplicity of SHG 
 
Non-linear multiphoton optical microscopy has gained a lot of interest in 
recent years, due to its unique ability of in-depth imaging of thick biological samples. 
Thus, it permits the observation of complex structures with a micrometric 3D resolution 
(Beaurepaire et al., 2007). These techniques include two-photon excited 
fluorescence (2PEF), as well as second- and third-harmonic generation (SHG and 
THG respectively) (Beaurepaire et al., 2007).  
Physical features of certain molecules and molecule assemblies determine if 
they can produce a second-harmonic generation phenomenon, and the first 
requirement for SHG is a lack centro-symetry. In addition, these molecules/assemblies 
have to fulfil the phase-matching condition, which means that the incident and the 
resulting second harmonic waves travel at the same velocity. Only materials with a 
high degree of organization and orientation meet this requirement, i.e. anisotropic 
crystals or certain structural protein arrays that are called harmonofors. Thus, SHG is a 
highly specific phenomenon, which is produced by a limited number of biological 
structures including type I collagen fibers, myosin II, and tubulin (Vielreicher et al., 
2013).  So far, the most important use of SHG was for collagen organisation detection 
in diseases such as sclerodermia and epithelial cancer types. Imaging type I 
collagen by SHG microscopy requires excitation laser wavelengths from 720-960 nm, 
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while the generated SHG signal will be exactly half of the excitation wavelength. This 
signal originates from intrinsic properties of the molecule and no additional staining 
or labelling is needed. Other convenient characteristics of SHG are that this 
technique is non-destructive, and that no special sample preparation protocol is 
required (Vielreicher et al., 2013). 
 
5.3. SHG application in bone tissue imaging  
 
Type I collagen is the major organic constituent of bone matrix. Collagen 
molecules (tropocollagen), mineralized with hydroxyapatite crystals, represent 
mineralized collagen fibrils that are the basic structural units of bone. These 
mineralized fibrils are bundled into fibers of 2–3 μm diameters that form woven or 
lamellar bone structures. Woven bone, found in the developing embryo and very 
young bone, is less organized and contains randomly distributed fibers. During bone 
maturation, woven bone is eventually resorbed and replaced by lamellar bone, 
which is made up of preferentially oriented collagen fibers, organized in 3–7-μm thick 
lamellae. Alterations to collagen's chemical composition and structural organization 
have serious implications on bone strength. This is the case for osteoporosis, 
osteogenesis imperfecta, and osteosarcoma. The ability to carry out both a 
qualitative and quantitative assessment of the composition and structural 
organization of collagen fibers in bone is critical for understanding its health and 
pathogenesis, and it could be used in early diagnosis of bone disorders (Ambekar et 
al., 2012). 
SHG microscopy's ability to image predominantly collagen fibers has been 
experimentally validated by numerous studies using techniques such as 
immunofluorescence-stained light microscopy and polarized light microscopy 
(Ambekar et al., 2012). To my knowledge, its potential has not yet been fully explored 
in bone imaging and the study of age-related structural alterations, with the 
exception of the vertebral endplate in the human lumbar spine (Paietta, Burger, & 
Ferguson, 2013). 
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II THESIS GENERAL OBJECTIVES 
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determine if Ga can affect cancer cells directly and also, if it can interfere with 
cancer cells-induced osteoclastogenesis. Consistently with the first part of the thesis, 
future developments will address the concept of using Ga-loaded bone substitutes 
to fill a defect generated by a bone tumour resection. 
The context and particular objectives of each of these approaches are briefly 
summarized before the two publications in preparation, and, in a more detailed 
manner, in the Introduction part of publication manuscripts. 
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PART ONE A: 
In vitro and in vivo effects of gallium-loaded calcium 
phosphate biomaterials on bone cells and bone 
reconstruction 
 
1. Context and objectives of the study 
 
In osteoporosis, one of the most common bone disorders, bone remodelling 
balance is shifted towards osteoclastic bone resorption, resulting in the weakining of 
bone structure and an increased risk of fracture. In osteoporotic fractures treatment, 
bisphosphonates are the most widely used therapeutic agents. Despite a proved 
clinical efficiency, important side-effects inducing also a poor patient compliance 
have prompted the investigation of alternative antiresorptive agents. 
Due to its inhibitory effect on osteoclastic bone resorption, the semi-metallic 
element gallium (Ga) has been used in systemic treatment of malignancy-induced 
hypercalcalemia. In their vast majority (80%), osteoporotic fractures occur at specific 
skeletal sites (femoral neck, spine and wrist), this opening the possibility for their local 
treatment and prevention. Mellier et al. have shown that Ga readily incorporates in 
the structure of calcium phosphate biomaterials (CaP), allowing the implantation of 
these bone substitutes within fragilized osteoporotic sites. By doing so, it is expected 
that intrinsinc properties of CaP would restore mechanical stability at the 
implantation site, while loaded Ga could locally reduce osteoclastic resorptive 
activity. Thus, investigating CaP-Ga biological properties is crucial in order to propose 
Ga as an attractive adjuvant candidate for the management of osteoporotic 
fracture. 
In the present study, we wanted to document in vitro the interactions of CaP-
released Ga with bone cells, as well as its performances in vitro in terms of bone 
defect reconstruction. Specific objectives were to determine whether Ga affected: 
(i) the viability, morphology and differentiation of human primary bone cells; (ii) bone 
reconstruction induced by CaP biomaterials in a critical-sized femoral defect in rats.  
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2. Methods and results 
 
Article I (in preparation): Incorporation of gallium enhances reconstructive properties 
of a calcium phosphate bone substitute   
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ABSTRACT  
 
Calcium phosphate-based (CaP) biomaterials are commonly used in bone reconstructive surgery 
while, due to its inhibitory action on osteoclasts, the semi-metallic element gallium (Ga) is used for the 
treatment of disorders associated with accelerated bone resorption. As it was demonstrated that Ga 
could be incorporated in the structure of CaP biomaterials, we investigated in the present work the 
biological properties of novel Ga-substituted CaP biomaterials. Culturing bone cells on Ga-CaP, we 
observed a decrease in osteoclast number and a downregulation of late osteoclastic markers 
expression, while Ga-CaP upregulated the expression of several osteoblastic marker genes. Using a 
murine bone defect-healing model, we next investigated in vivo bone reconstructive properties of 
Ga-CaP. All implanted biomaterials showed a good osseointegration into the surrounding host tissue, 
accompanied by a successful bone ingrowth and bone marrow reconstruction. Lastly, quantitative 
analysis of implants revealed that Ga enhanced total defect filling (3D micro-CT), as well as mature 
organised collagen synthesis (SHG). Taken together, our data indicate that Ga-CaP provides 
biocompatible and non-cytotoxic substrates for bone reconstruction. Moreover, acting both on 
osteoclasts and osteoblasts, Ga enhances new bone formation triggered by CaP bone substitutes. 
 
Key Words  
Bone reconstruction 
Calcium phosphate cement 
Gallium 
Osteoclast/osteoblast crosstalk 
Second Harmonic Generation (SHG) analysis 
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1. Introduction 
In the field of bone tissue engineering, major efforts are currently focused on the development of 
novel biomaterials usable for bone reconstruction. CaP biomaterials are considered to be the best 
alternative to bone grafting because of their chemical properties, which are suitable for bone 
remodelling [1-7]. In fact, CaP is the main component of bone and is a biocompatible and 
biodegradable biomaterial. Various forms of CaP biomaterials have been developed (granules, 
injectable suspensions, cements) that are suitable for different clinical applications including 
orthopaedics, and dental, ear, nose and throat surgeries. Among CaP biomaterials, CaP cements 
(CPCs), based on studies performed originally by LeGeros in 1982 [8] and Brown and Chow in 1986 [9], 
has considerably revolutionized the world of bone tissue engineering. To restore bone mechanical 
properties, an ideal biomaterial should be slowly resorbed while concomitantly replaced by natural 
bone. The concept of CPCs [10] as possible restorative materials might fulfil this requirement due to 
their bioactivity and ability to be resorbed. Optimized formulations of injectable bioresorbable CPCs 
have been developed for dental and orthopaedic indications, and these products are 
commercialized in both EU and US markets since 2009. 
Apatite cements are constituted of entangled microcrystals that are closer to biological apatites in 
terms of size and composition than hydroxyapatite ceramic particles [11-13]. One of the major 
advantages of CPCs is their moldability. CPCs can fit perfectly into the implant site, thus optimizing 
bone-biomaterial contact, even in geometrically complex bone defects. Moreover, due to their 
properties of injectability, CPCs are considered to be promising materials for minimally invasive surgery. 
After implantation into the bone defect, CPCs are able to self-set [14] and harden without any 
significant exothermic reaction that could be prejudicial to the bone tissue and/or loaded drug. CPCs 
rapidly integrate into the bone structure and are then progressively resorbed, mainly by cellular 
processes. Thus, CPC combined devices loaded with active molecules represent good candidates for 
local drug delivery [15]. 
In the early 1970s, it was demonstrated that Ga had several therapeutic effects (for review see [16]) 
including: (i) the decrease of accelerated bone mineral resorption, which occurs during osteolytic 
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bone diseases, and the subsequent lowering of elevated plasma calcium levels associated with these 
pathologies; (ii) the inhibition of neoplasic proliferation; (iii) the treatment of some intracellular 
pathogens such as species of Mycobacterium [17]. Studies on Ga, which were mainly focused on its 
antitumor activities [18], have shown that Ga caused a mild hypocalcaemia [19]. In this context, Ga 
has been used to treat hypercalcemia resulting from malignant tumours such as parathyroid 
carcinoma and Paget’s disease of bone [20-22]. This antihypercalcemic effect of Ga results from an 
inhibition of bone resorption [20, 23]. Indeed, due to its chemical characteristics, Ga presents an 
affinity for biological apatite that explains the presence of Ga deposits in bone tissue, and 
preferentially at sites of rapid bone remodelling such as active metaphyseal growth plate and healing 
fractures [24-26]. 
Few studies have explored the effect of Ga on bone cells. Hall et al. demonstrated that Ga 
inhibited bone resorption in a dose-dependent manner, and for example, at 100 µg/mL, Ga reduced 
the osteoclastic resorption activity by 64% without inducing modifications to the morphology or 
number of osteoclasts [27]. In contrast to these findings, Blair et al. showed a cytotoxic effect of Ga on 
osteoclasts [28]. Considering this discrepancy, we previously investigated the biological effect of Ga 
on bone cells. We reported that Ga used in solution inhibited both the differentiation and the 
resorbing activity of osteoclasts in a dose-dependent manner (0-100 µM) [29, 30]. Furthermore, Ga did 
not affect the viability or proliferation of osteoblasts [29].  
In addition to the medical applications reported above, a potential application of gallium 
compounds as anti-inflammatory agents has been described. Transferrin-gallium and gallium nitrate 
were shown to inhibit the mixed lymphocyte reaction and increase the survival of mice with severe 
graft-versus-host disease in a murine bone marrow transplant model [31]. Interestingly, gallium nitrate 
has been shown to prevent adjuvant inflammatory arthritis through suppression of macrophage 
function and T-cells in rat models [32]. Other studies showed that gallium nitrate suppressed lupus in 
MRL/lpr mice, a murine model of systemic lupus erythematosus (SLE) [33-35]. At last, and more 
recently, the elimination of arthritis pain and inflammation for over 2 years with a single 90 min, topical 
14% gallium nitrate treatment was reported [36]. 
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As a whole, these data strongly support the therapeutic potential of Ga compounds [37]. With a 
view to evaluate the impact of Ga addition on bone tissue engineering, we used apatitic matrices 
loaded with Ga [38] as a new model to document Ga action on bone cells in vitro and on bone tissue 
reconstruction in vivo.  
 
2. Materials and methods 
2.1 Biomaterial synthesis and preparation 
Graftys SARL (Aix-en-Provence, France) provided all biomaterials used in this study. Calcium 
phosphate cement (CPC) consisting of 80% α-tricalcium phosphate (α-TCP), 10% dicalcium 
phosphate anhydrous (DCPA) and 10% calcium-deficient apatite (CDA) was loaded with gallium (Ga) 
by chemical substitution with Ca2+ ions so that the final Ga content was 0.3%. The same composition of 
CPC without Ga was used as a control. Calcium-deficient apatite loaded with gallium (CDA/Ga) was 
synthesized as previously described in Mellier et al. [38]. Briefly, CDA/Ga was synthesized from a 
mixture of gallium nitrate hydrate, calcium nitrate tetrahydrate and diammonium hydrogen 
phosphate with (Ca+Ga)/P molar ratio at 1.51 and Ga/Ca molar ratio in the 0-0.08 range. X-ray 
powder diffraction (XRD) patterns were recorded to verify the level of gallium in the obtained powder 
(Philips PW 1830 (Cu Kα, 40 kV, and 30 mA) equipped with a vertical goniometer PW 1050 (Ɵ/2Ɵ) and 
PW 1711 Xe detector). CDA without gallium was used as a control. For in vitro experiments, the powder 
phase of CPC or CPC/Ga was mixed with 5% aqueous solution of Na2HPO4 (Merck, Germany) in ratio 
0.45, according to manufacturer’s instructions. The obtained paste was placed in silicon moulds and 
set at 37°C in physiological saline for 72h. Solidified pellets with surface of approximately 0.5 cm2 were 
polished and cleaned from dust three times for 15 sec in ultrasound bath. Pellets were steam-sterilized 
at 121 °C for 20 min and incubated 48 hours prior to cell seeding in 1 ml of α–minimal essential medium 
(α-MEM) (Sigma-Aldrich, USA) supplemented with 10% Hyclone FCS (GE Healthcare, USA), 100 U/ml of 
penicillin (Lonza, Switzerland), 100 U/ml of streptomycin (Lonza, Switzerland) and 2% of ultraglutamine 
1 (Lonza, Switzerland). Medium was replaced three times to neutralize the pH and ion exchange. For in 
vivo experiments, the powder phase of CPC, CPC/Ga, CDA and CDA/Ga was compacted, grinded 
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and water-sieved to retrieve microparticles of 80-200 µm diameters. Microparticles were further heat-
sterilized at 180°C for 3 h and placed in 1-ml syringes (Therumo Europe N.V., Belgium) before 
implantation.  
 
2.2 Cell culture 
Both cell types used in this study were cultured in α-MEM medium supplemented with 10% Hyclone 
FCS, 100 U/ml of penicillin, 100 U/ml of streptomycin and 2% of ultraglutamine 1 with the medium 
replacement every third day. Human primary osteoblasts (#CC-2538, Lonza, Switzerland) were 
expanded to P7 at 6 000 cells/cm². For experiments, 100 000 cells/pellet were seeded. Human primary 
monocytes were isolated from whole blood samples of healthy individuals (provided by Etablissement 
Français du Sang) using Uni-SepMaxi tubes (NOVAmed Ltd., Israel) and Easy Sep Human Monocyte 
Enrichment Kit (STEMCELLS Technologies, Canada) according to manufacturer’s instructions. For 
monoculture experiments, 200 000 cells were seeded on plastic or biomaterial pellets. Osteoclast 
differentiation was triggered by adding 66 ng/ml of receptor activator of NFκB ligand (RANK-L) 
(Peprotech, France) and 33 ng/ml of macrophage-colony stimulating factor (M-CSF) (Peprotech, 
France) in culture medium. For co-culture experiments osteoblasts were seeded at 100 000 cells/pellet 
and four hours later, monocytes were added at 200 000 cells/pellet. 
 
2.3 Cell viability assays 
At days 3, 6 or 14 of culture, cells were rinsed two times in phosphate-buffered saline (PBS) (Lonza, 
Switzerland) and incubated in 0.5 mg/ml of 3-(4.5-dimethylthiazol-2-yl)-2.5-diphenyltetrazolium 
bromide (MTT) (Sigma-Aldrich, USA) for 1h in cell incubator. MTT was aspirated delicately and 0.3 ml of 
lysis buffer (SDS 10%, HCl 0.01 N) was added/well and left overnight at room temperature, in dark. Next 
morning, supernatants were centrifuged 2 min at 20 000 g and absorbance was measured in 100 µl at 
562 nm. In parallel experiments, using increasing amounts of cells cultured on plastic or pellets, we 
verified the relationship between cell number and MTT assay result (data not shown). 
 
2.4 Tartrate-resistant acid phosphatase (ACP5) staining 
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After 7 or 14 days of culture, cells were rinsed two times in PBS and fixed in citrate/acetone solution 
for 30 s. ACP5+ cells were revealed using the Acid Phosphatase, Leukocyte kit following 
manufacturer’s instructions (# 387A; Sigma-Aldrich, USA). 
 
2.5 Gene expression analysis 
At day 7 and 14, cells were rinsed 2 times in PBS and incubated in 0.25 % trypsin/EDTA (Lonza, 
Switzerland) at 37 °C for 5 min. Total RNA was extracted using the NucleoSpin RNA XS kit (Macherey-
Nagel, Germany) following manufacturer’s instructions and RNA concentration was measured on 
Nanodrop 2000 spectrophotometer (Thermo Fisher Scientific, USA). 150 ng of RNA was used as a 
template for cDNA synthesis using random primers and SuperScript II reverse transcriptase (Invitrogen, 
USA) in Flexcycler (Analytik Jena, Germany). Total cDNAs were diluted ten times and 5 µl of template 
was used for quantitative real-time PCR assay (StepOne Plus, Life Technologies, USA). Reactions were 
performed in a 20-µl final volume with qPCR mastermix GoTaq (Promega, USA). Amplification 
conditions were as following: 2 min at 50 °C, 10 min at 95 °C, 40 cycles (15 s at 95 °C, 1 min at 60 °C). 
The expression of genes of interest was normalized to ribosomal protein large P0 (RPLP0) gene 
expression, quantified by comparative 2-∆Ct method and expressed as a fold change compared to 
control condition without Ga. Primers used in qPCR are listed in Table 1. Gene symbols (abbreviations) 
are as follows: ACP5, Acid Phosphatase 5 Tartrate Resistant; ALPL, Alkaline Phosphatase; BGLAP, Bone 
Gamma-Carboxyglutamate (Gla) Protein (Osteocalcin); COL1A1, Collagen Type I, Alpha 1; CTSK, 
Cathepsin K; FBJ, c-Fos; IBSP, Integrin-Binding Sialoprotein; ITGB3, Integrin, Beta 3; JDP2, Jun 
Dimerization Protein 2; MCSF, Macrophage Colony-Stimulating Factor 1; MMP9, Matrix 
Metalloproteinase 9; NFATC1, Nuclear Factor Of Activated T-Cells Cytoplasmic 1; ON, Osteonectin; 
OPG, Osteoprotegerin; OPN, Osteopontin; POSTN, Periostin Osteoblast Specific Factor; RANKL, 
Receptor Activator Of Nuclear Factor Kappa-B Ligand; RPLP0, Ribosomal Protein Large P0; RUNX2, 
Runt-Related Transcription Factor 2. 
 
2.6 Field-emission scanning electron microscopy analysis (MEB) 
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After an overnight fixation at 4°C in a buffered glutaraldehyde solution, samples were rinsed, 
dehydrated in a graded ethanol series, immersed in hexamethyldisilazane (Sigma-Aldrich) for 5 min, 
and dried at room temperature. The samples were then mounted on aluminium stubs and sputter 
coated with gold-palladium (Cressington, 308R, UK). Examination was performed using a field-emission 
scanning electron microscope (FESEM JEOL 6700F, Tokyo, Japan). 
 
2.7 Orthotopic implantation in rat 
All animal procedures obtained the approval of local animal health care committee (CIEPAL 
NCE/2012-69) and were conducted in accordance to European Community guidelines for the care 
and use of laboratory animals (Directive 2010/63/UE). Bilateral femoral implantations were performed 
on 17 male Lewis rats weighing approximately 300 g (Janvier Labs, France), in aseptic conditions 
under general anaesthesia induced by inhalation of isoflurane 5% and maintained by intramuscular 
injections of xylazine 10 mg/kg and ketamine 50 mg/kg. 60 mg of CPC, CPC/Ga, CDA or CDA/Ga 
microparticles were extemporaneously coagulated with 100 µl of previously prepared rat platelet-
poor plasma, 10 µl of 2 % CaCl2, 2 H20 (Merck, Germany) and 1 U of thrombin (Sigma-Aldrich, USA). 
After at least 15 min, coagulated microparticles were implanted in a 3 x 2.7 mm cylindrical critical-
sized defect at the distal epiphyso-metaphysal junction in rat femora. At the end of the experiment 
animals were sacrificed by inhalation of CO2 and the bone specimens were retrieved immediately 
and stored in 70 % ethanol.  
  
2.8 Three dimensional (3D) microtomography analysis 
Physiological saline-immersed rat femora were scanned with Skyscan 1172 microtomograph 
(Bruker, USA) equipped with 12-bit digital CCD camera. Samples were placed with the axis of the 
femur perpendicular to the plane of scanning and cross-section images are acquired under 90 kV 
voltage and 88 µA current with 1-mm aluminum filter. Rotation step was set at 0.7° and exposure time 
per step was 776 ms. 3D reconstruction of 6 µm-resolution cross-section images was done in NRecon 
software (Bruker, USA) using a modified Feldkamp cone-beam algorithm, as provided by 
manufacturer. The parameters were set as following: smoothing at 3, ring artifact correction at 10, 
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beam hardening correction at 50%, rotation angle 180 ° and image conversion values in 0.003-0.03 
ranges. To quantify bone regeneration and biomaterial degradation in the defects, the region of 
interest (ROI) was set to whole implant area excluding the cortical part. Regenerated bone was 
discriminated from biomaterial microparticles by manual grey scale thresholding in CTAn (Bruker, USA) 
performed by three independent operators. 
 
2.9 Histological preparation and analysis 
CPC and CPC/Ga samples were fixed for 24 h in neutral formalin solution (pH 7.2), and then 
dehydrated in baths with ethanol concentration increasing from 70% up to 100 % for (3 days/bath). 
Bone specimens were then infiltrated and embedded in methyl methacrylate (MMA) as previously 
described [39]. CDA and CDA/Ga samples were fixed for 24 h in neutral formalin solution (pH 7.2), and 
then decalcified in 10% EDTA (pH=8) for four weeks. For CPC and CPC/Ga implants, undecalcified 
serial 5-µm sections were cut using a hard tissue microtome (Supercut 2050, Reichert-Jung, Austria) 
equipped with a D profile tungsten carbide knife. From these sections, haematoxylin/eosin (HE) and 
Movat’s pentachrome staining were assessed to visualize mature bone, osteoid tissue, bone marrow 
and residues of biomaterial microparticles. Femurs with CDA and CDA/Ga implants were embedded 
in paraffin and 5-µm thick sections were prepared and stained with HES. All histological sections were 
imaged by Nikon Eclipse 80i for qualitative observations.  
 
2.10 SHG preparation and analysis 
Second harmonic generation (SHG) microscopy has intrinsic specificity for collagen fibres, which 
results in high contrast images, with no additional staining needed [40]. Thus, tissue sections prepared 
for histological study were also used for SHG imaging (Zeiss LSM 710 microscope, Germany). Mai Tai 
laser excitation wavelength was set to 880 nm and the SHG signal was detected in transmission and 
reflection mode. For CPC and CPC/Ga, 5-µm sections were qualitatively analysed and for CDA and 
CDA/Ga, 100-µm sections were prepared in order to do quantification as well. Quantitative 
comparison of collagen signal between Ga and control implants was performed on whole implant 
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area using an in-house quantification tool developed in Matlab programming language by S. Schaub 
from iBV PRISM platform (Platform of Resources in Imaging and Scientific Microscopy).  
 
2.11 Statistical analysis 
In vitro results are expressed as a mean ± standard deviation of three independent experiments 
each performed in triplicate. Differences between gallium and the control group were evaluated by 
bi-directional Mann and Whitney U test with the risk threshold set at 5 %. For microtomography 
experiments, significant differences in total defect filling between Ga and control groups were 
determined by bi-directional Kruskal-Wallis one-way analysis of variance with the risk threshold set at 5 
%. Fisher's combined probability test (confidence interval set at 95%) was used in assessment of the 
differences in biomaterial particles and newly formed tissue percentages between Ga and control 
group. For SHG quantitative analysis, bi-directional Mann and Whitney U test with the risk threshold set 
at 5 % was used to assess significant differences between Ga and control biomaterials. 
 
3. Results 
3.1 Human primary bone cells culture on apatitic matrices loaded with Ga 
Human primary monocytes were seeded on CPC or CPC/Ga pellets, and cultured for 3 or 6 days 
before performing an MTT assay. In parallel experiments (not shown), we verified that MTT assay results 
correlated with the number of viable cells seeded on apatitic matrices. As shown in Fig. 1A, and 
compared to CPC control condition, seeding monocytes on CPC/Ga resulted for both time in a 
slightly decreased cell viability/number. We also performed cell structure examination using MEB 
analysis. As depicted in Fig. 1B, we observed monocytes on CPC and CPC/Ga (white arrowheads), as 
well as cell processes interacting with the cement surface. In the presence of the osteoclastogenic 
agent RANKL (Receptor activator of nuclear factor kappa-B ligand), some cellular interactions 
foreshadowing osteoclastic differentiation were also observed. However, these events remained rare 
for both cements. Lastly, we performed RT-qPCR experiments to quantify the expression of early and 
late osteoclastogenesis marker genes (gene symbols are defined in Materials and Methods). As shown 
in Fig. 1C, RANKL induced the differentiation of monocytes seeded on plastic, as attested the 
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expression of early (NFATC1, JDP2) and late (ACP5, MMP9, CTSK) marker genes. By contrast, RANKL 
failed to induce any osteoclastic differentiation of monocytes seeded either on CPC or CPC/Ga. We 
also observed that, whatever the condition (control or RANKL), the expression of the transcription 
factors JDP2 and FBJ was diminished on CPC/Ga, while the late marker genes MMP9 and CTSK were 
induced in the presence of Ga. As a whole, this first set of experiments indicated that human primary 
monocytes did not efficiently differentiate into osteoclasts when seeded alone on CPC or CPC/Ga. 
We next seeded human primary osteoblasts on CPC or CPC/Ga and we quantified cells 
viability/number. As shown in Fig. 2A, after 3 days of culture, the presence of Ga induced a 40% 
inhibition of cell viability/number. At day 7, cellular proliferation was observed on both cements, while 
the inhibition observed in the presence of Ga tended to decline (30% instead of 40%). Cells structure 
was also examined using MEB analysis. Whatever the cement used, and as shown in Fig. 2B, 
osteoblasts proliferated and interacted with the surface of the biomaterial. Lastly, we used RT-qPCR 
experiments to quantify the expression of osteoblast marker genes (gene symbols are defined in 
Materials and Methods), and three kinds of situation were observed (Fig. 2C). Firstly, RUNX2, ALPL and 
OPN were expressed at similar levels at both times. Considering the cement, the expression of these 
tree genes was inhibited on CPC/Ga at day 3, and this inhibition tended to decrease at day 7. 
Secondly, BGLAP expression increased between day 3 and day 7, and no difference was observed 
comparing CPC and CPC/Ga. Thirdly, COL1A1, ISBP, ON and POSTN expression was identical on CPC 
or CPC/Ga at day 3. At day 7, the expression level of the four genes decreased on both cements but 
remained at higher levels on CPC/Ga compared to CPC (or stayed identical for POSTN). As a whole, 
these data indicated that following 7 days of primary osteoblasts culture on cements, the expression 
level was slightly diminished on CPC/Ga for RUNX2 and OPN, was identical for ALPL and BGLAP, and 
was enhanced on CPC/Ga for COL1A1, ISBP, ON and POSTN. 
To document monocyte/osteoblast interactions, human primary osteoblasts and human primary 
monocytes were then co-cultured up to 14 days on both cements, in the absence of any additional 
effectors such as MCSF and RANKL. As depicted in Fig. 3A, cell viability/number decreased between 
day 3 and day 7, and in a lesser extent between day 7 and day 14. Except for day 3, no difference 
was observed between the two cements. Regarding cellular morphology (Fig. 3B), we observed 
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osteoblasts on both surfaces (white arrowheads), as well as monocytes differentiating into osteoclasts 
(red arrowheads). We next performed histochemical demonstration of ACP5 activity. As shown in Fig. 
3C (left panels), osteoblasts were stained in yellow/brown (white arrowheads) and no difference was 
observed on CPC/Ga compared to CPC. Regarding osteoblasts/monocytes co-culture, a purple 
staining was observed within osteoclasts (right panels, red arrowheads) on both cements, but the 
number of differentiated cells was decreased on CPC/Ga compared to CPC. To further document 
this inhibition at the molecular level, we eventually performed RT-qPCR experiments (gene symbols are 
defined in Materials and Methods) using RNAs prepared from osteoblasts alone or from osteoblasts co-
cultured with monocytes (Fig. 3D). Concerning the transcription factors involved in the early steps of 
osteoclastogenesis, we observed that NFATC1, JDP2 and FBJ were expressed in both conditions 
(osteoblasts alone versus co-culture), with no significant differences between CPC and CPC/Ga. The 
same situation was observed for the late marker genes of osteoclastic differentiation ITGB3 and CTSK. 
By contrast, the late marker genes ACP5 and MMP9 were detected only in co-culture conditions and 
not in osteoblasts alone condition, suggesting an expression restricted to monocytes differentiated into 
osteoclasts. In this co-culture situation, ACP5 and MMP9 expression was strongly inhibited on CPC/Ga 
compared to CPC. Lastly, we also tested the expression of RANKL, MCSF and OPG, the triad of 
osteoblastic genes regulating osteoclastic differentiation. Considering the co-culture condition, we 
shown that no difference could be observed between CPC and CPC/Ga. In conclusion, we observed 
that ACP5 activity histochemical staining revealed an inhibition of osteoclastic differentiation on 
CPC/Ga compared to CPC. Moreover, this inhibition could also be quantified by RT-qPCR experiments 
measuring the expression of marker genes restricted to differentiated osteoclasts, i. e ACP5 and 
MMP9. 
 
3.2 Orthotopic in vivo implantation of apatitic matrices loaded with Ga 
We next performed in vivo implantation experiments to determine Ga impact on the reconstructive 
properties of the CPC under study. As illustrated in Fig. 4A, cements were first processed into 80-200 µm 
diameter microparticles, and then implanted within cylinder defects generated in distal position of rat 
femurs. After 2 months, implants were retrieved and processed to perform HES staining and SHG 
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analysis on tissue sections, as well as micro-CT quantification of the whole implant. Both HES (Fig. 4B) 
and SHG (Fig. 4C) methods demonstrated for CPC and CPC/Ga a successful bone reconstruction 
including newly formed tissue up to the central part of implants and a complete cortical bone 
restoration. Based on image acquisitions illustrated in Fig. 4D, micro-CT was used to quantify total 
defect filling. Results presented in Fig. 4E did not show any significant impact of Ga on bone 
reconstruction. 
With a view to increase Ga content of biomaterial used for bone defects filling, we shifted from 
CPC to calcium deficient apatite (CDA) loaded or not with Ga. Indeed, as detailed in Materials and 
Methods, Ga was brought to CPC through the CDA part (10%) of the cement formulation. Thus, using 
pure CDA allowed increasing Ga content by a factor of ten. As illustrated by HES staining and SHG 
analysis (Fig. 5A-5B), and similarly to CPCs, CDA and CDA/Ga implantations led after 2 months to a 
good osseointegration into the surrounding host tissue, accompanied by a successful bone ingrowth 
and bone marrow reconstruction. Taking advantage of the power of SHG thresholding, we performed 
100-µm sections in order to do quantification on larger implant areas. As shown in Fig.5B (right panel), 
we measured a 39% increased SHG signal mean intensity with CDA/Ga. These data indicated that 
higher amounts of fibrillar collagen where synthetized when the reconstruction occurred in the 
presence of Ga. Lastly, 3D micro-CT was used to quantify total defect filling (Fig.5C). We found that 
Ga induced a significant 23 % increase of defect filling (53.51% versus 76.89%). As a whole, our results 
indicated that the Ga presence within CDA used for bone defect filling led to a significant enhanced 
bone reconstruction.  
 
4. Discussion 
In vitro, using CPC and CPC/Ga as growing surfaces, primary human monocytes do not 
differentiate into osteoclasts when cultured alone in the presence of MCSF/RANKL, while successful 
differentiation was achieved on plastic surface. In a previous publication characterizing the properties 
of the cements used in the present study, an increase of the gallium release was observed over time in 
the presence of RAW264.7 cells seeded on the surface of cement pellets and stimulated with 20 nM 
RANKL [41]. It should be noted that, compared to the human primary cells we used for the present 
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study, RAW264.7 is a mouse cell line which required only the presence of RANKL to differentiate into 
osteoclasts. We can hypothesize that human primary monocytes are more demanding in terms of 
environment to initiate osteoclastic differentiation. Indeed, co-culture conditions in the presence of 
primary human osteoblasts proved to be sufficient for osteoclastogenesis in the absence of any 
exogenous effectors.  
In co-culture experiments, it is difficult to comment Ga impact on marker genes which expression is 
found also in osteoblasts alone. Osteoblastic expression has been reported for transcription factors 
NFATC1 and AP1 family members (Fos/Jun) [42, 43], as well as for ITGB3 and CTSK [44, 45]. However, 
regarding genes restricted to osteoclasts such as ACP5 and MMP9, Ga exerts an unambiguous and 
pronounced inhibitory action. Interestingly, Ga impact on ACP5 expression was further support at the 
protein level, as attested by ACP5 histochemical staining presented in Fig.3. Lastly, we do not observe 
any Ga-induced variation of RANKL, MCSF or OPG genes expression, suggesting that Ga inhibition is 
not mediated through a modulation of the RANKL/OPG ratio.  
Considering the complexity of the molecular regulations impacting bone reconstruction in vivo, a 
23% positive impact on bone defect filling is a very promising result. This is probably linked to the dual 
effect Ga exerts, i.e. a decrease of osteoclastogenesis together with an increased production by 
osteoblasts of factors favouring bone construction. Indeed, Ga stimulates COL1A1 expression, which 
obviously contributes to the new tissue formation as the most abundant bone extracellular matrix 
protein [46]. We also observe that the expression of genes encoding for non-collagenous proteins was 
enhanced including IBSP, ON, and POSTN. Bone sialoprotein II (IBSP or BSP II) is a phosphorylated 
glycoprotein, which is involved in the initial steps of bone tissue mineralization [47, 48]. Osteonectin 
(ON; or SPARC for “secreted protein, acidic and rich in cysteine“) is also linked to tissue mineralization 
along development, remodelling and bone repair [49]. Regarding periostin (POSTN, originally known 
as “osteoblast-specific factor“ or OSF2), this glutamate-containing protein is preferentially located in 
the periosteum, and its expression is enhanced during bone fracture repair [50]. These data are 
reminiscent with results we published earlier. In this previous study, using the MC3T3-E1 osteoblast 
precursor murine cell line, we shown that Ga treatment enhanced the expression of marker genes 
including alkaline phosphatase (Alpl), osterix (Osx) and runt-related transcription factor 2 (Runx2) [29]. 
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Furthermore, in a study published in 1993, Bockman et al. reported that Ga increased type I collagen 
and fibronectin mRNA, as well as collagen protein levels in primary cultures of rat calvarial osteoblasts 
[51]. The same year, Jenis et al. published results indicating that Ga increased basal type I collagen 
mRNA levels and reduced basal osteocalcin mRNA levels in normal rat osteoblasts in vitro [52]. They 
also reported that systemic Ga administration decreased serum calcium levels and reduced 
osteocalcin steady-state mRNA levels, while having no effect on type I collagen mRNA levels or bone 
mineral density in vivo. 
Taken together, and in addition to Ga inhibitory action on osteoclastogenesis, our data support the 
hypothesis that Ga-induced enhancement of bone repair we measure in vivo could also be linked to 
the stimulated expression of genes involved in bone tissue formation. In addition, the comparison with 
the results from Jenis et al. [52] point out how crucial could be the delivery mode of a 
pharmacological agent. Indeed, using systemic administration of a therapeutic dosage used for the 
treatment of Paget’s disease, they did not observe any impact on bone mineral density of left femur in 
normal rats treated with gallium, while we measured a positive effect. This discrepancy could be 
related to the local delivery mode of Ga we used, this leading to higher local concentrations of an 
active molecule released continuously. In addition, and these hypothesis are not exclusive, Jenis et al. 
reported Ga effect on normal bone remodelling, while we addressed the issue of bone reconstruction 
following the creation of a defect. Thus, these different physiological situations could also account for 
our respective observations. 
Lastly, using calcium deficient apatite (CDA), we demonstrated that the presence of Ga induced a 
significant stimulation of bone reconstruction, as attested by two types of quantification, i. e. 3D micro-
CT scan and SHG analysis. Regarding SHG, these results are in agreement with the data we obtained 
measuring COL1A1 gene expression. Actually, SHG analysis allows the quantification of fibrillar 
collagen (Fig. 5B) and we also observed that Ga stimulated COL1A1 gene expression in primary 
osteoblasts (Fig. 2C). Together, these data reinforce the correlation between molecular data we 
obtained in vitro and bone reconstruction we measured in vivo.  
Importantly, it should be stressed that to our knowledge, this is the first time that the use of SHG is 
reported in the field of bone reconstruction quantification within a bone substitute implanted in vivo. 
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Indeed, concerning osteo-articular applications, SHG analysis has been used to evaluate osteogenic 
cell differentiation in vitro [53-57], or to study tissue samples retrieved from normal or pathological 
situations [40, 58-66]. Based on the consistency we observe with gene expression and 3D micro-CT 
scan quantification data, we demonstrate in the present report that SHG analysis is also fully suitable 
to monitor the reconstructive properties of a bone substitute upon its implantation in vivo. 
 
5. Conclusions 
We propose that Ga positive impact we report in this study is linked to a decreased osteoclastic 
differentiation coupled to an increased new bone tissue formation. In terms of mechanisms, this is 
understated by in vitro data obtained at the molecular level through genes expression analysis. This is 
confirmed in vivo by the Ga-induced enhancement of bone reconstruction we observe using 
CDA/Ga to fill bone defects generated in a rat model. 
Interestingly, in addition to the positive impact on bone formation we report here, Ga offers other 
worthwhile prospects. Indeed, as detailed in the Introduction section above, Ga displays anti-
neoplasic, anti-infectious and anti-inflammatory properties [16]. Further studies are required to fully 
evaluate the potentialities of Ga-loaded bone substitutes used for the filling of bone defects for which 
tumour development and infections represent critical issues. 
Lastly, as a beneficial side-effect of our quantification experiments, we provide strong data 
supporting the use of SHG technique to address the issue of in vivo tissue reconstruction within a bone 
substitute. 
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Table 1. 
Human primers for qPCR.  
Gene Forward primer (5’->3’) Reverse primer (5’->3’) GI 
ACP5 gaccaccttggcaatgtctctg tggctgaggaagtcatctgagttg 161377454 
ALPL gtacgagctgaacaggaacaacg cttggcttttccttcatggtg 294712525 
BGLAP ggtgcagcctttgtgtccaa ggctcccagccattgatacag 314122170 
COL1A1 ctcctgacgcacggcc ccgttctgtacgcaggtgatt 110349771 
CTSK tgaggcttctcttggtgtccatac aaagggtgtcattactgcggg 315075295 
FBJ tgcctctcctcaatgaccctga ataggtccatgtctggcacgga 254750707 
IBSP ctgtgccactcactgccttg caaaatgctgagcaaaattaaagc 167466186 
ITGB3 cattactctgcctccactacca aacggattttcccataagca 47078291 
JDP2 cttcttcttgttccggcatc cttcctggaggtgaaactgg 205277420 
MCSF tgcagcggctgattgaca gatctttcaactgttcctggtctaca 166235151 
MMP9 cctggagacctgagaaccaatc ccacccgagtgtaaccatagc 74272286 
NFATC1 gcatcacagggaagaccgtgtc gaagttcaatgtcggagtttctgag 27502384 
ON accagcaccccattgacg aggtcacaggtctcgaaaaagc 48675809 
OPG cctccaagcccctgaaggtt cctgggtggtccacttaatgg 148743792 
OPN agaagtttcgcagacctgacatc gatggccttgtatgcaccatt 91598938 
POSTN ttgaaggtggtgatggtcatttatt cgtcttctagatccttgaacttttttgt 209862910 
RANKL ctcagccttttgctcatctcact ccaagaggacagactcactttatgg 197927084 
RPLP0 tgcatcagtaccccattctatcat aggcagatggatcagccaaga 49087144 
RUNX2 gcttcctgccatcaccga tcagtgagggatgaaatgcttg 226442790 
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Fig. 1. Cellular proliferation, morphology and differentiation of human primary monocytes on CPC or CPC/Ga pellets. (A) MTT 
assay. 90 000 monocytes were cultured during 3 or 6 days. Data represent the mean +/- SD of 3 independent experiments, with each 
including five MTT measures. (B) Field-emission scanning electron microscopy analysis of pellets seeded with monocytes, and cultured 
during 5 days in the presence of hM-CSF (33 ng/mL; upper panels) or in the presence of hM-CSF/hRANKL (33 ng/mL and 66 ng/mL 
respectively; lower panels). White arrowheads indicate cells (scale bars: 10 µm). (C) Real-time PCR quantification of 
osteoclastogenesis markers. Monocytes were cultured during 2 days (NFATC1, JDP2) or 5 days (ACP5, MMP9, CTSK), in the 
presence of 33 ng/mL hM-CSF (Control) or 33 ng/mL hM-CSF and 66 ng/mL hRANKL (RANKL). Data represent the mean +/- SEM of 3 
independent experiments, each performed in triplicate. Data were normalized with respect to gene expression on plastic/control or on 
CPC/control for cell culture on cements pellets. * Statistically significant compared to plastic/control or to CPC/control (p<0.05, bi-
directional analysis). 
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Fig. 2. Cellular proliferation, morphology and differentiation of human primary osteoblasts on CPC or CPC/Ga pellets. (A) MTT 
assay. 50 000 osteoblasts were cultured during 3 or 6 days. Data represent the mean +/- SD of 3 independent experiments, with each 
including five MTT measures. (B) Field-emission scanning electron microscopy analysis of osteoblasts cultured during 5 days on 
pellets. White arrowheads indicate cells (scale bars: 10 µm). (C) Real-time PCR quantification of osteoblastic markers after 3 or 7 days 
of cell culture. Data represent the mean +/- SEM of 3 independent experiments, each performed in triplicate. Data were normalized with 
respect to gene expression on CPC at day 3. * Statistically significant compared to CPC/day 3 (p<0.05, bi-directional anamysis). 
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Fig. 3. Cellular proliferation, morphology and differentiation of human primary monocytes co-cultured with human primary 
osteoblasts on CPC or CPC/Ga pellets. (A) MTT assay. 100 000 osteoblasts and 200 000 monocytes were co-cultured during 3, 6 or 
14 days. Data represent the mean +/- SD of 3 independent experiments, with each including five MTT measures. (B) Field-emission 
scanning electron microscopy analysis of osteoblasts and monocytes co-cultured during 14 days on pellets. White and red arrowheads 
indicate osteoblasts or osteoclasts respectively (scale bars: 10 µm). (C) Histochemical staining of differentiated monocytes positive (red 
arrowheads) for ACP5 activity. 100 000 osteoblasts were cultured alone or in the presence of 200 000 monocytes during 14 days 
(scale bars: 100 µm). (D) Real-time PCR quantification of osteoclastic markers after 6 or 14 days of osteoblast culture or 
osteoblasts/monocytes co-culture. Data represent the mean +/- SEM of 3 independent experiments, each performed in triplicate. For 
each condition (osteoblasts or co-culture) data were normalized with respect to gene expression on CPC. * Statistically significant 
compared to CPC (p<0.05, bi-directional analysis). 
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Fig. 4. Femoral implantation in rat of CPC and CPC/Ga. 2 months after implantation: (A) qualitative 3D micro-CT; (B) HES 
histological staining; (C) second harmonic generation analysis (SHG); (D) quantitative 3D micro-CT analysis; (E) total defect filling 
quantification. Results are expressed as total defect fill rate. 
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Fig. 5. Femoral implantation in rat of CDA and CDA/Ga. 2 months after implantation: (A) HES histological staining; (B) second 
harmonic generation (SHG) sections (lefts panels, white circles point implant area), and fibrillar collagen quantification (right panel). 
Data are normalised with respect to mean SHG intensity per pixel in CDA condition; (C) quantitative 3D micro-CT analysis. * 
Statistically significant compared to CDA (p<0.05, bi-directional analysis). 
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PART ONE B: 
 
Development of quantitative second-harmonic generation 
microscopy for bone tissue engineering applications 
 
1. Context and objectives of the study 
 
Classical histomorphometry is a gold standard in bone tissue assessement 
despite its major limitation only to 2D analysis. More recent 3D micro-CT 
quantification tolls allowed the study of whole implant volumes. Nevertheless, this 
technique is poorly resolutive in assessment of new bone ingrowth within calcium 
phosphate biomaterials implanted in vitro. On the other hand, second-harmonic 
generation (SHG) microscopy was recently proposed as a powerful tool for bone 
imaging, due to its intrinsic specificity for organized collagen fibrils.  
In the present study we emarked on confirming SHG specificity for bone 
collagen by direct comparison with classical HES histological slides. Our previous 
quantitative micro-CT results showed a significant increase in total defect filing when 
CDA/Ga was implanted, comared to control. Since discriminative thresholding with 
micro-CT was not possible, we decided to use the novel SHG microscopy technique 
in order to quantitatively asses bone reconstruction induced by calcium phosphate 
biomaterials.  
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2. Methods  
 
Sample preparation and SHG imaging 
 
As stated before, SHG microscopy has intrinsic specificity for collagen fibres, 
which results in high contrast images, with no additional staining needed and no 
additional steps in sample preparation. Upon retrieval, rat femoral implants were 
fixed for 24 h in neutral formalin solution (pH 7.2), and then decalcified in 10% EDTA 
(pH=8) for four weeks. Next, samples were embedded in paraffin and 5-µm 
histological sections were prepared and stained with HES. The same histological 
slides were used for SHG imaging (Zeiss LSM 710 microscope, Germany). Mai Tai laser 
excitation wavelength was set to 880 nm and the SHG signal was detected in 
transmission and reflection mode.  
 
SHG analysis 
 
For CPC and CPC/Ga samples at 1 and 8 weeks postoperatively, 5-µm 
sections were qualitatively assessed and for CDA and CDA/Ga samples, 100-µm 
sections were prepared in order to do quantification as well. Quantitative 
comparison of collagen signal between Ga and control implants was performed on 
whole implant area (excluding the cortical bone) using an in-house quantification 
tool developed in “Mathlab” programming language by S. Schaub from iBV PRISM 
platform (Platform of Resources in Imaging and Scientific Microscopy).  
 
3. Results and discussion  
 
 Firstly, we compared CPC samples retrieved 1 and 8 weeks after implantation. 
As expected (Figure 17) due to its specificity for organized collagen fibrils, SHG signal 
completely coincided with mature bone tissue areas observed on HES-stained 
histological slides. Furthmore, we observed an uneven distribution of SHG signal in 1-
week implants, while the 8-week CPC exhibited homogenous signal distribution with 
complete cortical bone reconstruction. These findings are in accordance with the 
well-established hypothesis that upon calcium phosphate biomaterial implantation, 
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CDA samples analysis, it is important to notice that the use of 100 µm sections instead 
of 5 µm sections increased by a factor of 20 the power of the quantification. 
However, this is not without certain problems related to the thickness of the section, 
which make sometimes difficult an accurate delimitation of the implant area. 
For future developments, we envision the use of more sections per implant but 
with a thickness limited to 25 µm, which seems to us a very workable compromise 
between the power of the analysis and the accuracy of the ROI (region of interest) 
delimitation. 
 
4. Conclusions 
 
Microscopy techniques based on non-linear optical processes allow for 
specific imaging of unmodified samples at high spatial resolution in three dimensions. 
By doing so, they provide powerful tools for the specific characterization of bone 
reconstruction within calcium phosphate biomaterials. Furthermore, quantitative 
assessement of collagen fiber organization confirmed the results observed in micro-
CT analysis, suggesting that SHG can function as a complementary quantifying tool 
in bone-tissue engineered constructs. It would be further interesting to apply SHG 
microscopy in studying the in vitro 3D tissue-engineered constructs, as well as 
subcutanous biomaterial implants. 
All in all, the results of this work show that quantitative SHG microscopy can 
serve as a valuable tool for evaluating the organized collagen fibers within a 
biomaterial, this providing an easy-to-use, accurate, and powerfull technique to 
score the performance of bone substitutes under development upon their 
implantation in vitro.  
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PART TWO: 
 
 
Effects of gallium in a bone metastatic model 
 
1. Context and objectives of the study 
 
Bone tissue is a common metastatic soil for a great number of solid tumours, 
including breast cancer. Upon homing to bone, cancer cells intensely secrete 
factors that stimulate osteoclastic differentiation and subsequent excessive bone 
resorption, leading to the release of high amount of TGF-β, the most prominent 
cytokine in tumour cells activation. This vicious cycle between tumour cells and 
osteoclasts results in painful osteolytic lesions that further induce severe skeletal 
events, e.g. fractures or spinal cord compression. Given the burden on patients’ life 
quality, the development of treatments targeting the disruption of the crosstalk 
between tumour cells and bone cells appears as a promising strategy to attenuate 
bone metastasis expansion. 
Due to its chemical affinity for bone tissue, its established antiresorptive 
potential, and its antineoplastic properties, gallium (Ga) represents an attractive 
candidate for bone metastases treatment and/or prevention. Given that no study 
has yet assessed Ga effects on bone metastases, we embarked on investigating if 
Ga can successfully disrupt the vicious cycle driving osteolytic lesions. 
We used a co-culture model that mimicks physiological metastatic bone 
environment to study if Ga can reverse cancer cell-induced excessive osteoclastic 
differentiation. Next, taking advantage of a bone-seeking clone derived from an 
aggressive breast cancer cell line, we assesed Ga possible effect on proliferation, 
viability and marker genes expression.  
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2. Methods and results 
 
Article II (in preparation): Gallium, a promising candidate to disrupt the vicious cycle 
driving osteolytic metastases 
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Abstract  
Bone metastases of breast cancer typically lead to a severe osteolysis due to an excessive 
osteoclastic activity. Considering the inhibitory resorption activity of Ga and its bone affinity, 
we decided to explore the in vitro effect of Ga on osteoclastogenesis in an aggressive bone 
metastatic environment based on a co-culture model. Ga inhibits in a dose-dependent 
manner the formation of mature osteoclasts, which in turn may block the release of TGF-β1 
from bone matrix preventing the vicious circle between bone cells and tumour cells. In 
addition, Ga strongly affects proliferation, viability and expression of critical markers of MDA-
231BO cells, a specific bone metastatic clone of MDA-MB-231 cells line.. This is the first time 
that antitumor properties of Ga have been studied especially in the context of bone 
metastases. These data strongly suggest that Ga may be a promising candidate for the 
prevention and/or treatment of bone metastases in patients with breast cancer. 
 
 
 
 
 
 
 
 
 
Keywords: breast cancer, bone metastasis, gallium, osteoclastogenesis 
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1. Introduction 
Bone tissue is one of the most favoured sites for metastasis of breast tumours and bone 
lesions are preferentially localized in spine and pelvic bone (Verron et al., 2014). Up to 80% of 
all patients diagnosed with breast cancer will develop bone metastases characterized by 
severe osteolytic lesions. Subsequently, bone metastases lead to severe bone pain, bone 
instability, fractures, spinal cord compression, hypercalcemia and bone marrow aplasia 
(Mercadante, 1997). As described in a retrospective study including 617 women with breast 
cancer, 52% experienced at least one of these skeletal-related events (SREs) (Delea et al., 
2006). Focussing on spinal, metastasis, about 20% of cases exhibited neurological deficit 
symptoms due to: (i) mechanical compression of spinal cord directly by the tumour or caused 
by the displacement of bone fragments, kyphotic deformity; (ii) vascular insufficiency as a 
consequence of segmental artery occlusion by tumour emboli, venous thrombus, and spinal 
cord injury due to oedema caused by internal haemorrhage of spinal cord. Consequently, it 
appears crucial to prevent or delay the onset of SREs since their development considerably 
affects patients’ quality of life and in some cases increases the risk of death (Saad et al., 
2007).  
Bone homeostasis is regulated through a balanced communication between the major 
cells forming and remodelling bone tissue, i.e. osteoclasts, osteoblasts and osteocytes. Breast 
tumour cells invasion into bone shifts the balance of bone turnover to favour resorption 
processes through an enhanced osteoclastic activity (Roodman, 2004). Indeed, breast 
cancer cells promote the formation and the activity of osteoclasts by secreting osteolytic 
cytokines including parathyroid hormone-related peptide (PTHLH), tumour necrosis factor-α 
(TNF-α), interleukins (such as IL-8 and IL-11), as well as matrix metalloproteinases that are 
involved in bone protein matrix destruction (Akhtari et al., 2008). In addition, breast cancer 
cells negatively affect osteoblasts in terms of proliferation and activity leading to a decrease 
of bone formation (Chen et al., 2010a). Consequently, due to the development of these 
breast cancer cells-induced osteolytic lesions, regulatory growth factors stored in large 
quantities within bone tissue are massively released. Among these factors locally available, 
transforming growth factor-β (TGF- β1 is the most implied in tumour cells activation (Chen et 
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al., 2010b; Buijs et al., 2011a; Buijs et al., 2011b; Juarez et al., 2011). As postulated by Stephen 
Paget, this microenvironment can be considered as a soil that provides a favourable niche 
for the growth and the development of tumour cells (Ribatti et al., 2006). In turn, tumour cells 
produce angiogenic factors such as vascular endothelial growth factor (VEGF-A) (Kakonen 
et al., 2003; Roodman, 2004; Sterling et al., 2011). This unfavorable phenomenon stimulates 
tumour neovascularization, which favor oxygen and nutriments supply, as well as tumour cells 
dissemination. 
The disruption of the vicious cycle described above represents a promising therapeutic 
strategy. This could be achieved through interfering with the cross talk between cancer cells 
and osteoclasts, with a view to reduce osteolytic bone lesions and to limit tumour cell growth 
at the bone metastatic site. In this attempt, Gallium (Ga) could be a promising candidate for 
the prevention or the treatment of bone metastasis due to (i) its chemical affinity for 
biological hydroxyapatite, (ii) its antiresorptive activity (Verron et al., 2012a) and (iii) its 
potential antitumor properties. Indeed, Ga significantly decreases osteoclasts differentiation 
and activity, without negatively interacting with osteoblasts (Verron et al., 2010a), and we 
also demonstrated at the molecular level that Ga decreased the RANKL-induced initial 
expression and auto-amplification of NFATc1, the major factor of osteoclast differentiation 
(Verron et al., 2012b). Moreover, through transferrin-dependent and independent 
mechanisms, Ga accumulates at sites of accelerated cellular proliferation including 
malignant tissue (Bernstein, 1998). Once internalized into tumor cells, Ga blocks DNA synthesis 
and alters plasma membrane permeability and mitochondrial functions, these events leading 
to cell apoptosis (Bernstein, 1998; Collery et al., 2002). 
Ga antineoplastic activity has been demonstrated in lymphoma and bladder cancer 
(Chitambar, 2012). However, it has never been studied in the context of breast carcinoma 
and its severe bone metastasis. Considering Ga antineoplastic potential together with its 
inhibitory action on osteoclastogenesis and bone resorption, we were interested in evaluating 
its effects on one of the most aggressive human breast carcinoma cell line (MDA-MB-231), 
characterized by the absence of expression of receptor of oestrogen and its high ability to 
metastasize to bone tissue. In order to achieve this goal, and taking advantage of a model 
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established by Guo et al. (Guo 2008), we designed experiments associating 
adenocarcinoma cells and RAW 264.7 monocytes. Based on this system, we studied Ga 
impact on the cross talk occurring between cancer cells prone to spread to bone (MDA-MB-
231) and precursor cells able to resorb bone tissue upon differentiation into osteoclasts (RAW 
264.7).  
 
2. Materials and Methods 
 
Materials 
Alpha Minimum Essential Medium (α-MEM) and Dulbecco’s Modified Eagle’s Medium 
(DMEM), glutamine, antibiotics (penicillin: 100 units/mL and streptomycin: 100 μg/mL), 
Phosphate Buffered Saline (PBS) and trypsin/EDTA were obtained from Gibco (Paisley, UK). 
Foetal bovine serum (FBS) for MDA-MB-231 cellular culture was purchased from Pan Biotech 
GmbH (Aidenbach Germany) and Foetal bovine serum (FBS, Hyclone) for RAW 264.7 cellular 
culture was obtained from Thermo scientific (Braunschweig, Germany). Ga nitrate, TGF-β1, 
zoledronic acid and TRAP staining kit (cat. no. 386) were provided by Sigma (SaintQuentin 
Fallavier, France). The 3-(4.5-dimethylthiazol-2-yl)-2.5-diphenyltetrazolium bromide (MTT) assay 
was obtained from Sigma-Aldrich, USA. Mouse effectors were produced as fusion proteins 
with GST. GST-Rankl was produced as previously described (Beranger et al., 2007). For all the 
experiments using cells of murine origin, a GST protein, produced and purified using the same 
protocol, was used as a control. Co-culture experiments were performed in 24-well transwell 
plate (3.0 μm pore size, Cat No 3399, Corning, France). qRT-PCR experiments were performed 
using: NucleoSpin RNA II kit provided by Macherey- Nagel (Duren, Germany); RT Mix 
containing primers, oligo dTs, RT buffer and RT enzyme from Invitrogen Corp. (Paisley, UK); 
nuclease-free water (Amidon, USA); MasterMix from Applied Biosystems (USA).  
 
Cell culture 
The mouse monocyte cell line RAW264.7 was obtained from ATCC (Ref. # TIB-71; LGC 
Standards, Molsheim, France). Cells were cultured in DMEM containing 5% foetal bovine 
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serum (Hyclone serum, Thermo Fisher Scientific, Brebière, France). For osteoclastic 
differentiation experiments, RAW264.7 cells were seeded at 5,000 cells/cm2 in α-MEM 
containing 5% Hyclone serum and effectors were added immediately. RANKL (Receptor 
Activator of Nuclear Factor-κ B Ligand) was used at 20 nM. Cells were cultured for four days 
with a renewal of the medium at day 2.  
The oestrogen-independent human breast adenocarcinoma cell line MDA-MB-231 was 
obtained from ATCC. Cells were cultured in DMEM medium supplemented with 10% of foetal 
bovine serum and 1% of antibiotics (Chen et al., 2001). 
The bone-seeking (MDA-231BO) clone established from MDA-MB-231 cell line (Yoneda 
et al., 2001) was kindly provided by  Dr. Toshiyuki Yoneda (University of Texas Health Science 
Center at San Antonio). Cells were cultured in glutamine-supplemented DMEM medium plus 
5% FCS and 1% of antibiotics.   
 
RAW 264.7 cells differentiation in presence of conditioned medium  
For the preparation of conditioned medium (CM), MDA–MB–231 cells were plated in T-
75 tissue culture flasks and cultured as described previously. When cells reach confluency, the 
medium was collected, filtrated using a 0.22 μm pore filter, and stored at -80°C. A second 
type of conditioned medium was collected from MDA–MB–231 cells treated with TGF–β1. 
Briefly, when cells reach confluency, they were deprived of growth factors by an overnight 
incubation in the presence of 0.1% serum, before a 20 hours treatment with 10 ng/ml of TGF–
β1. This conditioned medium was then collected and treated as described above. 
For differentiation experiments, RAW 264.7 cells were washed with pre-warmed PBS prior 
a 4 days treatment with RANKL. Depending on the experiment, cell cultures were 
supplemented at the same time with conditioned medium from MDA–MB–231 cells (up to 
20%) and gallium (up to 100 μM).  
 
Co-culture of RAW 264.7 cells with MDA-MB-231 cells 
For co-culture experiments, insert systems (0.4 m pore-size transwell inserts in 24 well 
plates) were used. RAW 264.7 cells were seeded at cell density of 5 000 cells/cm2 on the lower 
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chamber and were treated with 20 nM RANKL for 2 days, prior to combining with MDA-MB-
231 cells that were preliminary grown for 2 days on separate upper chambers (inserts) at cell 
density of 10 000 cells/cm2. In basal condition, MDA-MB-231 cells were pre-cultured in DMEM 
medium supplemented with 10% FBS and 1% P/S. In stimulated conditions mimicking bone 
metastases microenvironment, 10 ng/mL of TGF-β1 was added during this pre-culture phase, 
and maintained after combining cell lines for 2 days. For both conditions (basal or TGF-β1-
treated conditioned medium), Ga was added at the beginning of the co-culture period.  
 
Culture of MDA-231BO cells for Ga/TGF- experiments 
MDA-231BO cells were seeded in F-75 flask at a density of 1.5 x 106. Cells were then 
cultured 4 days, with medium renewal at day 2, in presence of Ga (100 and 300 μM) or 
vehicle. Alternatively, MDA-231BO cells were cultured 4 days, with medium renewal at day 2, 
then serum-starved overnight and treated 20h with TGF-  β1 at 10 ng/mL or vehicle. Lastly, 
MDA-231BO cells were cultured 4 days in the presence of Ga or vehicle, with medium 
renewal at day 2, then serum-starved overnight and treated 20 hours with TGF-  β1 at 10 
ng/mL or vehicle. For cells initially treated with Ga, it was maintained during starvation and 
TGF-β1 treatment.  
 
Tartrate resistant acid phosphatase (TRAP) staining 
RAW 264.7 cells were rinsed gently with pre-warmed PBS before fixation, and TRACP 
staining was performed using the leukocyte acid phosphatase kit according to the 
manufacturer’s instructions to detect the presence of TRAP-positive cells. Stained cells were 
observed using a light microscope (Axioplan 2, Zeiss, Germany). TRAP-positive multinucleated 
cells containing at least three nuclei were counted as osteoclasts.  
 
Proliferation Assay 
MDA-231BO cells were seeded at a density of 20 000 cells/cm2 and treated with 0, 100, 
200 and 300 μM of Ga during three days. Cellular proliferation was quantified by scoring cells 
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manually after Trypan blue staining. Results were expressed as a mean ± SD of three 
independent counting. 
 
Viability Assay 
MDA-231BO cells were seeded at a density of 20 000 cells/cm2 and treated with 0, 100, 
200 and 300 μM of Ga during three days. At days 1, 2 and 3 of culture, cells were rinsed two 
times in phosphate-buffered saline (PBS) and incubated in 0.5 mg/ml of 3-(4.5-dimethylthiazol-
2-yl)-2.5-diphenyltetrazolium bromide (MTT) for 1h in cell incubator. MTT was aspirated 
delicately and 0.3 ml of lysis buffer (SDS 10%, HCl 0.01 N) was added/well and left overnight in 
dark at room temperature. Supernatants were then centrifuged 2 min at 20 000 g, and 
absorbance at 562 nm was measured in 100 µl.  
 
Quantitative real-time PCR 
For RNA isolation, cells were lysed with lysis buffer provided by manufacturer of kit and 
RNA was isolated with NucleoSpin RNA II according manufacturer instructions. Quantity of 
RNA and purity of samples were measured on NanoDrop 1000 (Thermo Scientific, 
(Courtaboeuf, France)). Integrity of RNA was analyzed on BioAnalyser 2100 (Agilent 
Technologies, Austria). 
For reaction of reverse transcription, 1 μg of isolated RNA and mixture, which contained 
random primers, StrataScript enzyme, oligo dT and nuclease free water, were used. 
Conditions of reaction were 25°C for 10 minutes, 50°C for 30 minutes and 85°C for 5 minutes in 
Thermocycler (Eppendorf, Le Pecq, France). PCR was conducted with 25 ng of cDNA and 
mixture of ROX and SYBER GREEN dyes, gene specific primers and nuclease free water. 
Controls consisted in samples without cDNA (NTC) and samples without RT enzyme (NRT). The 
following temperature profile was used: 40 cycles of 30 s at 95°C, 1 min at 60°C and 30 s at 
72°C. Amplification curves were analysed using the MxProV3 software (Stratagene). PCR 
products with Ct over 35 cycles were considered as undetectable. The delta Ct (dCt) (cycle 
threshold) method was used to calculate relative expression levels. Cycle thresholds were 
normalized against Hypoxanthine Phosphoribosyltransferase 1 (HPRT1) gene expression, in 
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order to control for cDNA quantification differences. Results are reported as the fold change 
in gene expression relative to control conditions. 
Primers used in qPCR. Gene symbols (abbreviations) are as follows: CXCR4, Chemokine 
(C-X-C Motif) Receptor 4; HPRT1, Hypoxanthine Phosphoribosyltransferase 1; MMP9, Matrix 
Metalloproteinase 9; MMP13, Matrix Metalloproteinase 13; PTHLH, Parathyroid Hormone-Like 
Hormone; TGFBR1, Transforming Growth Factor Beta Receptor 1; VEGFA, Vascular Endothelial 
Growth Factor A. 
 
Statistical Analysis 
The data shown is representative of at least three independent experiments. Results are 
expressed as mean +/- standard deviation of three determinations. The statistical differences 
between two independent groups were evaluated using the Mann & Whitney test (bi-
directional analysis). Comparative analysis of more than two independent groups was 
performed using the Kruskal-Wallis test (bi-directional analysis). The differences measured 
were considered to be statistically significant for p<0.05. 
 
3. Results 
3.1 Effect of Ga on breast cancer cells-induced osteoclastic formation 
3.1.1 RAW 264.7 cells differentiation in presence of conditioned medium  
 
Conditioned medium from MDA–MB–231 cells 
Raw 264.7 cells were cultured 4 days in presence of RANKL (20 ng/mL) or vehicle, and 
the number of multinucleated TRAP+ cells was quantified (Fig. 1A). The result obtained in the 
presence of RANKL was used as control condition (100%). In parallel, the same differentiation 
experiments were performed in the presence of 10% or 20% conditioned medium (CM) 
isolated from MDA–MB–231 cells culture. As shown in Fig. 1A, we observed that 10% CM 
significantly increased osteoclast formation by 62% as compared to control condition (cells 
treated with RANKL during 4 days in absence of CM). By contrast, this stimulatory effect 
disappeared when 20% CM was tested. 
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Based on these results, we next evaluated Ga impact on conditioned medium-induced 
osteoclastic differentiation in the presence of 10% CM from MDA–MB-231 cells. As shown in 
Fig. 1B, a 4 days treatment with Ga decreased in a dose-dependent manner the number of 
mature osteoclasts measured in presence of 10% CM. Using 100 M Ga, we observed that 
the number of multinucleated TRAP+ cells decreased by approximately 90% as compared to 
the control condition.  
 
Conditioned medium from TGF–β1-treated MDA–MB–231 cells 
In order to mimic an aggressive bone metastatic environment, MDA–MB-231 were 
cultured as described under Experiment Procedures, in the presence of 10 ng/mL TGF–β1 or 
vehicle. Increasing amounts of this conditioned medium were used as an adjuvant during 
RAW 264.7 cells differentiation. As shown in Fig. 1C, incubating RAW 264.7 cells with CM from 
TGF–β1-treated MDA–MB-231 cells significantly increased the number of osteoclasts as 
compared to control condition. The addition of 20% CM was the most effective dose and 
increased the number of osteoclasts by 236 % as compared to cells treated with RANKL 
alone.  
Based on these results, we next evaluated Ga impact on conditioned medium-induced 
osteoclastic differentiation in the presence of 20% CM from TGF–β1-treated MDA–MB-231 
cells. As shown in Fig. 1D, a 4 days treatment with Ga decreased in a dose-dependent 
manner the number of mature osteoclasts measured in presence of 20% CM. Using 10 µM Ga, 
we observed that the number of multinucleated TRAP+ cells decreased by 68% as compared 
to the control condition, and this effect further increased with higher doses of Ga. 
Interestingly, when compared to the results obtained with CM from MDA–MB-231 cells (Fig. 
1B), Ga impact was more pronounced in the presence of CM from TGF–β1-treated MDA–MB-
231 cells. 
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3.1.2 Co-culture of RAW 264.7 cells with MDA-MB-231 cells 
 
Basal condition  
We first performed co-culture of MDA-MB-231 cells with RAW-264.7 cells previously 
primed with 20 nM of RANKL. As compared to RAW 264.7 cells alone, co-culture with MDA-
MB-231 cells almost doubled the number of mature osteoclasts (data not shown). We next 
tested Ga impact on RAW 264.7 cells osteoclastogenesis occurring in the presence of MDA-
MB-231. A shown in Fig. 2A, a 48 hours Ga treatment significantly inhibited in a dose-
dependent manner the formation of multinucleated TRAP+ cells, and Ga at 100 μM induced 
the most effective inhibition (approximately 85%). 
 
Treatment with TGF–β1  
In an effort to mimic bone metastases microenvironment conditions, MDA-MB-231 cells 
were treated 10 ng/mL TGF-β before and during the co-culture with RANKL-primed RAW 264.7 
cells. As shown in Fig. 2B, the formation of multinucleated TRAP+ cells was increased 
significantly by 15% as compared to the control condition. Considering more qualitative 
aspects, we observed that in the presence of TGF-β, multinucleated TRAP+ cells were bigger 
and contained more nuclei (Fig. 2B, right panels). 
Using these co-culture conditions in the presence of TGF-β, we then tested Ga on RAW 
264.7 cells osteoclastogenesis. As shown in Fig. 2C, a 48 hours Ga treatment inhibited the 
formation of multinucleated TRAP+. Similarly to the results obtained in the absence of TGF-β 
(Fig. 2A), Ga at 100 μM induced the most effective inhibition (approximately 85%). 
 
3.2 Effect of Ga on bone-seeking (MDA-231BO) clone 
To determine whether Ga may also affect metastatic tumour cells with a bone tropism, 
we quantified Ga impact on the bone-seeking MDA-231BO clone, which has been 
established by repeating sequential passages, in nude mice and in vitro, of MDA-MB-
231tumour cells isolated from bone metastases.  
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3.2.1 Effect of Ga on MDA-231BO cells proliferation and viability 
Cellular proliferation scoring was based on cell number quantified along three days of 
culture in the presence of increasing Ga concentrations. As shown in Fig. 3A, Ga inhibited in a 
dose-dependent manner MDA-231BO cells proliferation and at day 3, 300 μM Ga decreased 
by 84% cell proliferation as compared to untreated cells. We also observed that Ga affected 
MDA-231BO cells viability, as illustrated by the 64 % inhibition measured at day 3 in the 
presence of 300 μM Ga (Fig. 3B).  
 
3.2.2 Effect of Ga on tumoral markers expression 
To determine Ga impact on the osteolytic potential of MDA-231BO cells, we quantified 
the expression of selected marker genes upon Ga treatment, in the absence or presence of 
TGF–β1. As shown in Fig. 4, in the absence of TGF–β1 (left part of histograms), PTHLH gene 
expression was reduced by 71 % in the presence of 100 µM Ga, with no further inhibition with 
a higher dose. In the presence of TGF–β1, we observed in basal condition a non-significant 
decrease of PTHLH gene expression. Adding Ga led to an inhibition that reached 66 % in the 
presence of 300 µM Ga.  
Treating MDA-231BO cells with 100 µM and 300 µM Ga inhibited also MMP9 gene 
expression by 69% and 84% respectively. When TGF–β1 was added, a strong up regulation (5- 
to 6-fold) of basal expression was measured. The addition of Ga abolished this increase and 
restored the level of MMP9 gene expression in the absence of any treatment. 
Concerning MMP13, TGF–β1 or 100 µM Ga treatments did not modify gene expression. 
By contrast, regardless the absence or presence of TGF–β1, 300 µM Ga stimulated the 
expression of MMP13 gene. 
We also observed that Ga enhanced VEGFA gene expression (approximately 2-fold 
stimulation for both concentrations), while TGF–β1 by itself also induced the same increase. 
Adding 300 µM Ga to TGF–β1 further stimulated VEGFA gene expression by 50%. 
Similarly to PTHLH, TGFBR1 gene expression was down regulated by Ga treatment in the 
absence or presence of TGF–β1, reaching respectively 66% and 48% with 300 µM Ga. 
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Lastly, regardless the absence or presence of TGF–β1, CXCR4 gene expression was not 
modified by a 100 µM Ga treatment. By contrast, either for control or TGF–β1 condition, 
incubating cells with 300 µM Ga induced a 2.5-fold stimulation of gene expression. 
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4. Discussion 
Bone metastases of breast cancer typically lead to a severe osteolysis due to an 
excessive osteoclastic activity. Considering its bone affinity, as well as its inhibitory action on 
resorption, we decided to explore in vitro Ga effects on osteoclastogenesis, using conditions 
mimicking an aggressive bone metastatic environment. To address this issue, we used the 
human breast cancer cell line MDA-MB-231, as well as a bone-seeking clone (MDA-231BO 
cells), which has been isolated from bone metastases of MDA-MB-231tumour cells.  
First of all, and similarly to Guo et al (Guo et al., 2008), we observed that factors derived 
from breast cancer cells supported mature osteoclasts formation from RANKL-primed 
precursors in the absence of supporting cell types. We firstly stimulated RAW264.7 cells with 
breast cancer-derived factors by using conditioned medium (CM) isolated from MDA-MB-231 
cell culture. According to Gallet et al, MDA-MB-231 cells release several soluble factors such 
as M-CSF and PTHLH, which both act on osteoclastogenesis and mature osteoclasts survival 
(Gallet et al., 2004). After 4-days incubation in the presence of conditioned medium, Ga 
caused a significant decrease in mature osteoclasts number. Interestingly, this inhibitory 
effect was more pronounced when MDA-MB-231 cells were previously treated with TGF-β1, a 
factor present within an aggressive bone metastatic environment.  
These preliminary experiments focused on the direct impact of Ga on osteoclast and 
did not ascertain whether Ga may disrupt the vicious circle between osteoclasts and tumour 
cells. In this attempt, RAW264.7 cells were co-cultured with MDA-MB-231 cells, in the absence 
or presence of TGF-  β1. As compared to using conditioned medium, co-culture conditions 
closely mimics the in vivo situation by producing a dynamic and continuous renewal of 
growth factors released by tumours cells. In line with this, Salamanna et al. demonstrated that 
co-culture of RAW264.7 cells with MRMT-1 breast cancer cells induced a higher formation of 
multinucleated TRAP+ cells than by using conditioned medium alone (Salamanna et al., 
2013). In addition, since Ga was administrated 48 hours after the stimulation of MDA-MB-231 
cells and RAW264.7 cells with TGF-  β1 and RANKL respectively, this co-culture model may 
document Ga actions when the metastatic process is in progress. Using this model, we 
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demonstrated that 48-hours treatment with Ga significantly diminished osteoclastogenesis in 
an aggressive bone metastatic environment.  
These results suggested that Ga could also impact on tumour cells. To address this 
question, we used a bone-seeking clone (MDA-231BO cells), which has been isolated from 
bone metastases of MDA-MB-231 tumour cells. We first confirmed previous results published by 
Yoneda et al. concerning the greater production of parathyroid hormone–related protein 
(PTHLH) by MDA-231BO as compared to the parental MDA-MB-231 cells (data not shown). This 
phenotypic change allows breast cancer cells to survive, proliferate into bone and promote 
osteoclastic bone resorption, which in turn leads to the establishment of severe osteolytic 
bone metastases. Interestingly, we observed that Ga inhibited in a dose-dependent manner 
both the proliferation and the viability of MDA-231BO cells, further supporting the interest of 
using this cell clone in experiments related to a bone metastases context. 
To ascertain whether Ga may also affect the activity of these aggressive cells in terms 
of angiogenesis, invasion, and osteolysis, we next embarked on measuring the expression of 
major critical marker genes by performing real-time PCR experiments. To our knowledge, this 
is the first time that TGF-β1 action on the expression by MDA-231BO cells of these critical 
marker genes is quantified. 
Firstly, we evaluated Ga impact on the major osteolytic marker, PTHLH, which is 
produced by bone metastatic cells. Reducing by 71% PTHLP expression in basal conditions, 
Ga may directly impact MDA-231BO cells osteolytic properties. Indeed, PTHLH up regulates 
the expression of RANKL in bone marrow stromal cells, which in turn stimulates the 
differentiation and activation of osteoclasts, hence favouring tumour progression and bone 
destruction (Nakamura et al., 2008). Consequently, TGF- that is among the most abundant 
growth factor stored in bone (Hauschka et al., 1986) is released continually into the bone 
marrow cavity in active form. In response to TGF-, increased PTHLH production may be one 
of the most critical properties for breast cancer cells to accelerate osteolytic bone metastasis 
(Yin et al., 1999; Kakonen et al., 2003). Mimicking these conditions, we used TGF- β1-treated 
MDA-231BO cells and we found that the expression of PTHLH gene was inhibited by 300 µM 
Ga. Thus, Ga antitumor activity could be mediated in part through the downregulation of 
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PTHLH gene expression by tumoral cells, and in other part by disturbing the RANK signalling 
pathways in osteoclasts, as described in our previous study (Verron et al., 2010b). Taken 
together, Ga may disrupt the vicious cycle by interfering with the cross talk between breast 
cancer cells and osteoclasts, which consequently may reduce osteolytic bone lesions and 
affect tumour cells growth in bone metastases.  
By hydrolysing components of the extracellular matrix (ECM), Matrix MetalloProteinases 
(MMPs), which are a family of zinc-dependent endopeptidases, play a pivotal role in the 
migration, the invasion and the development within bone of breast carcinoma cancer cells 
(Kakonen et al., 2003). It has been shown that MDA-MB-231 cells expressed high levels of 
MMP1, 3 and 9 during the degradation of the ECM, whereas MMP2 and 7 were not 
detectable (Bachmeier et al., 2001; Barrett et al., 2002). Interestingly, MMP1 and 9 expressions 
were much higher in bone-seeking clone as compared to parental cells (Yoneda et al., 
2001). In preliminary experiments, we found that MDA-231BO cells expressed higher level of 
MMP9 and 13 as compared to MDA-MB-231 (data not shown). Concerning MMP13, we did 
not show any significant action due to TGF–β1 treatment, while 300 M Ga stimulated MMP13 
gene expression in both conditions. Next, treating MDA-231BO cells with Ga, we first observed 
an inhibition of MMP9 gene expression. Interestingly, even when MMP9 expression was 
strongly up-regulated by TGF–β1, Ga was able to restore the basal expression level in the 
absence of any treatment. It should be noted that the lowest Ga concentration (100 µM) was 
sufficient to inhibit MMP9 expression, while it did not impact MMP13 expression. Moreover, 
performing real time PCR quantifications, we observed that MMP13 was ten-fold less 
expressed than MMP9. Taken together, these data suggest that Ga could exert positive 
actions on matrix proteases expression and cancer cells invasion. 
Anti-angiogenic therapies have raised major interests and promises in cancer therapy 
in general, and more specifically for the treatment of hyper-vascularized skeletal metastases 
that are observed in patients with renal carcinoma. Indeed, cutting the blood supply to a 
tumour is a pertinent approach. Ga induced VEGFA expression regardless of the condition 
(absence or presence of TGF–β1), and this could be prejudicial for the patient. Nevertheless, 
this specific clinical context requires bone reconstruction after tumour resection. In this 
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attempt, sufficient vascularization is essential to favour resorption/substitution of the 
implanted-bone substitutes leading to neoformation of bone tissue, and angiogenic 
properties of Ga may be desired. Moreover, before concluding on the putative angiogenesis 
properties of Ga, further experiments performed on endothelial vascular cells are required. 
Similarly to anti-angiogenic therapies, targeting TGF-  β1 has also been applied to 
cancer (Korpal et al., 2010; Buijs et al., 2011a). Given that TGF-  β1 has been described to 
stimulate angiogenesis and suppress immune surveillance of tumour cells (Buijs et al., 2011b), 
these treatments may also reduce bone invasion by tumour cells. In this way, different classes 
of TGF-  β1 inhibitors have been tested in clinical trials of bone metastases including 
monoclonal neutralizing TGF-  β1 antibodies (Edwards et al., 2010; Juarez et al., 2011). 
Considering this therapeutic target of bone metastases, we wanted to decipher whether Ga 
could disturb TGF-  β1signalling. Similarly to PTHLH, TGFBR1 gene expression was down 
regulated by Ga treatment in the absence or presence of TGF–β1, reaching respectively 66% 
and 48% with 300 µM Ga. It is well documented that TGF–β1 is able to promote cancer 
metastases acting at different levels (tumour microenvironment and immune response) 
(Padua et al., 2009). Thus, Ga action on one of the TGF–β1 receptor (TGFBR1) could represent 
a substantial benefit in terms of disrupting the vicious cycle involved in bone metastases 
development. However, TGF–β1 is also involved in tumour-inhibiting pathways (Padua et al., 
2009), and anti-TGF–β1 therapies should be carefully evaluated. In this line, and this may be of 
great interest to avoid drawbacks due to systemic administration, it should be noted that Ga 
coupled to a bone substitute could exert its action locally and directly on cancer cells, as 
demonstrated by this report.  
As mentioned in the Introduction section, interactions between breast tumour cells and 
bone microenvironment are implied in the establishment of bone metastases. Among 
chemokine receptors expressed by osteotropic cancer cells to mediate their adhesion to 
endothelium, chemokine (C-X-C motif) receptor 4 (CXCR4), the receptor for SDF-1 (stromal 
cell derived factor-1, or CXCL12) has been shown to play a pivotal role in tumour cell homing 
to bone (Muller et al., 2001; Smith et al., 2004). However, even if CXCR4 has been found to 
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closely correlate with the incidence, development, treatment and prognosis of breast cancer 
(Sterling et al., 2011), overexpression of individual proteins was insufficient to accelerate bone 
metastases (Kang et al., 2003). By contrast, up regulating the expression of CXCR4, Ga would 
favour tumour cells retention within CXCL12-rich bone  microenvironment, this preventing 
their dissemination towards other organs. Moreover, keeping metastatic cells in close contact 
with Ga, which displays a strong affinity for bone mineral, should favour Ga direct actions on 
cancer cells that are reported above. 
To summary, Ga regulates excessive osteoclastogenesis by acting directly on 
osteoclasts differentiation. Indirectly, Ga inhibits of PTHLH and MMP9 secretion by tumour 
cells, and consequently blocks TGF-β1 release from the bone matrix. Together with the 
inhibition Ga exerts on TGFBR1 expression, these actions could lead to the disruption the 
vicious circle involving bone cells and tumour cells (Fig. 5). In addition, we demonstrate that 
Ga affects both proliferation and viability of bone metastatic cells. This is the first time that 
antitumor properties of Ga have been studied in the context of bone metastases, and our 
data strongly suggest that Ga is a promising candidate for the treatment of patients with 
bone metastases from breast cancer. 
 
  
 
 
Figure 1. Ga effect on RAW 264.7 cells differentiation in the presence of conditioned medium from MDA-
MB-231 cells. (A) RAW 264.7 cells were treated during 4 days with 20 nM RANKL (RL) or vehicle, in the 
presence of conditioned medium (CM; 10% or 20%) isolated from untreated MDA-MB-231 cells. (B) Ga effect on 
RAW 264.7 cells differentiation measured in the presence of 10% conditioned isolated from untreated MDA-MB-
231 cells. (C) RAW 264.7 cells were treated during 4 days with 20 nM RANKL (RL) or vehicle, in the presence of 
conditioned medium (CM; 5%, 10% or 20%) isolated from MDA-MB-231 cells treated with 10 ng/mL TGF-β. (D) 
Ga effect on RAW 264.7 cells differentiation measured in the presence of 20% conditioned medium isolated from 
MDA-MB-231 cells treated with 10 ng/mL TGF-β1. *p < 0.05, statistically significant compared to untreated cells 
(Kruskall-Wallis test, bidirectional analysis). For A and C experiments, results are normalised according to TRAP+ 
cell number in 0%CM/+RL condition. For B and D experiments, results are normalised according to TRAP+ cell 
number in 0 µM Ga condition. 
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Figure 4. Gene expression in MDA-231BO cells: Ga effect in absence or presence of TGF-β1. MDA-231BO 
cells were cultured 4 days in the presence of Ga or vehicle, with medium renewal at day 2, then serum-starved 
overnight and treated 20h with TGF-β1 (10 ng/mL) or vehicle. For cells initially treated with Ga, it was maintained 
during starvation and TGF-β1 treatment. Results are reported as fold change in gene expression relative to 
untreated cells (0 µM Ga/-TGF-β1) after normalization against HPRT-1. * p < 0.05, statistically significant 
compared to “0 µM Ga“ condition; # p < 0.05, statistically significant compared to “0 µ Ga/-TGF-β1 “ condition 
(Kruskall&Wallis test, bidirectional analysis).  
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The introduction of calcium phosphate-based biomaterials in 1980s has 
revolutionized the field of orthopaedic surgery. Although their mechanical resistance 
and reconstructive properties fall behind the autograft performance, CaPs are still 
considered as one of the best alternatives to autologous bone grafting. Their ability 
to be resorbed and gradually replaced by new bone tissue at the implantation site 
has promoted their extensive use in clinical practice. 
Different pathological situations, such as bone remodelling disorders, 
infections, excessive inflammation, or residual metastatic cells after tumour resection, 
can compromise the local bone neoformation and result in considerable 
postoperative pain. In this view, it is advantageous if an implanted biomaterial, 
besides its basic mechanical and reconstructive properties, can partially or 
completely counteract the pathological situation. Indeed, the investigation of 
different modes of integration of pharmacological compounds into biomaterial 
structure is one of the main efforts in current development of bone substitutes. As a 
beneficial side effect of this approach, the strategy of local drug delivery 
circumvents the major drawbacks of systemic administration namely, poor drug 
bioavailability, important side effects and in some cases poor patient compliance. 
Moreover, considering the particular situation of non load-bearing orthopaedic 
indications, injectable CaP cements (CPC) can easily adapt to complex irregular 
bone defects providing mechanical support at the injury site and also an 
osteoconductive surface that promotes bone ingrowth. After implantation, a CPC 
setting occurs through negligible exothermic reaction, which doesn’t damage the 
surrounding bone tissue or the possible loaded therapeutic agent. 
 The mentioned properties point out CPCs as highly convenient vectors for 
local drug delivery in pathological bone context.  
 
 
Bone tissue reinforcement 
 
Some of the studied biomaterial-active molecule combinations include: 
bisphosphonates-loaded CaP for osteoporotic fracture prevention (Elise Verron, 
Gauthier, Janvier, Pilet, et al., 2010); CaP loaded with analgesics for postoperative 
pain management (Elise Verron, Gauthier, Janvier, Le Guen, et al., 2010); 
orthopaedic prosthesis coatings with antibiotics (Tran et al., 2015); CPC coupled to 
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chemotherapeutic agents for residual metastases eradication (Lopez-Heredia et al., 
2011). As an additional example, and in line with the use of this type of bone 
substitutes loaded with active molecules, Tian et al. have studied a calcium 
phosphate biomaterial loaded with strontium, which displayed anti-osteoporotic 
properties (Tian et al., 2009).  
Osteoporosis is definitely one of the most prominent bone diseases today, as 
attested by the constant increase in incidence of osteoporotic fractures that tend to 
heal slowly and can result in considerable chronic pain and reduced patient’s 
mobility. These fractures mainly occur in the conditions of excessive osteoclastic 
resorption and diminished osteoblastic bone-forming activity. Several small-scale 
clinical trials reported on positive effects of Ga administration on excessive bone 
resorption and concomitant hypercalcaemia. Later, it was shown that Ga 
antihypercalcemic effect stems from its inhibitory action on osteoclasts and 
consequently on bone resorption. Even though Ga presents a strong affinity to bone, 
upon oral administration it is poorly absorbed and mainly concentrated in the 
kidneys and liver (E. Verron, Bouler, & Scimeca, 2012), possibly resulting in organ-
specific toxicity. Therefore, it would be preferable to increase Ga bioavailability at 
the bone site, without increasing the total administrated dose. This could be 
achieved by local Ga delivery directly to the aimed tissue, taking into account that it 
is crucial to control the timing and kinetics of Ga in situ release. Indeed, after the 
delivery to the bone site, a burst Ga release would display short-term effects, and a 
loss of long-term beneficial actions on bone tissue. Moreover, although osteoporosis 
is a systemic disease, a high percentage of fractures occurs at specific sites, i.e. 
femoral neck, spine and wrist, which justifies the local approach in fracture 
prevention and/or treatment. Having these requirements in mind, calcium 
phosphate cements (CPCs) seem good vectors for local Ga delivery, due to their 
progressive in vitro resorption that assures the sustained and controlled release of the 
loaded drug. 
Considering this objective, Mellier et al. (C Mellier et al., 2011; Charlotte Mellier, 
Fayon, Boukhechba, Verron, LeFerrec, et al., 2015) showed that Ga could be loaded 
into a CPC structure via substitution with calcium. Given the multiple possible Ga 
therapeutical effects, this CPC/Ga combined device presents interesting properties 
for implantation in pathological situations, such as fragilized osteoporotic bone, or in 
cavities generated by bone tumours resection.  
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To examine its properties in vitro, we implanted CPC/Ga in a critical rat 
femoral defect. Contrary to our speculations that Ga could enhance bon 
reconstruction by decreasing osteoclastic bone resorption, Ga-loaded CPC did not 
exhibit any effect on defect healing compared to its commercially available non-
loaded version. To explain this lack of effect, we speculate that the slow CPC 
dissolution rate in vitro did not permit a sufficient Ga release into the implant 
microenvironment. Thus, the local Ga concentration was suboptimal to have any 
significant impact on bone cells, including osteoclasts. In order to increase Ga 
concentration at the implantation site, we used another type of CaP-based 
substitute, i.e. calcium deficient apatite (CDA) microparticles, which contained a 
higher amount of Ga, and which were more resorbable. Using CDA/Ga, and 
compared to the control CDA, we observed an increase in total defect filling and 
fibrillar collagen amount as shown by our SHG analysis. These results suggest that 
enhancing Ga concentration at the implantation site can have beneficial effects on 
bone reconstruction. Although CDA microparticles are not yet a suitable bone 
substitute for clinical application, these results clearly established the proof of 
concept demonstrating the advantage of Ga incorporation into the structure of a 
bone substitute. Certainly, further developments of CPCs with higher Ga content are 
envisioned, as well as their characterization in osteoporotic animal models (rat, ewe) 
in order to assess their performances in a pathological bone environment.  
To further decipher the mechanisms of Ga action on bone cells observed in 
vitro, we used a model of human osteoblasts and monocytes co-cultured on 
calcium phosphate pellets. Compared to classical monoculture on plastic surface, 
the concomitant culture of bone forming and bone resorbing cells on a calcium 
phosphate substrate resembles more closely to the physiological bone environment. 
Indeed, as underlined by Nakamura et al. and Boukhechba et al., there is a 
difference in osteoclastic actin ring organisation(M. Nakamura et al., 2013) between 
cells cultured on plastic or in the presence of calcium phosphate substrates. In our 
model, osteoblast-monocyte crosstalk on CPC pellets allowed for the complete 
osteoclastic differentiation in absence of any exogenous ligands, i.e. M-CSF and 
RANKL, as attested by osteoclast-characteristic TRAP staining. Ga-loaded CPC was 
able to reduce the number of TRAP+ multinuclear cells, compared to control CPC, 
and this was also confirmed by a significant inhibition of typical osteoclastic markers 
ACP5 (TRAP) and MMP9. Since MMP9 is an important proteinase involved in bone 
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matrix degradation, its inhibition would possibly result in a decreased bone resorption 
in vitro. In addition, Hayman et al. reported disrupted endochondral ossification and 
mild osteopetrosis in ACP5-deficient mice (Hayman et al., 1996). As a whole, our in 
vitro observations strongly suggest that Ga released from CPC structure is able to 
interfere with osteoclastic differentiation, which is in accordance with previously 
reported Ga antiosteoclastic effects (Blair et al., 1992; T. J. Hall & Chambers, 1990; 
Elise Verron, Masson, Khoshniat, Duplomb, Wittrant, Baud&apos;Huin, et al., 2010), 
which may account for a shift of the resorption/construction balance towards bone 
formation.  
On the other hand, we found that CPC/Ga possibly stimulated osteoblastic 
activity by up regulating the expression of several marker genes involved in bone 
matrix synthesis and mineralization, i.e. collagen, bone sialoprotein II, osteonectin 
and periostin. These results corroborate with the increase in total bone defect filling 
and collagen synthesis we observed in vitro within Ga-loaded biomaterial implants. 
In addition, we showed that Ga could reduce osteoblastic proliferation in vitro, 
possibly suggesting that osteoblasts enter in their final maturation phase. This is 
supported by the upregulated expression of IBSP, ON, and POSTN, which are 
characteristic markers of later phases of osteoblastic maturation. In contrast to our 
study, it was previously reported that Ga does not affect osteoblastic viability and 
proliferation of primary murine cells and MC3T3 –E1 cell line (Elise Verron, Masson, 
Khoshniat, Duplomb, Wittrant, Baud&apos;Huin, et al., 2010). This discrepancy could 
be explained by the fact that the mentioned results were obtained with murine cell 
line models, while our study was conducted on human primary osteoblasts. 
Secondly, osteoblasts cultured on plastic surface may respond differently from those 
cultured on bone-mineral resembling substrate, which is the case for CPC pellets. 
Interestingly, Boukhechba et al. showed that, compared to plastic seeding, 
osteoblastic marker genes are differentially expressed in cells seeded on calcium 
phosphate microparticles (Boukhechba et al., 2009). This puts in advance the 
importance of relevant culture models, which more accurately predict in vitro 
responses to therapeutic agents. Altogether, the exact molecular mechanisms of Ga 
action on bone forming osteoblasts are still unknown, and further research is needed 
to elucidate the signalling pathways governing Ga effects on this bone cell type.  
Concerning the very first step of Ga interaction with cells, it is now well 
accepted that Ga cellular internalization is mediated by transferrin receptor (Collery 
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et al., 2002; E Verron et al., 2012). Nevertheless, some authors proposed calcium 
channels as alternative mechanisms for Ga cellular entry (Abe et al., 2007; Sohn et 
al., 1993). It would be interesting to further document on Ga interaction with Ca2+ 
channels having in view their importance in osteoclastic differentiation. Lastly, when 
it comes to the Ga intracellular localization, an early study on very small number of 
Paget’s disease patients reported almost exclusive nuclei localization in osteoclasts, 
which is different from tumour cells where a high association of Ga with the lysosome 
fraction within the cytoplasm was reported (Mills, Masuoka, Graham, Singer, & 
Waxman, 1988). These sub-cellular localisation data suggest areas for future research 
on Ga antiresorptive and antitumor properties. 
Another gap in our knowledge about Ga action on bone is the osteocyte. 
Osteocytes are involved in the control of both osteoblasts and osteoclasts, and they 
have a remarkable role in the orchestration of bone remodelling. Given that no 
study has already evaluated Ga effect on osteocytes, it is important to establish 
whether Ga can interact as well with this ultimate stage of osteoblastic 
differentiation. The lack of good in vitro cell models, together with the difficulties to 
isolate primary osteocytes, have hampered the research in osteocyte biology in 
general and a fortiori, the investigation about possible Ga effects on the most 
abundant cell type in bone. As mentioned above, we found that Ga upregulated 
the expression of several rather late osteoblastic marker genes, and it would be 
interesting to see if this effect would persist in further osteoblastic maturation towards 
osteocyte. Furthermore, it would be suitable to study the possible Ga effects on 
osteocyte formation in a 3D culture systems including calcium phosphate substrates, 
such as described in several reports (Boukhechba et al., 2009), (Vazquez et al., 2014) 
or (Quent, Theodoropoulos, Hutmacher, & Reichert, 2015). Even more, the 
development of dynamic 3D osteoblast-osteocyte models, with mechanical forces 
applied to the cells, promises to yield relevant data more comparable to in vitro 
physiological situation (Takai, Mauck, Hung, & Guo, 2004). 
In addition to develop new models suitable for bone cells study, the use of 
accurate and reliable techniques to quantify bone tissue formation constitutes an 
issue. Considering more specifically CaP-based biomaterials, the precise 3D 
quantification of newly formed bone within calcium phosphate substitutes was so far 
hindered by difficulties in micro-CT thresholding between biomaterial and bone 
mineral phase. Considering that type I collagen is the main constituent of bone 
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organic matrix, its molecular organisation permits for second-harmonic generation 
(SHG). Indeed, this peculiar microscopy mode can be employed to quantify the 
organized collagen fibrils in different samples, ranging from in vitro engineered bone 
tissue constructs to osseous biomaterial implants. In the present work, we report for 
the first time the use of SHG microscopy to quantitatively assess osteogenesis after a 
bone substitute implantation. This powerful technique opens the door to non-
destructive and highly specific 3D quantification of bone reconstruction in the field of 
bone tissue engineering.  
Taken all together, our data promote Ga-CaP biomaterial combined devices 
as interesting candidates for local osteoporotic fracture prevention. In decades to 
come, increasing life expectancy will probably lead to a higher number of 
osteoporotic patients and even greater medical and economical toll for 
osteoporotic management. In such a situation, the development of efficient 
treatments that delay osteoporotic bone loss and/or prevent fractures without 
important side-effects is a major public health challenge.  
 
Bone metastasis treatment  
 
Given the great number of solid tumours that metastasises to bone, leading to 
devastating and painful complications associated with bad patient outcome, 
another important challenge is to successfully block the metastatic process and 
tumour expansion in bone tissue. In the past years, advances in bone metastasis 
treatment, including surgical approaches, radiotherapy, and targeted 
pharmacological therapy, have somewhat improved life quality of the patients. 
Nevertheless, for the moment, these strategies remain only palliative and do not 
significantly improve overall patient survival (Krzeszinski & Wan, 2015).  
In the case of breast cancer, up to 80% of patients develop bone metastases 
characterized by severe osteolytic lesions. Nowadays, the main approach in their 
treatment consists of surgical excision, in some cases accompanied by appropriate 
chemotherapy. The remaining bone cavity is filled by a suitable bone substitute, 
which provides mechanical support for the fragilized bone site and also contributes 
to reduce pain that could be due to the bone void after the resection surgery. Then, 
depending on its formulation, the substitute can be gradually resorbed and replaced 
by new bone tissue. However, residual metastatic cells can hamper this bone 
141 
 
reconstruction process. Indeed, tumour-resection surgeries aim to remove the 
diseased tissue with a minimal damage to the surrounding healthy tissue. This 
sometimes results in incomplete tumour removal leading to cancer recurrence either 
at the same site or in a distant organ. To counteract this risk, a local delivery of 
chemotherapeutic agents via bone substitutes constitute an attractive perspective, 
as proposed by Lopez-Heredia et al. (Lopez-Heredia et al., 2011) who developed 
and characterized a calcium phosphate cement (CPC) loaded with 
chemotherapeutic agent paclitaxel. By seeding osteosarcoma U2OS and metastatic 
breast cancer MDA-MB-231 cells on CPC/paclitaxel composite biomaterial, they 
observed that CPC-released paclitaxel could efficiently decrease tumour cell 
viability. These results strongly support the concept of local delivery of anticancer 
agents at the bone metastatic site.  
Among the different therapeutic actions of Ga compounds, antineoplastic 
properties are the most extensively studied. Numerous studies are in favour of Ga 
antiproliferative and antimitogenic actions on cancer cells. It was previously 
demonstrated that Ga is capable of interfering with cancer cells DNA synthesis, 
chromatin function and protein synthesis (Collery et al., 2002). Due to its chemical 
similarity with Fe3+ ion, Ga can bind to different Fe3+-binding proteins and thus, disrupt 
substantial iron-dependent intracellular pathways, as well as mitochondrial function. 
Furthermore, Ga was found to alter enzymatic activity of ATPases, DNA polymerases, 
ribonucleotide reductase, and tyrosin-specific protein phosphatases, as well as to 
provoke a cell cycle arrest (Collery et al., 2002) directing the tumour cell into 
apoptosis.  
Having in mind the mentioned antitumor potential of Ga compounds, we 
hypothesize that delivering Ga into bone metastatic environment can inhibit tumour 
cells proliferation and abolish or delay metastasis progression. In one similar attempt, 
Zeimaran et al. synthesized poly(octanediol citrate)/gallium-containing bioglass 
scaffolds as a possible prevention tool of metastatic relapse in tumour resection 
cavities (Zeimaran et al., 2014). 
Given that no study has investigated Ga effect on bone metastases, we 
decided to use MDA-MB-231, as one of the most aggressive human breast 
carcinoma cell lines, and its bone-seeking clone MDA-231BO, in order to asses Ga 
anti-metastatic potential. Breast cancer cells are shown to induce osteoclast 
maturation (Salamanna et al., 2013), this leading to the resorption of bone matrix 
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and consequently, the release of high amounts of TGF-β1, which is the most implied 
cytokine in tumour cells activation. Thus, this crosstalk between osteoclasts and 
tumour cells is the very basis of bone metastasis vicious cycle, and targeting this 
dialogue represents a promising therapeutic strategy for metastasis attenuation. In 
our co-culture model, we demonstrated that Ga treatment was able to dose-
dependently reverse the MDA-MB-231-mediated differentiation of osteoclast 
precursor cells. To further mimic physiological bone metastatic environment, these 
experiments were reproduced in the presence of TGF-β1 cytokine. In this more 
aggressive condition, Ga treatment remarkably abolished MDA-MB-231-mediated 
osteoclastogenesis. We demonstrate here that, in addition to a direct action on 
osteoclasts, Ga can possibly reduce bone osteolytic lesions by affecting tumours 
cells viability and proliferation, as well as through an inhibition of critical markers 
genes directly responsible of the vicious cycle, i.e. PTHLH, MMP9 and TGFBR1. 
A step closer to the real pathological situation would be to perform in vitro 
studies on a bone-resembling substrate, such as calcium phosphate, loaded with 
Ga. In the same way that calcium phosphate cement (CPC) was employed for in 
vitro investigation of Ga effect on human primary osteoclasts and osteoblasts in non-
pathological context, it could be used to study Ga effect on bone metastatic cells 
alone or in co-culture with osteoclast precursors. It would be interesting to see if CPC-
released Ga could interfere with bone metastasis vicious cycle, as observed when 
Ga was administered in solution. Further studies of vicious cycle markers, like TNF-α 
and SDF-1, are needed to better understand and therapeutically target the 
osteoclasts- tumour cells interactions between osteoclasts and tumour cells.  
Envisioning in vitro studies, a rat model of bone metastases resection was 
recently developed by Gouget-Surmenian et al. (unpublished data). This model 
represents an interesting approach to assess in vitro CPC/Ga potential in a 
metastatic environment, and to establish if delivering Ga in this environment via a 
bioresorbable bone substitute is beneficial in fighting the residual metastatic cells.  
Regarding the metastatic relapse, some preclinical evidence suggest that 
metastatic tumour cells can home to and localize in the HSC niche of the bone and 
survive in a dormant state for long periods (Weilbaecher et al., 2011). Due to the 
gradual CPC degradation in vitro, sustained Ga release could also act on cancer 
cells in dormancy over a longer period of time.  
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At last, studies using different tumour cell lines showed that Ga could 
potentiate the antitumor activity of some putative chemotherapeutics and 
circumvent drug resistance of tumour cells. This is of particular interest in treatment of 
multiresistant tumour cell subpopulations (Collery et al., 2002). Thus, combining the 
chemotherapy with Ga-loaded bone substitutes could decrease the total 
administrated dose of the chemotherapeutic agent, mitigating the major side 
effects that usually accompany these treatments.  
Taken together, our data indicate that Ga is a plausible candidate for 
coupling with bone substitutes implanted after tumour resection, due to its potent 
disruption of vicious cycle by inhibiting on one side the excessive osteoclastogenesis, 
and on the other side metastatic cells expansion and activity.  
 
Prevention of postoperative infections  
 
As discussed above, multiple benefits from the presence of Ga in bone 
pathological environment strongly support also its use as an adjuvant in orthopaedic 
implants. Besides its antiresorptive and antineoplastic properties, Ga can participate 
in the prevention of postoperative risks due to its antimicrobial and anti-inflammatory 
action. Indeed, the first described therapeutic use of Ga compounds was the 
treatment of syphilis in a rabbit model and the eradication of Trypanosoma evansi in 
a mouse model (Bernstein, 1998). To date, Ga was proved efficient against several 
pathogens including Mycobacterium tuberculosis, Pseudomonas aeruginosa, 
Acinetobacter baumannii, and Staphylococcus aureus (Rangel-Vega et al., 2015). 
An interesting recent approach, which takes advantage of Ga antibacterial 
properties, is gallium and silver ions coating of titanium bone implants to counteract 
the biofilm formation after implantation (Cochis et al., 2014).  
 
Concluding remarks 
 
On the whole, we propose that Ga incorporation enhances biological 
properties of calcium phosphate substitutes for bone tissue engineering. In terms of 
applications, gallium could be exploited for: (i) its antiresorptive potential for the 
prevention of osteoporotic fractures; (ii) its antitumor effects that may be beneficial 
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to reconstructing bone tissue after tumour resection; (iii) its antimicrobial action that 
could counteract postoperative infections.  
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Article III : Molecular effects of gallium on osteoclastic differentiation of mouse and 
human monocytes 
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We had previously reported that gallium (Ga) inhibited both the differentiation and resorbing activity of
osteoclasts in a dose-dependent manner. To provide new insights into Ga impact on osteoclastogenesis,
we investigated here the molecular mechanisms of Ga action on osteoclastic differentiation of
monocytes upon Rankl treatment. We ﬁrst observed that Ga treatment inhibited the expression of Rankl-
induced early differentiation marker genes, while the same treatment performed subsequently did not
modify the expression of late differentiation marker genes. Focusing on the early stages of osteoclast
differentiation, we observed that Ga considerably disturbed both the initial induction as well as the
autoampliﬁcation step of Nfatc1 gene. We next demonstrated that Ga strongly up-regulated the
expression of Traf6, p62 and Cyld genes, and we observed concomitantly an inhibition of IkB degradation
and a blockade of NFkB nuclear translocation, which regulates the initial induction of Nfatc1 gene
expression. In addition, Ga inhibited c-Fos gene expression, and subsequently the auto-ampliﬁcation
stage of Nfatc1 gene expression. Lastly, considering calcium signaling, we observed upon Ga treatment
an inhibition of calcium-induced Creb phosphorylation, as well as a blockade of gadolinium-induced
calcium entry through TRPV-5 calcium channels. We identify for the ﬁrst time Traf6, p62, Cyld, IkB,
NFkB, c-Fos, and the calcium-induced Creb phosphorylation as molecular targets of Ga, this
tremendously impacting the expression of the master transcription factor Nfatc1. In addition, our
results strongly suggest that the TRPV-5 calcium channel, which is located within the plasma membrane,
is a target of Ga action on human osteoclast progenitor cells.
 2011 Elsevier Inc. All rights reserved.
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jo u rn al h om epag e: ww w.els evier .c o m/lo cat e/b io c hem p har m1. Introduction
Gallium (Ga) was discovered in 1875 by the French chemist
Paul-Emile Lecoq de Boisbaudran, who choose this name in honor
of Gallia (France) [1]. In the early 1970s, it was demonstrated that
Ga had several therapeutic uses including (i) the decrease of
accelerated bone mineral resorption, which occurs during osteo-
lytic bone diseases, and the subsequent lowering of elevated
plasma calcium levels associated with these pathologies; (ii) the
inhibition of neoplastic proliferation; (iii) the treatment of some
intracellular pathogens such as species of Mycobacterium [2].
Studies on Ga, which were mainly focused on its antitumor* Corresponding author at: INSERM U791, Faculte´ de Chirurgie Dentaire, 1, place
Alexi Ricordeau, 44042 Nantes, France. Tel.: +33 2 40 41 29 16;
fax: +33 2 40 08 37 12.
E-mail address: elise.verron@univ-nantes.fr (E. Verron).
0006-2952/$ – see front matter  2011 Elsevier Inc. All rights reserved.
doi:10.1016/j.bcp.2011.12.015activities [3], have shown that Ga caused a mild hypocalcemia [4].
In this context, Ga has been used to treat hypercalcemia resulting
from malignant tumors such as parathyroid carcinoma and Paget’s
disease of bone [5–7]. This antihypercalcemic effect of Ga results
from an inhibition of bone resorption rather than an increase of
urinary calcium excretion [5,8]. Indeed, due to its chemical
characteristics, Ga presents an afﬁnity for biological apatite that
explains the presence of Ga deposits in bone tissue, and
preferentially at sites of rapid bone remodeling such as active
metaphyseal growth plate and healing fractures [9–11].
Despite these observations, few studies have explored the effect
of Ga on bone cells [8,12,13]. Hall et al. demonstrated that Ga
inhibited bone resorption in a dose-dependent manner, and for
example, at 100 mg/mL, Ga reduced the resorption activity by 64%
without inducing modiﬁcations to the morphology or number of
osteoclasts [12]. In contrast to these ﬁndings, Blair et al. showed a
cytotoxic effect of Ga on osteoclasts [13]. Considering this
discrepancy, we previously investigated the biological effect of
Table 1
Mouse gene-speciﬁc primers used for real time RT-PCR analysis.
Mouse gene Primer sequence GI
36B4 Forward 50-tccaggctttgggcatca-30 118131200
Reverse 50-cgctgggaacactcgatagg-30
Nfatc1 Forward 50-tgaggctggtcttccgagtt-30 118131200
Reverse 50-cgctgggaacactcgatagg-30
Traf6 Forward 50-aactgtgctgtgtccatggc-30 38348245
Reverse 50-cagtctcatgtgcaactggg-30
Sqstm1 (p62) Forward 50-atgtggaacatggagggaaga-30 118130186
Reverse 50-ggagttcacctgtagatgggt-30
Cyld Forward 50-caacatggatgccaggttgc-30 28972434
Reverse 50-gcctgaactcattgtgacagta-30
c-Fos Forward 50-gggacagcctttcctactaccat-30 31560587
Reverse 50-gatctgcgcaaaagtcctgtg-30
E. Verron et al. / Biochemical Pharmacology 83 (2012) 671–679672Ga on bone cells. We reported that Ga inhibited both the
differentiation and the resorbing activity of osteoclasts in a
dose-dependent manner (0–100 mM) [14]. Furthermore, Ga did
not affect the viability or proliferation of osteoblasts. Despite these
results strongly suggesting a therapeutic potential of Ga, many
unknowns remain concerning the mechanism of Ga action. With
this in mind, we examined the molecular mechanisms of Ga action
on osteoclasts.
Osteoclasts are giant multinucleated cells of monocyte-
macrophage origin that degrade bone matrices [15]. RANKL
(receptor activator of NFkB ligand) and M-CSF (macrophage
colony stimulating factor) are the critical factors that regulate
osteoclastic differentiation [16]. RANKL is expressed by osteoblasts
and triggers pre-osteoclast differentiation [17] whereas M-CSF,
secreted by osteoblasts, provides differentiated cells with a
survival signal [18]. RANKL strongly induces the expression of
nuclear factor of activated T cells, cytoplasmic 1 (Nfatc1), a
transcription factor that is a master regulator of osteoclast
differentiation. Nfatc1 induction is dependent on both NFkB and
c-Fos pathways [19–22]. More speciﬁcally, the initial induction of
Nfatc1 synthesis requires the activation of the NFkB pathway
through the signaling molecule Traf6 (tumor necrosis factor
receptor-associated factor 6), as well as the nuclear translocation
of the transcription factor Nfatc2, that is constitutively expressed
in precursor cells. Upon RANKL binding to its receptor RANK, the
complex cooperates with costimulatory receptors to activate
calcium signaling that stimulates both the initial induction and the
auto-ampliﬁcation phase of Nfatc1 expression [23]. Indeed, Nfatc1
binds to its own promoter, thus leading to robust induction of
Nfatc1 protein synthesis [20,24]. An activator protein (AP)-1
complex containing RANKL-activated c-Fos is also required for the
auto-ampliﬁcation of Nfatc1 [23]. Eventually, AP-1/Nfatc1 com-
plexes turn on a transcriptional program leading to the expression
of osteoclast-speciﬁc genes, and the acquisition of mature
phenotypic markers such as tartrate-resistant acid phosphatase
(Acp5), calcitonin receptor (Ctr), matrix metalloproteinase 9
(Mmp9), integrin-b3 (Itg-b3) or a speciﬁc osteoclastic proton
pump namely ATP6V0A3.
In this study, we investigated Ga effects on RANKL-induced
osteoclastic differentiation of monocytes, comparing ﬁrst the early
and late stages of the process. We next focused on molecular
events governing osteoclastic differentiation in its early phase,
including the regulation of Nfatc1 gene expression. Lastly, we
hypothesized that Ga may act on calcium uptake and we tested this
hypothesis.
2. Materials and methods
2.1. Materials
Alpha minimal essential medium (a-MEM), Dulbecco’s Modi-
ﬁed Eagle’s Medium (DMEM), antibiotic mixture (P/S; 100 U/mL
penicillin, 100 mg/mL streptomycin), phosphate-buffered saline
(PBS), Hanks’ Balanced Salt Solution (HBSS), ionomycin, Fluo-3AM
and Fura-RedAM were purchased from Invitrogen Corporation
(Paisley, UK). Fetal calf serum (FCS), culture plates and plastics
were obtained from Dominique Dutscher (Brumath, France).
Gallium nitrate and gadolinium nitrate were obtained from Sigma
(Saint Quentin Fallavier, France). Recombinant human M-CSF and
RANKL were provided by PeproTech (Rocky Hill, NJ, USA).
2.2. Cell culture
RAW 264.7 cell line (Ref. # TIB-71) was obtained from ATCC
(LGC Standards, Molsheim, France). Cells were cultured in DMEM
containing 5% fetal bovine serum (Hyclone serum, Thermo FisherScientiﬁc, Brebie`re, France). For osteoclastic differentiation experi-
ments, RAW 264.7 cells were seeded at 5000 cells/cm2 in a-MEM
containing 5% Hyclone serum and effectors were added immedi-
ately. RANKL (Receptor Activator of Nuclear Factor-k B Ligand) was
used at 20 nM. Cells were cultured for four days with a renewal of
the medium at day 2.
Human osteoclast precursors were puriﬁed from blood samples
from healthy donors (obtained from the EFS, Etablissement
Franc¸ais du Sang, Marseille, France). Human CD11b+ cells were
puriﬁed using a CD11b MicroBeads kit (catalogue # 130-049-601)
from Miltenyi Biotec (Paris, France) according to the manufac-
turer’s instructions. For osteoclastic differentiation experiments,
CD11b+ cells were seeded at 30,000 cells/cm2 in a-MEM contain-
ing 10% Hyclone serum, and cultured in the presence of 33 ng/mL
hM-CSF and 66 ng/mL hRANKL as previously described [25].
2.3. Human cytokines and mouse effectors production (GST control
protein, RANKL)
Human recombinant cytokines were purchased from Pepro-
Tech (Recombinant Human M-CSF, #300-25; Recombinant Human
soluble RANK Ligand, #310-01). Mouse effectors were produced as
fusion proteins with GST. GST-Rankl was produced as previously
described [26]. For all the experiments using cells of murine origin,
a GST protein, produced and puriﬁed using the same protocol, was
used as a control.
2.4. Real-time PCR experiments
Total RNA samples were prepared using NucleoSpin RNA II kit
(Macherey Nagel, Hoerdt, France), and reverse transcription
(Superscript II/Rnase H/Reverse transcriptase, Invitrogen) was
performed with 1 mg of RNA and random primers. A 10-fold
dilution of cDNAs was used in ampliﬁcation reactions. PCR
experiments reported in Table 1 were performed using an ABI
PRISM 7000 system (Applied Biosystems, Life Technologies SAS,
Villebon-sur-Yvette, France), and qPCR Mastermix Plus was
purchased from Eurogentec (Eurogentec France SASU, Angers,
France). Reactions were performed in a 20 mL ﬁnal volume using
5 mL of diluted cDNAs. Ampliﬁcation conditions were as follows:
50 8C, 2 min; 95 8C, 10 min; (95 8C, 15 s; 60 8C, 1 min) cycled 40
times. The 36B4 housekeeping gene (Acidic Ribosomal Phospho-
protein P0) was used for normalization of the results. Real-time
PCR reactions were performed using mouse and human gene-
speciﬁc primers listed in Tables 1 and 2.
2.5. Immunolabeling
Cells were grown on glass coverslips in 24-well plates. After
ﬁxation and blocking with PBS containing 10% normal goat serum
Table 2
Human gene-speciﬁc primers used for real time RT-PCR analysis.
Human gene primer sequence GI
36B4 Forward 50-tgcatcagtaccccattctatcat-30 49087144
Reverse 50-aggcagatggatcagccaaga-30
NFATC1 Forward 50-gcatcacagggaagaccgtgtc-30 27502392
Reverse 50-gaagttcaatgtcggagtttctgag-30
JDP2 Forward 50-cttcttcttgttccggcatc-30 205277415
Reverse 50-cttcctggaggtgaaactgg-30
JUND Forward 50-gtctacgcgaacctgagcagcta-30 169234622
Reverse 50-ctcgtccttgagcgcagccaggc-30
FRA2 Forward 50-tagatatgcctggctcaggcag-30 44680151
Reverse 50-ggttggacatggaggtgatcac-30
C-FOS Forward 50- tgcctctcctcaatgaccctga-30 6552332
Reverse 50-ataggtccatgtctggcacgga-30
ATP6V0A3 Forward 50-gaagaggaacatgagcagcc-30 19924144
Reverse 50-ccgctaccaggaggtcaac-30
ACP5 Forward 50-gaccaccttggcaatgtctctg-30 161377452
Reverse 50-tggctgaggaagtcatctgagttg-30
MMP9 Forward 50-gtgctgggctgctgctttgctg-30 74272286
Reverse 50-gtcgccctcaaaggtttggaat-30
CTR Forward 50-tggtgccaaccactatccatgc-30 46361988
Reverse 50-cacaagtgccgccatgacag-30
ITGB3 Forward 50-cattactctgcctccactacca-30 47078291
Reverse 50-aacggattttcccataagca-30
BIM Forward 50-atccccgcttttcatcttta-30 116734657
Reverse 50-aggacttggggtttgtgttg-30
BCLXL Forward 50-atggcagcagtaaagcaagc-30 20336334
Reverse 50-cggaagagttcattcactacctgt-30
BCL2 Forward 50-atgtgtgtggagagcgtcaacc-30 72198188
Reverse 50-tgagcagagtcttcagagacagcc-30
BAX Forward 50-gctgttgggctggatccaag-30 163659848
Reverse 50-tcagcccatcttcttccaga-30
BAD Forward 50-cgagtgagcaggaagactcca-30 197116381
Reverse 50-aggagtccacaaactcgtcact-30
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dilution of an anti-Nfatc1 antibody (Cat. # sc-7294, Santa Cruz
Biotechnology, Heidelberg, Germany) or with a 1/50 dilution of an
anti-NFkB antibody (Cat. # 4764S, Cell Signaling Technology,
Danvers, MA 01923) in PBS containing 1.5% normal goat serum
(Rockland, Gilbertsville, USA), for 60 min at room temperature.
After washes in PBS, cells were subsequently incubated with a 1/
500 dilution of a secondary antibody coupled to FITC (Cat. # sc-
2010, Santa Cruz Biotechnology, Heidelberg, Germany), in PBS
containing 3% normal goat serum, for 45 min at room temperature
in the dark. Cells were counterstained with DAPI (Fig. 3A) or Topo-
3 (Fig. 3B) for nuclear staining. Immunoﬂuorescence was visual-
ized using a confocal laser scanning microscope (LSM5, Zeiss).
2.6. Western-blot
RAW 264.7-cells were lysed in lysis buffer containing 0.2%
Nonidet 40, 50 mM Tris, pH 7.5, 0.1 mM EDTA, pH 8.0, 0.1 mM
EGTA, pH 8.0, 1 mM DTT, including a protease inhibitor cocktail
(‘‘Complete Mini’’, Roche Diagnostics, Meylan, France) and
phosphatase inhibitors (50 mM NaF and 1 mM Na3VO4). Following
a centrifugation step at 15,000  g for 15 min, protein concentra-
tion in the supernatant was determined using a BCA Protein Assay
Kit from Pierce (Perbio Science). Proteins were separated by SDS-
PAGE on 10% gels, and transferred to polyvinylidene diﬂuoride
(PVDF) membranes. Membranes were blocked with 5% BSA in Tris-
buffered saline (TBS) containing Tween-20 (TTBS) at room
temperature for 1 h 30 and then incubated for 2 h with primary
antibodies: mouse anti-phospho-IkB (Cat. # 9246), mouse anti-IkB
(Cat. # 4814), mouse anti-phospho-Akt (Cat. # 4051), mouse anti-
Akt (Cat. # 2967), mouse anti-phospho-CREB (Cat. # 9196), mouse
anti-b-Actin (Cat. # 3700) (all primary antibodies were from Cell
Signaling Technology, Danvers, MA 01923). Horseradish peroxi-
dase-conjugated anti-mouse antibody (Cat. # sc-2005, Santa Cruz
Biotechnology, Heidelberg, Germany) was used as a secondaryantibody (45 min incubation). The antigen–antibody complexes
were visualized using ECL Plus Kit (Amersham Biosciences,
Piscataway, USA).
2.7. Measurement of intracellular Ca2+ oscillations
CD11+ cells suspended at 1.5  106 cells/mL in HBSS were
preincubated with 100 mM Ga for 1 h at 37 8C. Cells were loaded
during 30 min with cell-permeable calcium indicators, in HBSS
medium containing 2.6 mM Fluo-3 AM (Cat. # F-1242) and 5.5 mM
Fura-Red AM (Cat. # F-3021) (calcium indicators were from
Invitrogen Corporation, Paisley, UK). Cells were next washed once
and resuspended in HBSS medium (1.5  106 cells/mL). Where
noted, reagents including ionomycin, EGTA, gallium, and gadolini-
um were added to the medium after an equilibration period of
1 min. Using speciﬁc ﬁlters, the Fluo-3/Fura-Red emission ratio of
ﬂuorescence was analyzed by ﬂow cytometry (FACS Aria
cytometer, BD Biosciences, Le Pont de Claix, France).
2.8. Statistical analysis
The data shown is representative of at least three independent
experiments. Results are expressed as mean  standard deviation of
three determinations. The statistical differences between two
independent groups were evaluated using the Mann & Whitney test
(bi-directional analysis). Comparative analysis of more than two
independent groups was performed using the Kruskall–Wallis test
(bi-directional analysis). The differences measured were considered
to be statistically signiﬁcant for p < 0.05.
3. Results
3.1. Effects of Ga on differentiation and survival of human osteoclasts
Human CD11b+ cells isolated from peripheral blood were
cultured in differentiating medium for 2 or 7 days, before a 12-h
incubation in the presence of 100 mM Ga, the pharmacological
dose which was demonstrated to be optimal in our previous study
[14]. As depicted in Fig. 1A, 100 mM Ga signiﬁcantly down-
regulated the expression of speciﬁc osteoclastic differentiation
early marker genes including NFATC1, FRA2, JDP2 and JUND.
Conversely, when cells were incubated in the presence of 100 mM
Ga after seven days of differentiation, Ga did not modify the
expression of speciﬁc osteoclastic differentiation late marker genes
such as ACP5, ATP6VOA3, MMP9, CTR and ITGB3 (Fig. 1A).
On the whole, a 12-h Ga treatment inhibited the induction of
early differentiation marker gene expression, while the same
treatment performed subsequently did not modify the expression
of late differentiation marker genes.
As RANKL and M-CSF are also largely involved in osteoclastic
survival, we wanted to determine whether Ga may have an effect
on apoptosis induction both in precursor and mature osteoclasts.
Thus, we explored Ga impact on the expression of pro- and anti-
apoptotic genes. Human CD11b+ cells were differentiated in the
presence of hM-CSF and hRANKL. After 2 or 7 days, cells were
treated for 12 h with 100 mM Ga (Fig. 1B), and the expression of
pro- and anti-apoptotic genes was quantiﬁed by RT-PCR. As shown
in Fig. 1B, Ga treatment did not affect the expression of the most
prominent pro- and antiapoptotic factors, as measured in both
osteoclastic precursor cells and in mature osteoclasts.
3.2. Ga effect on Nfatc1 expression
Given that Ga disturbed expression of early marker genes
(Fig. 1A), we next focused on this early phase of osteoclastic
differentiation, and more particularly on the initial induction of
Fig. 1. Ga effect on differentiation (A) and apoptosis (B) of osteoclasts. Human CD11b+ cells were cultured in the presence of 33 ng/mL hM-CSF and 66 ng/mL hRANKL. After
two days (blue) or seven days (gray), cells were treated for 12 h with 100 mM Ga (+) or its vehicle (). Quantitative real-time PCR analysis was performed using 36B4 as
housekeeping gene. *p < 0.05, statistically signiﬁcant compared to untreated cells (Mann & Whitney test, bidirectional analysis). (A) Real time PCR analysis of the main
osteoclastic differentiation marker genes. (B) Real time PCR analysis of the main cellular survival and apoptosis marker genes. (For interpretation of the references to color in
the text, the reader is referred to the web version of the article.)
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to Nfatc1 protein level upregulation.
We had previously demonstrated that Ga reduced, in a dose-
dependent manner, the initial induction of Nfatc1 gene in RAW
264.7 cells incubated in the presence of Rankl for 12 and 24 h [14].
To investigate Ga impact on the auto-ampliﬁcation stage, which
occurs subsequent to the initial induction, we measured Nfatc1
gene expression after a 48 h incubation period of cells with both
Rankl and Ga. As shown in Fig. 2A, Ga induced a downregulation of
Nfatc1 gene expression, and this inhibition reached 40% when
100 mM Ga was used.
To correlate these effects of Ga at the transcript level with
Nfatc1 protein content, we performed immunolabeling of RAW
264.7 cells treated with RanklL/Ga for 48 h (Fig. 2B). In the absence
of Rankl, we detected a weak labeling of cells (Fig. 2B, b), while
Rankl treatment induced a strong expression of Nfatc1 protein
expression (Fig. 2B, c and d). Lastly we observed that a 100 mM Ga
treatment prevented Rankl-induced Nfatc1 protein expression
(Fig. 2B, e and f).
In summary, we found that in addition to the initial induction of
Nfatc1 (12–24 h), Ga treatment impacted latter ampliﬁcation step
(48 h), both at the transcript and protein levels.
3.3. Ga effect on initial induction of Nfatc1
As NFkB activation plays a critical role in initiating a robust
induction of Nfatc1, we next wanted to decipher the effect of Ga on
the NFkB signaling pathway.The phosphorylation of IkB is a marker for ubiquitination and
subsequent proteasome-mediated degradation. The degradation of
inhibitory kB (IkB) unmasks the nuclear localization signal motif of
NFkB, thus allowing its nuclear translocation and participation in
the initial induction of Nfatc1 gene expression. As shown in Fig. 3A,
Rankl induced IkB phosphorylation within 15 min. Concomitantly,
IkB protein was degraded, as shown at 30 min, before resynthesis
between 45 and 60 min. Ga did not block IkB phosphorylation, but
rather weakly stimulated it at 45 min. In contrast, we observed
that 100 mM Ga partially inhibited Rankl-induced IkB degradation
detected at 30 and 45 min.
Overall, while Ga treatment did not reduce IkB phosphorylation
within differentiating osteoclast progenitor cells, Ga partially and
transitorily blocked Rankl-induced IkB degradation. To deepen Ga
effect on NFkB signaling pathway, we determined whether this
blockage had repercussions on nuclear NFkB translocation by
performing immunostaining of NFkB protein. As shown in Fig. 3B(a),
NFkB, which is preferentially located in the cytoplasm following a
15 min Rankl treatment, is progressively translocated within the
nucleus as observed after a longer incubation period with Rankl. In
contrast, a 100 mM Ga treatment blocked NFkB nuclear transloca-
tion, at least up to 45 min following Rankl addition (Fig. 3B, b).
Upstream signaling of NFkB by Rankl involves the recruitment
of Traf6 following the binding of Rankl to its receptor Rank. In
addition, NFkB nuclear translocation is mediated by the interac-
tion of Traf6 with p62 and IKK [27]. Moreover, p62 interacts with
deubiquitinating enzyme Cyld to negatively regulate Rank
signaling [28]. Thus, we next wanted to evaluate Ga impact on
Fig. 2. Ga effect on the expression of Nfatc1gene and Nfatc1 protein. (A) Real-time PCR analysis of Nfatc1 gene expression. RAW 264.7 cells were differentiated for 48 h with
20 nM Rankl, in the presence of 10 mM or 100 mM Ga. Results are expressed as a percentage of Nfatc1 gene expression level in control condition. *p < 0.05, statistically
signiﬁcant compared to untreated cells (Kruskall–Wallis test, bidirectional analysis). (B) Immunostaining analysis of Nfatc1 protein expression. (a) Control immunostaining
without primary antibody; (b) control differentiation without Rankl treatment; (c–f) RAW 264.7 cells were cultured for 48 h with 20 nM Rankl, in absence (c, d) or in presence
(e, f) of 100 mM Ga. (bar = 10 mm).
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100 mM Ga signiﬁcantly increased Traf6, p62 and Cyld gene
expression when compared to the quantiﬁcation upon cells
treatment with Rankl alone.
3.4. Ga effect on Nfatc1 auto-ampliﬁcation
Nfatc1 positively regulates its own gene expression through an
auto-ampliﬁcation mechanism involving its recruitment to its ownFig. 3. Ga effect on Rankl-induced NFkB signaling pathway. (A) Ga effect on Rankl-induc
medium containing 0.2% BSA, pretreated with 100 mM Ga (+) or its vehicle () for 1 h, an
phosphorylation. Cell extracts were analyzed using antibodies directed against the tota
loading control. (B) Ga effect on Rankl-induced nuclear NFkB translocation. RAW 264.7 ce
or its vehicle (a) for 1 h, and stimulated with 20 nM Rankl for the indicated time. Immpromoter as an AP-1 complex containing c-Fos [19,20,23]. Using
RAW 264.7 cells, we observed that a 100 mM Ga treatment reduced
Rankl-induced c-Fos gene expression by 53% in comparison to
control condition (Fig. 5).
3.5. Ga effect on Rankl-induced Akt and Creb phosphorylation
Akt signaling is one of the pathways that interact with NFkB
and c-Fos in response to Rankl [29,30]. Rankl stimulation triggersed IkB phosphorylation. RAW 264.7 cells were cultured for 16 h in serum-depleted
d stimulated with 20 nM Rankl for the indicated time. Western-blot analysis of IkB
l form or the phosphorylated form of IkB (p-IkB). b-actin detection was used as a
lls were cultured as described in (A). Next, cells were pretreated with 100 mM Ga (b)
unostaining analysis of NFkB protein expression was performed. (bar = 10 mm).
Fig. 4. Ga effect on Rankl-induced Traf6, p62 and Cyld gene expression in mouse cells. Real-time PCR analysis of Traf6, p62 and Cyld gene expression. RAW 264.7 cells were
differentiated for 48 h with 20 nM Rankl, in the presence or in the absence of 100 mM Ga. Quantitative real-time PCR analysis was performed using 36B4 as housekeeping
gene. *p < 0.05, statistically signiﬁcant compared to untreated cells (Mann & Whitney test, bi-directional analysis).
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(IKK), which phosphorylates IkB [31]. Phospho-Akt is also involved
in the phosphorylation of the transcription factor Creb (cyclic
AMP-responsive element-binding), and Creb-mediated induction
of c-Fos is implied in the transcriptional control of Nfatc1 during
osteoclastogenesis [32]. Thus, we investigated Ga effect on Rankl-
induced Akt- and Creb phosphorylation.
Using RAW 264.7 cells, and as shown in Fig. 6A, Rankl treatment
induced the phosphorylation of both Akt and Creb. In addition, Ga
pretreatment did not modify Rankl-induced phosphorylation of
both Akt and Creb.
3.6. Ga effect on calcium signaling pathway
Ga has been shown to substitute calcium in biological apatite
[9]. Considering the essential role of calcium signaling during
osteoclastic differentiation, as well as the chemical similarity
between Ga and calcium, we examined the effects of Ga on
calcium-induced intracellular signaling and on calcium entry
within osteoclast precursor cells.
Rankl activates calcium signaling, which triggers the CaMK-
Creb pathway. As shown in Fig. 6A, Rankl stimulated Creb protein
phosphorylation, and in these experimental conditions, a treat-
ment with 100 mM of Ga did not exert any inhibitory effect. In
addition to the release of stores coming from the endoplasmic
reticulum, intracellular calcium oscillations may also result from
the entry of extracellular calcium through speciﬁc calcium
channels present at the cell surface. Thus, we studied Creb
phosphorylation in response to extracellular calcium, in the
presence or in the absence of gallium. As shown in Fig. 6B, a
10 min treatment of RAW 264.7 cells with 10 mM Ca2+ induced aFig. 5. Ga effect on Rankl-induced c-Fos gene expression in mouse cells. Real-time
PCR analysis of c-Fos gene expression in mouse cells. RAW 264.7 cells were cultured
with 20 nM Rankl, and 50 mM or 100 mM of Ga for 12 and 24 h. Results are
expressed as a percentage of c-Fos gene expression level in control condition.
*p < 0.05, statistically signiﬁcant compared to untreated cells (Kruskall–Wallis test,
bidirectional analysis).strong upregulation of Creb phosphorylation. In contrast, a 1 h cells
pretreatment with 100 mM Ga completely reversed the calcium-
induced Creb phosphorylation.
Lastly, we wanted to determine whether Ga could interfere
with extracellular calcium uptake through a speciﬁc calcium
channel, i.e. TRPV-5A (Transient Receptor Potential cation channel
subfamily V member 5A). TRPV-5A is a calcium channel highly
expressed in human osteoclasts [33], and which is largely involved
in intracellular calcium oscillations. Using gadolinium (Gd) as a
speciﬁc agonist of this channel, as well as human CD11b+ cells, we
examined whether Ga may block calcium entry through this
channel. As shown in Fig. 7, the addition of 50 mM Gd induced a
signiﬁcant increase in intracellular calcium in CD11b+ cells. In
contrast, when cells were simultaneously treated with 50 mM Gd
and 100 mM Ga, Gd did not trigger anymore intracellular calcium
increase.Fig. 6. Ga effect on Akt and CREB phosphorylation in mouse cells. (A) Western-blot
analysis of Rankl-stimulated Akt and Creb phosphorylation. RAW 264.7 cells were
cultured for 16 h in serum-depleted media containing 0.2% BSA, pretreated with
100 mM Ga (+) or its vehicle () for 1 h, and stimulated with 20 nM Rankl for the
indicated time. Cell extracts were analyzed using antibodies directed against the
phosphorylated forms of Akt (p-Akt) or Creb (p-Creb). b-actin detection was used as
a loading control. (B) Western-blot analysis of Ca2+-stimulated Creb
phosphorylation. RAW 264.7 cells were starved for 5 h in DMEM containing 0.2%
BSA, preincubated with 100 mM Ga (+) or its vehicle () for 1 h, and treated (+) or
not () with 10 mM Ca2+ for 10 min. Cell extracts were analyzed using antibodies
directed against the phosphorylated form of creb (p-creb). b-actin detection was
used as a loading control.
Fig. 7. Ga effect on Ca2 uptake in human cells. Flow cytometry analysis of
gadolinium-stimulated calcium uptake. Human CD11b+ cells were loaded with
Fluo-3 and Fura-Red for 30 min. Cells were treated with (+) or without () 100 mM
Ga and 50 mM Gd. After 5 min, Ca2+ uptake was monitored for 1 min. Results are
expressed as the mean of Fluo-3/Fura-Red emission ratio (n = 7).
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we observed an inhibition of calcium-induced Creb phosphoryla-
tion, as well as a blocking of gadolinium-induced calcium entry
through the TRPV-5A calcium channel.
4. Discussion
In our previous studies, we demonstrated that Ga inhibited the
process of osteoclastic differentiation in a dose-dependent
manner, which results in blocking osteoclast resorptive activity
[14]. To obtain pertinent results about a potential distinct
sensitivity to Ga of precursor and mature cells respectively, we
investigated this issue using human CD11b+ cells isolated from
peripheral blood as a source of osteoclast progenitors [25]. We
observed that Ga speciﬁcally affected the expression of marker
genes within differentiating osteoclastic precursors rather than in
mature osteoclasts. Furthermore, we observed that Ga did not
disturb the expression of pro and antiapoptotic markers both inFig. 8. Molecular targets of Ga action on osprecursor and mature osteoclasts. These data conﬁrm our
preliminary experiment performed on mature osteoclasts
obtained upon RAW 264.7 cells differentiation, a cell line that is
considered more resistant than human primary cells. Results
obtained from a human model of osteoclast-like cells strengthen
the relevance of our basic data. For practical reasons, we continued
using the murine RAW 264.7 cells.
We had previously reported that Ga reduced the expression of
Nfatc1 gene in a dose-dependent manner at the early stages (12–
24 h) of osteoclastic differentiation in the murine RAW 264.7 cell
line [14]. Using the same model, we show here that this inhibitory
effect of Ga on Nfatc1 gene expression persists for 48 h in Rankl-
treated cells (Fig. 2A), and that this transcriptional effect impacts
Nfatc1 protein content of the cells (Fig. 2B). From these results, we
conclude that Ga inhibits both the initial and auto-ampliﬁcation
steps of Nfatc1 induction (Fig. 8).
Focusing on NFkB activation, we have documented Ga impact
on the initial induction of Nfatc1. NFkB forms a complex with its
inhibitory element (IkB) that prevents its translocation into the
nucleus. Phosphorylation of IkB induces its own degradation
resulting in activation of NFkB. As shown in Fig. 3A, Ga partially
protect IkB from degradation without inhibiting its phosphoryla-
tion. This result, suggesting that Ga interacts with IkB degradation,
is in accordance with a study from Chen et al. [34], which describes
an inhibition of the proteasome activity by gallium(III) complexes.
Furthermore, Ang et al. reported in 2009 [35] that proteasome
inhibitors modulate NF-kB activation and osteoclast formation.
We hypothesize that by blocking proteasome-mediated IkB
degradation, p-IkB protein accumulates in the cytoplasm (Fig. 3).
Further supports to this hypothesis come from our data on Traf6
and p62. Traf6 is known to interact with p62 and IKK, thereby
mediating IkB degradation [36]. We demonstrate that 100 mM Ga
increases Traf6 and p62 gene expression (Fig. 4), and this is
interesting considering that the accumulation of p62 appears to
impact the ubiquitine/proteasome system by delaying the delivery
of ubiquitinated proteins to the proteasome [27]. Thus, signalingteoclast precursor cells differentiation.
E. Verron et al. / Biochemical Pharmacology 83 (2012) 671–679678repression observed upon p62 overexpression in NFkB reporter
assays might be explained by an impaired clearance of IkB via the
ubiquitine proteasome system [36]. Ga-induced Cyld overexpres-
sion further documents the molecular mechanisms of Ga action on
NFkB signaling pathway (Fig. 4). Cyld is a deubiquitinating enzyme
which is considered as a crucial negative regulator of osteoclas-
togenesis [28]. Indeed, Cyld appears to be recruited through a
direct interaction with the p62, and this negatively regulates NFkB
pathway by removing the ubiquitin modiﬁcation from TRAF6 [36].
As a whole, these data contribute to explain how NFkB signaling
pathway, and more speciﬁcally IkB degradation, is impaired upon
Ga treatment.
To determine whether IkB degradation inhibition had an
impact on nuclear NFkB translocation, we studied cellular
localization of NFkB following Ga treatment by performing
immunostaining analysis (Fig. 3B). In the absence of Ga treatment,
NFkB translocates within the nuclear compartment following a
45 min Rankl treatment. By contrast, the treatment with 100 mM
Ga, maintained preferentially NFkB within the cytoplasm. Overall,
the inhibition of IkB degradation observed with 100 mM Ga
treatment was accompanied by a blockage of Rankl-induced NFkB
nuclear translocation, this leading to the disruption of Nfatc1
initial induction (Fig. 8).
We also observe that Ga down-regulates c-Fos gene expres-
sion within differentiating osteoclast progenitors. Thus, we
conclude that Ga also impacts the auto-ampliﬁcation of Nfatc1,
since c-Fos is known to be critical for this stage of osteoclastic
differentiation [23].
To further investigate the molecular mechanisms of Ga action,
we were interested in ﬁnding intracellular targets that could
interact with both NFkB and c-Fos. We focused on Akt, a
downstream target of PI3K, which is also activated by Rankl
[29,30].
In the canonical pathway, Akt activates the IKK complex that
phosphorylates and degrades IkB [31], and Sugatani et al. have
shown that Akt regulates NFkB activity through an Akt phosphor-
ylation site present within the IKK complex [37]. Our data clearly
indicate a lack of Ga effect on Akt activation, this indicating that Ga
effect on IkB phosphorylation we observe at 45 min (Fig. 3) is not
mediated through Akt. Akt phosphorylates also the transcription
factor Creb, which regulates c-Fos expression [32]. However,
according to the literature, Rankl-induced c-Fos expression is only
partially understood. In our study, pretreatment with 100 mM Ga
for 1 h did not alter the activation of either Akt or Creb in response
to Rankl. From these data, it is unlikely that Ga directly modulates
c-Fos expression via Creb.
NFkB activation occurs through two distinct mechanisms. The
most important mechanism is based on IkB phosphorylation that
governs the proteasome-mediated IkB degradation. This mecha-
nism includes both classical (canonical) and alternative (non-
canonical) NFkB signaling pathways. In contrast to this phosphor-
ylation process, another NFkB activation pathway through the
polymerization-mediated depletion of free IkB has been recently
described [38]. This pathway is mediated by transglutaminase 2
(TGase 2)/mcalpain. Brieﬂy, TGase 2 is a crosslinking enzyme
involved in cellular processes such as cell migration, adhesion, and
differentiation. TGase 2 induces polymerization of IkB which
becomes a substrate for mcalpain, a non-lysosomal thiolprotease
[39]. This proteolytic pathway is independent of the ubiquitin-
proteasome degradation system. It will be interesting to investi-
gate the effects of Ga on this pathway, especially considering that
the activity of these enzymes (TGase 2 and mcalpain) depends on
calcium ions.
Although many unknowns remain concerning how Ca2+
signaling triggers Nfatc1 activation, Ca2+ is critical for osteoclastic
proliferation, differentiation and survival. For example, theCa2+-CaMK-Creb pathway is not only important for the initial
induction of c-Fos but it also regulates the expression of osteoclast-
speciﬁc genes in cooperation with Nfatc1 [23]. In addition, it is now
well-established that osteoclasts can sense environmental level of
Ca2+ through the Ca-sensing receptor (CaR) leading to intracellular
signaling which notably stimulates Creb phosphorylation and
therefore differentiation of osteoclasts [40]. Using mouse RAW
264.7 cells stimulated with an elevated extracellular Ca2+
concentration, we observe that Ga completely inhibits calcium-
induced Creb phosphorylation. This result suggests an interaction
between Ga and calcium signaling.
Given the chemical similarity of Ga and calcium, we hypothe-
sized that Ga may interact with Ca2+-signal by blocking Ca2+ entry.
Extracellular Ca2+ entry is of particular importance for human
osteoclasts since it is responsible for a signiﬁcant increase in
intracellular Ca2+ in response to RANKL. Indeed, in a human
osteoclast model, Chamoux et al. showed that none of the
traditional calcium-channels was involved in the RANKL-induced
calcium spike [33]. They described that RANKL treatment opens a
speciﬁc calcium-channel, namely TRPV-5, which belongs to the
TRP channel family. This phenomenon allows extracellular Ca2+
entry, and thus intracellular oscillations of Ca2+ concentration
independently from the signaling pathway involving PLCg and
intracellular calcium stores. In an effort to determine whether Ga
may block this critical Ca-channel, we used gadolinium as a
speciﬁc agonist of TRPV-5 in primary human osteoclast precursors
isolated from peripheral blood, and we report that Ga completely
abolishes intracellular Ca2+ oscillations induced by gadolinium.
This result strongly suggests that Ga could also act by blocking a
speciﬁc Ca-channel in the plasma membrane of osteoclasts, thus
disturbing intracellular Ca2+ oscillations (Fig. 8).
5. Conclusion
In summary, we identify for the ﬁrst time Traf6, p62, Cyld, IkB,
NFkB, c-Fos, as well as calcium-induced Creb phosphorylation, as
molecular targets of Ga during osteoclast differentiation, this
tremendously impacting the expression of the master transcrip-
tion factor Nfatc1. In addition, our results strongly suggest that
the TRPV-5 calcium channel, which is located within the plasma
membrane, is a target of Ga action on human osteoclast
progenitor cells.
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